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Mitochondrial DNA (mtDNA) that escapes from autophagy-mediated degradation 
after hemodynamic stress can cause inflammation in the heart by activating TLR9 
signalling pathway, in which unmethylated CpG motifs bind to TLR9. DNA 
methyltransferases (DNMTs) such as DNMT1 and DNMT3A are involved in 
nuclear DNA methylation. It has also been reported that two additional potential 
transcription initiation codons exist at 5’ region to the original DNMT1 and that 
this 1st-to-3rd ATG sequence fused to GFP cDNA can localise in mitochondria, 
suggesting that DNMT1 might affect mtDNA methylation patterns. The aim of this 
study is to elucidate the role of DNMT1 in mtDNA methylation. To achieve this 
aim, three different isoforms of mouse DNMT1 sequences (“nuclear DNMT1”, 
“whole DNMT1” and “mtDNMT1”) as well as a mouse DNMT3A  isoform were 
generated through molecular cloning. Mitoprot II software analysis predicted a 
high chance of mitochondrial localization (>90%) for both whole DNMT1 and 
mtDNMT1 isoforms. Western blotting analysis confirmed overexpression of all 
DNMT1 constructs, and immunocytochemistry experiments confirmed the 
predicted localisation of DNMT1 isoforms. DNMT3A localisation was detected at 
nuclear level, but not at mitochondrial level. Adenoviral vectors for nuclear 
DNMT1 and mtDNMT1 were generated and the methylated-DNA 
immunoprecipitation/qPCR methylation analysis of the D-Loop showed a 3-to-5 
fold increase in total methylation levels in mtDNMT1 overexpressed mouse 
cardiac endothelial cells. However, global percentage of methylation is low. CoIP-
MS analysis after mtDNMT1 overexpression failed to highlight any candidates for 
mtDNMT1 co-interaction. These data suggest that the 1st-to-3rd ATG sequence 
contains the mitochondrial localisation signal for DNMT1, and that DNMT1 can 
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1.1 Heart failure 
Heart failure (HF) is a leading cause of morbidity and mortality1, with 2.3 million 
people in the UK diagnosed with this complex clinical syndrome; the lifetime risk 
of developing heart failure is roughly one in five for a person aged 40 years, and 
with the number of new cases detected each year increasing rapidly. Thus, 
understanding the pathogenesis of heart failure is highly important to develop 
new therapies against this condition. The heart is a pump that drives blood 
carrying oxygen and nutrients to the organs around the body and heart failure 
happens when the heart is not capable of pumping enough blood to meet the 
systemic metabolic demands. This can have complications and leads to 
symptoms such as excessive tiredness, shortness of breath, dizziness and 
oedema. Heart failure is associated with a number of molecular signs such as 
elevated levels of catecholamines2 and proinflammatory cytokines (tumour 
necrosis factor alpha, interleukin 6, interleukin 8, interleukin 1 beta)3,4, and is 
caused by structural and/or functional cardiac abnormalities, leading to myocyte 
death and/or ventricular remodelling5. The classification can be based on the time 
from ventricular dysfunction to clinical manifestations6, the ejection fraction (the 
fraction of blood in the left and right ventricles pumped out with each heartbeat), 
or the main site of congestion. Heart failure is a chronic illness which develops 
gradually over time, and long-term therapies are used to treat patients with the 
symptoms. It is generally triggered as a secondary effect of other conditions, such 
as diabetes and high blood pressure (HBP), which indirectly damage the heart. 
Acute heart failure is due to cardiac-related events, such as myocardial infarction 
(MI). An MI occurs when blood stops flowing properly to a part of the heart 
(myocardial ischemia), and the heart muscle is injured because it is not receiving 
enough oxygen. Conventionally, HF was seen to result from the failure of the 
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heart to pump enough blood into the circulation due to ventricular systolic 
dysfunction (heart failure with a reduced ejection fraction, HFrEF), but patients 
with non-decreased left ventricular ejection fraction (LVEF) can develop HF when 
higher filling pressures are needed to achieve a normal end-diastolic ventricular 
volume6 (Figure 1.1). Half of patients with heart failure have a preserved left 
ventricular ejection fraction (HFpEF), and while morbidity and mortality in HFpEF 
are similar to values observed in patients with HFrEF, no effective treatment has 
been identified7. While early research focused on the importance of diastolic 
dysfunction in the pathophysiology of HFpEF, recent studies have revealed that 
multiple non-diastolic abnormalities in cardiovascular function also contribute8. 
Heart failure may also be defined based on which side of the heart is not 
functioning effectively6,9. When the left ventricle is not pumping adequately, a 
build-up of blood in the left atrium and the lungs affects the supply of oxygenated 
blood to the rest of the body, and this is known as left-sided heart failure. The 
main symptoms include shortness of breath, fatigue and lung congestion. On the 
other hand, when the right ventricle is not pumping adequately, systemic 
congestion develops, leading to liver congestion, appetite loss, fluid retention and 
swelling in the legs and ankles. Right-sided heart failure usually occurs as a direct 
result of left-sided heart failure but can also be caused by severe cardiac 
hypertrophy, lung diseases or valvular diseases10. Although many conditions may 
lead to HF, the predominant aetiologies are myocardial ischemia and HBP with 
coronary artery disease (CAD) being the initiating cause in almost 70% of cases 






Figure 1.1: Types of heart failure. Abbreviations: HF, heart failure; HFrEF, heart 
failure with reduced ejection fraction; HFpEF heart failure with preserved ejection 
fraction. Adapted from Pazos-Lopez P. et al, The causes, consequences, and 




1.2 Cardiac remodelling and hypertrophic responses 
Under conditions such as HBP or during exercise, the heart must adapt itself to 
conduct extra work and normalize the load. The hypertrophic response is 
initiated, enlarging the size of cardiomyocytes and leading to increased wall 
thickness. This improves the pumping function of the cardiac muscle and 
decreases ventricular wall tension12. Three different types of cardiac remodelling 
(defined as the changes in size, shape, structure and physiology of the heart after 
injury to the myocardium) exist: physiological hypertrophy, pathological 
hypertrophy and cardiac dilation13 (Figure 1.2). 
Physiological hypertrophy, also known as eccentric hypertrophy, happens in 
response to stimuli such as exercise or pregnancy. The heart undergoes a 
uniform cardiac hypertrophic response in which the sarcomeres are added in 
series elongating the cardiomyocytes, and there is a matched increase in 
ventricular wall thickness and chamber dimensions. This type of adaptive 
response is accompanied with normal or enhanced cardiac function12. 
Pathological hypertrophy occurs due to sustained hypertension (high blood 
pressure), MI, diabetes and several types of cardiomyopathies. It is associated 
with increased protein synthesis, reactivation of the foetal gene program (that 
involves increased size of cardiomyocytes) and increased expression of atrial 
natriuretic factor (ANF), brain natriuretic peptide (BNP) and β-myosin heavy chain 
(βMHC)14,15. During pathological hypertrophy, the cardiomyocytes undergo 
concentric hypertrophy that corresponds to thicker ventricular and septal walls, 
but with a decrease in chamber dimensions. These changes altogether can 
improve the pumping function of the heart at first16, however over time this type 
of cardiac remodelling alters the extracellular matrix leading to impaired cardiac 
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function due to fibrosis and cell death of myocytes. This results in an increased 
risk of adverse cardiac events16,17 (Figure 1.3). 
Finally, cardiac dilation has a similar yet harsher phenotype than pathological 
hypertrophy, in which cardiac fibrosis and myocardial cell death are detected and 
there is eccentric growth of the cardiomyocytes. Sarcomeres are added in series 
making the cells longer, inducing dilatory growth of the cardiac muscle and 
leading to heart failure13. 
 
 
Figure 1.2: Cardiac hypertrophic responses. The adaptive and reversible 
physiological hypertrophic response to exercise and pregnancy leads to eccentric 
cell growth. Pathological hypertrophy induces concentric hypertrophy, leading to 
a greater increase in cardiomyocyte width, rather than length. These changes 
can aid cardiac function, however over time this type of cardiac remodelling is 
detrimental as fibrosis and cell death impair the cardiac function. Cardiac dilation 
may occur from normal hearts under conditions such as myocardial infarction (MI) 
or dilated cardiomyopathy (DCM), or from severe pathological hypertrophy. 
Abbreviations: RV, right ventricle; LV, left ventricle; DCM, dilated 
cardiomyopathy. Taken from Heineke J. et al, Regulation of cardiac hypertrophy 
by intracellular pathways, Nature Reviews Molecular Cell Biology, 2006.
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Figure 1.3: Pathological hypertrophic response. Myocardial injury leads to the 
activation of mechanical and neurohumoral signalling pathways to aid the cardiac 
workload. Stimulating these signalling pathways leads to pathological 
hypertrophy with an increase in myocyte size, increased protein synthesis, 
altered gene expression and changes in sarcomeric organization. The initial 
adaptive response is beneficial to the heart, but over time it becomes pathological 




1.3  Inflammation 
The mammalian immune system possesses a variety of strategies to defend the 
body against external pathogens and tumors18, which are divided in two 
branches: innate and acquired immunity. The innate immune system is the first 
line of host defence against pathogens and is mediated by phagocytes including 
macrophages and dendritic cells (DCs). Inflammation is part of the innate 
immunity and is an initial and fast-acting immune defence mechanism that 
removes injurious stimuli and initiates the healing process19. The tissue-residing 
macrophages and the complement system detect the presence of foreign 
substances and antigens, stimulating the release of chemotactic cytokines 
(chemokines) such as interleukin (IL)-8 and proinflammatory cytokines such as 
IL-1, IL-6 and Tumour necrotic factor α (TNFα). Complement activation stimulates 
mast cells to degranulate releasing histamine and prostaglandins into the 
extracellular space, which in turn instigates dilation of local blood vessels and 
permeabilisation of the capillaries, leading to the recruitment and extravasation 
of leukocytes to the area2. The increased blood flow and warmth to the injured 
area are unfavourable for micro-organisms and result in swelling of the affected 
area, isolating the foreign substance from further contact with bodily tissues. 
Inflammation will persist until the microorganism has been eradicated. However, 
if the inflammation is too much or lasts for a long time, it can result in damage to 
the host tissues and lead to neurodegenerative and autoimmune disorders2, 
thereby requiring for inflammation to be tightly regulated to maintain homeostasis.  
Increased levels of circulating proinflammatory cytokines, such as TNFα, IL-6 and 
IL-1β 3,4 are associated with the progression and adverse outcomes of heart 
failure in chronic heart failure patients. Moreover, inflammation has been 
implicated with the pathogenesis of this condition, even though infection by micro-
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organisms is most likely not involved20, and the mechanisms responsible for 
initiating and integrating inflammatory responses within the heart remain poorly 
defined. 
 
1.3.1 Toll-like receptors (TLRs) 
Macrophages and dendritic cells are important sentinels for detecting infectious 
material. Infectious material is sensed by pattern recognition receptors (PRRs) 
found at the plasma membrane or intracellularly. PRRs recognize non-self, 
exogenous pathogen-associated molecular patterns (PAMPs) or endogenous 
danger-associated molecular patterns (DAMPs) such as heat shock proteins21. A 
subset of PRRs includes the toll-like receptors (TLRs). Toll, the founding member 
of the TLR family, was initially identified as a gene product essential for the 
development of embryonic dorsoventral polarity in Drosophila, and was later 
shown to play a critical role in the antifungal response of flies22. TLRs are 
evolutionarily conserved, from the worm Caenorhabditis elegans to mammals23, 
and 12 members of the TLR family have currently been identified in mammals. 
TLRs are type I integral membrane glycoproteins characterized by the 
extracellular domain containing varying numbers of leucine-rich repeat (LRR) 
motifs and a cytoplasmic signalling domain homologous to that of the interleukin 
1 receptor (IL-1R), termed the Toll/IL-1R homology (TIR) domain24. Based on 
their primary sequences, TLRs can be further divided into several subfamilies, 
each of which is capable of recognizing different types of PAMPs: the subfamily 
of TLR1, TLR2 and TLR6 recognizes lipids, whereas the highly related TLR7, 
TLR8 and TLR9 recognize nucleic acids. However, some TLRs (i.e. TLR4) are 
unusual in a way that they can recognize several structurally unrelated PAMPs 
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such as lipopolysaccharide (LPS), fibronectin, heat shock proteins and many 
others. 
TLRs are expressed on various immune cells such as macrophages, dendritic 
cells, B cells, specific types of T cells, and sometimes even on nonimmune cells 
such as fibroblasts and epithelial cells. Activation of TLRs instigates an 
intracellular signalling pathway which is typical for each TLR, but all end up by 
activating the inflammatory cascade25. 
 
1.3.2 Autophagy 
Autophagy is a general term for the non-selective degradation of cytoplasmic 
components within lysosomes26. The principal role of autophagy is to supply 
nutrients for survival27, and a level of constitutive autophagy is required in order 
to maintain cell function through controlling the quality of proteins and 
organelles28. The process is distinct from endocytosis-mediated lysosomal 
degradation of extracellular and plasma membrane proteins, and there are three 
types of autophagy – macroautophagy, microautophagy, and chaperone-
mediated autophagy29. The non-selective nature of this process is in contrast to 
the ubiquitin-proteasome system, which specifically recognizes only ubiquitinated  
proteins for proteasomal degradation, and has numerous specific functions as it 
can selectively target a wide range of substrates. Autophagy has also been 
involved in the regulation of a variety of physiological and pathophysiological 
roles such as starvation adaptation, development, anti-aging, cell death, tumour 
suppression30, and it consists of several sequential steps (Figure 1.4). A portion 
of cytoplasm, including organelles, is enclosed by an isolation membrane to 
compose an autophagosome. The outer membrane of the autophagosome 
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subsequently fuses with the endosome and then the lysosome, and the internal 
material is degraded.  
As previously mentioned, growing evidence suggests that cardiac inflammation 
contributes to progression of heart failure, and altered autophagy has been 
observed in various heart diseases31,32. Moreover, it has been reported that 
autophagy plays a different role in cardiomyocytes in the basal state and in 
response to hemodynamic stress through pressure overload experiments33. 
Constitutive autophagy in the heart, under baseline conditions, is a homeostatic 
mechanism for maintaining cardiomyocyte size and cardiac structure and 
function, whereas under conditions of hemodynamic stress it becomes an 
adaptive response to protect cardiac tissues from damage33. Despite 
accumulating evidence that inflammation is involved in pathogenesis, an infection 
with microorganisms is not involved in the development of the majority of heart 
failure cases34, though elevated levels of circulating pro-inflammatory cytokines 
are present. This state is called “sterile inflammation”3, and the underlining 
mechanism and involvement of sterile inflammation in the development of heart 
failure is currently subject of intense studies. 
 
Figure 1.4: The process of macroautophagy in mammalian cells. Following 
formation of the autophagolysosome, the material internalised by the 
autophagosome formation is degraded. Abbreviations: PAS, Pre-
autophagosomal Structure. Figure taken from Mizushima N., Autophagy: process 
and function, Genes and development, 200729. 
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1.3.2.1 Involvement of mitochondrial DNA in cardiac inflammation and heart 
failure 
The TLR9 receptor usually recognizes unmethylated CpG motifs found within 
bacterial and viral DNA35, but it has also been reported that mtDNA that escapes 
from autophagy is capable of triggering a TLR9-mediated inflammatory 
response36 (Figure 1.5). 
Endosomally located TLR9 recognizes unmethylated CpG motifs on DNA. 
Activation of TLR9 leads to the recruitment of the adaptor protein MyD88, which 
forms a complex with IL-1R-associated kinase 4 (IRAK4), E3 ubiquitin ligase 
(E3UL) and TNFR-associated factor 6 (TRAF6). E3UL ubiquitinates TRAF 6 
enabling regulatory proteins Transforming growth factor beta-activated kinase 1 
(TAK1), TGF-beta-activated kinase 1 and MAP3K7 binding protein 2 (TAB2) and 
TGF-beta-activated kinase 1 and MAP3K7 binding protein 3 (TAB3) to bind to the 
ubiquitinated sites of TRAF6. Activated TAK1 phosphorylates inhibitor of nuclear 
factor kappa-B kinase (IkB) subunit beta (IKKβ) within the IKK complex, which in 
turn phosphorylates the inhibitor of nuclear factor kappa B (IκBα). This 
phosphorylation leads to degradation of IκBα via the ubiquitin-proteasome 
system and the release of nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB). NF-κB translocates into the nucleus and activates the 
transcription of proinflammatory cytokine genes and type 1 interferons (such as 
IFNα). TRAF6 activates interferon regulatory factor (IRF)-5 to enter into the 
nucleus and activate the transcription of proinflammatory cytokine genes. In 
addition, MyD88 also forms a signalling complex with TNFR-associated factor 3 
(TRAF3), IL-1R-associated kinase 1 (IRAK1) and inhibitor of nuclear factor 
kappa-B kinase subunit alpha (IKKα), and phosphorylation of interferon 
40 
 
regulatory factor 7 (IRF7) by IRAK1 or IKKα enables IRF7 to enter into the 
nucleus, which in turn initiates the transcription of type 1 interferons25. 
 
 
Figure 1.5: Downstream signalling of the TLR9 receptor. After recognition of 
unmethylated CpG motifs by TLR9 (1), MyD88 adaptor protein is recruited and 
forms a complex with the IRAK-4-TRAF6 complex (2). Ubiquitination of TRAF6 
allows for TAK1, TAB2 and TAB3 binding (3). Phosphorylation of IKKβ by TAK1 
triggers IκBα phosphorylation, which leads to the release of NF-κB (4). This 
allows for NF-κB nuclear translocation and the subsequent production of 
proinflammatory cytokines (5). MyD88 also allows for nuclear localisation of IRF7 
through a signalling complex with TRAF3, IRAK1 and IKKα (6), which leads to 





1.4.1 Structure and role 
The mitochondrion is a cellular organelle that derives from an ancient α-
proteobacterium that, according to the endosymbiotic theory, was taken up by a 
primordial eukaryotic cell ~1.5-2 billion years ago37. Mitochondria have a central 
role in energy conversion and are thus termed the powerhouses of eukaryotic 
cells. The complexes of the respiratory chain in the mitochondrial inner 
membrane use energy, which is gained from the oxidation of food molecules, to 
pump protons across the membrane and generate a membrane potential (Δψ). 
The proton gradient is then used to drive the mitochondrial ATP synthase that 
produces the bulk of ATP for the cell, although eukaryotic cells also integrated 
mitochondria into multiple metabolic and signalling pathways38,39. 
Like Gram-negative bacteria, mitochondria contain two membranes (an outer 
membrane and an inner membrane) and two aqueous spaces (the 





Figure 1.6: Mitochondrion inner structure. The mitochondrion contains 2 
membranes (outer and inner) with an inter membrane space in between. The 
mtDNA is trapped within the matrix, along with ATP synthase particles. 
 
1.4.2 Similarities between mitochondria and bacteria 
Mitochondria are the only organelles of bacterial origin within eukaryotic cells40,41, 
and due to their origin, they share several similarities with bacteria (Table 1.1). 
The most striking similarity is the presence of a closed circle DNA molecule, 




Table 1.1: Similarities between mitochondria and bacteria. 
Characteristic Mitochondria Bacteria 
Size (Width) 0.2-1 µ 0.2-2.0 µ 
Size (Length) 1.0-4.0 µ 0.3 – 10.0 µ 
Lipoprotein membrane 60-70 Å 70-80 Å 
DNA shape Closed circle Closed circle 
Inhibitor of protein synthesis Chloramphenicol Chloramphenicol 
Ribosomes 60S-78S 70S 
 
1.4.3 The mitochondrial genome 
Mitochondria carry a DNA sequence known as mitochondrial DNA (mtDNA). The 
mtDNA is a circular double-stranded genome which is about 16,600 bp long in 
humans (Figure 1.7) and 16,300 bp in mouse cells, and carries a total of 37 
genes, encoding 13 of the ~90 different proteins present in the respiratory chain 
of mammalian mitochondria (Cytb, ND1-2-3-4-4L-5-6, CO1-2-3, ATP6-8) and that 
are all essential for cellular ATP production by oxidative phosphorylation, 2 
ribosomal RNAs (rRNAs) and 22 transfer RNAs43 (tRNAs) which are needed for 
mitochondrial translation, whereas the nuclear genome encodes for thousands 
other proteins necessary for mitochondrial structure, function and for mtDNA 
replication and transcription44. The existence of mtDNA is explained by the widely 
accepted endosymbiotic theory according to which, during the course of time, 
ancestral bacterial genes have been transferred from the mitochondrial to the 
nuclear genome, as presence of orthologous genes in the mitochondrial or 
nuclear genomes of some species has been reported45. This gene transfer also 
explains why all proteins necessary for mtDNA replication, as well as transcription 
and translation of mtDNA-encoded proteins, are encoded in the nucleus. 
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Currently, there are a few theories regarding why mitochondria have retained 
their genetic material, and why elaborate enzymatic machineries are necessary 
to replicate and express a separate genome containing only a few genes. For 
example, it has been suggested that due to the fact that some hydrophobic 
proteins are difficult to import across the mitochondrial membranes, they must be 
produced within the mitochondrion46. 
In mammalians, mtDNA is maternally inherited and mitochondria in mammalian 
sperm are destroyed by ubiquitination inside the oocyte cytoplasm and later on 
subjected to proteolysis during preimplantation development47. This usually 
blocks the transmission of paternal mtDNA, although it has been reported that 
interspecific crosses of mice can lead to transmission of low levels of paternal 
mtDNA48. A somatic mammalian cell contains ~1000-10,000 copies of mtDNA, 
which are continuously turned over and replicated during the entire cell cycle, 
displaying no strict phase specificity as is the case with nuclear DNA synthesis49. 
In mammals, oxidative stress results in stabilization of peroxisome proliferator -
activated receptor γ-coactivator 1α (PGC1α), which activates the transcription of 
several nuclear encoded transcription factors, including nuclear respiratory factor 
1 (NRF1). PGC1α and NRF1 form a complex that in turn up-regulates 
transcription of transcription factor of activated mitochondria (TFAM) and multiple 




Figure 1.7: Map of human mtDNA. Transcription starting at the Light strand 
promoter (LSP) produces the NADH-ubiquinone oxidoreductase chain 6 (ND6) 
mRNA molecule and primers for initiations of DNA synthesis at OH, whereas 
heavy strand transcription is initiated from two sites, H1 and H2. Each of the 
protein and rRNA genes is immediately flanked by at least one tRNA gene, and 
excision of tRNA molecules is required to produce mature mRNA and rRNA 
molecules. Key abbreviations: HSP, heavy strand promoter; LSP, light strand 
promoter, OH, origin of replication of the heavy strand; OL, origin of replication of 
the light strand; H1, heavy strand promoter 1; H2, heavy strand promoter 2. 
Figure taken from Falkenberg M et al, DNA Replication and Transcription in 




1.4.4 Mitochondria in inflammation 
As previously mentioned, mtDNA has many similarities with bacterial DNA 
because of their shared common ancestry. Increasing evidence demonstrates 
mtDNA to be a potent danger signal that is recognised by the innate immune 
system and can directly modulate the inflammatory response through 
inflammatogenic unmethylated CpG motifs51-53. Freely circulating mtDNA can be 
detected, and studies have associated mtDNA in plasma and serum with several 
diseases including HIV54, rheumatoid arthritis55, septic shock56, liver failure57, 
stroke58-60, several types of cancer61-63 and heart disease64-67. 
In the heart, damaged mitochondria are usually degraded by autophagy, which 
acts as an adaptive mechanism to protect the tissues from haemodynamic 
stress33, and involves the sequestration of cytoplasmic contents in a double-
membraned vacuole, the autophagosome and the fusion of the autophagosome 
with the lysosome68. A recent study showed that when mitochondrial DNA 
escapes from the autophagy process, it can be recognized by TLR9 receptors, 
thereby triggering the cascade of signals that lead to inflammation and contribute 
to heart failure36. Thus, mtDNA methylation may also play a role in its ability to 





1.5.1 Definition and epigenetic marks 
An epigenetic mechanism is defined as any mitotically heritable change which 
does not alter the genomic sequence but results in different gene expression 
potential69. In mammalians, all cells in the body carry the same DNA complement, 
and highly orchestrated epigenetic mechanisms facilitate the complex patterning 
required to ensure normal development and support stable regulation of 
appropriate patterns of gene expression in diverse cell types. All these 
mechanisms are highly regulated by a large number of proteins that establish, 
read, and erase specific epigenetic modifications, thereby defining where and 
when transcriptional machinery can access the primary DNA sequences to drive 
normal growth and differentiation. 
In the nucleus, there are several types of epigenetic marks that work in concert 
in order to drive appropriate gene expression: DNA methylation70 and 
modifications of histone proteins71 (Figure 1.8) are the main marks, but non-
coding RNAs (ncRNAs)72 and other complementary and unique mechanisms also 
exist73,74. Though these mechanisms are often described separately, it is worth 
mentioning that there is cross-talk between the different marks to regulate the 
epigenome75,76. Epigenetic mutations that arise can lead to a variety of disorders, 
and environmental factors such as maternal starvation during foetal development 
can result in epigenetic alterations that persist through adulthood and can 
contribute to late-onset disorders such as cardiovascular disorders and type 2 
diabetes77-79. 
Recently, the ENCODE (ENCyclopedia Of DNA Elements) Project was born as 
a large collaborative effort to define all of the functional elements in the human 
genome, and over the past few years several data sets of transcription, histone 
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modifications, and additional protein binding data were published80,81. Since this 
project’s main focus is the methylation of mtDNA sequences, the phenomenon of 
DNA methylation will be described in detail in the upcoming chapter. 
 
 
Figure 1.8: Covalent modifications of histone proteins and DNA methylation. 
Histone modifications are regulated by several enzymes including hystone 
acetyltransferases (HACs) and deacetylases (HDACs). Acetylation of histone 
proteins results in a relaxed state of chromatin (euchromatin) and is associated 
with active transcription, whilst deacetylation of histone proteins and methylation 
of DNA is a hallmark of a condensed state of chromatin (heterochromatin), which 
is associated with transcriptional repression. Abbreviations: HACs, histone 
acetyltransferases; HDACs, hystone deacetylases; DNMTs, DNA 
methyltransferases. Figure taken from Inbarg-Feigenberg M. et al, Basic 




1.5.2 DNA methylation principles 
Among the epigenetic processes, DNA methylation is the best understood 
epigenetic adaption and the most common DNA modification83. DNA methylation 
at the 5 position of cytosine has the specific effect of reducing gene expression 
and has been found in every vertebrate examined. In adult somatic cells, DNA 
methylation typically occurs in a CpG dinucleotide context, as non-CpG 
methylation is prevalent in embryonic stem cells84. 
This reversible process is a result of the enzymatic activity of the DNMT family, 
which catalyses the transfer of a methyl group from S-adenosyl methionine (SAM) 
to cytosines in CpG dinucleotides. First, methionine receives an adenosine group 
from ATP, a reaction catalysed by S-adenosyl-methionine synthetase, to give 
SAM. SAM then transfers the methyl group to an acceptor molecule, (i.e., DNMT 
as an intermediate acceptor in the process of DNA methylation). Two methylated 
cytosine-derived bases, 5-methylcytosine (5mC) and 5-hydroximethylcytosine 
(5hmC), have been detected in the DNA. 5mC is derived from incorporation of a 
methyl group at position 5 of cytosine (mediated by DNMTs), whereas 5 hmC is 
produced from 5mC through a hydroxymethylation reaction catalysed by the Ten-
Eleven translocation (TETs) family of proteins85 (Figure 1.9). 
 
 
Figure 1.9: Cytosine methylation and hydroxymethylation. Abbreviations: DNMT, 
DNA methyltransferase; SAH, S-Adenosyl Homocysteine; SAM, S-Adenosyl 
Methionine; TET, Ten-Eleven translocation methylcytosine dioxygenase. 
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1.5.3 DNA methyltransferases 
The DNMT family of enzymes catalyse the transfer of a methyl group to DNA. 
DNA methylation serves a wide variety of biological functions, and all the known 
DNA methyltransferases use SAM as the methyl donor. DNMTs can be divided 
into three different groups on the basis of the chemical reactions they catalyse: 
 
- m6A, that generate N6-methyladenine 
- m4C, that generate N4-methylcytosine 
- m5C, that generate C5-methylcytosine 
 
The first two groups of methyltransferases (m6A and m4C) are only found in 
prokaryotes and will not be discussed. On the other hand, C-5 cytosine-specific 
DNA methyltransferases (m5C) are found in some lower eukaryotes, in most 
plants, and in animals. These methyltransferases can specifically methylate the 
C-5 carbon of cytosines in DNA to produce C5-methylcytosine86. Three active 
DNMTs have been identified in mammals: DNMT1, DNMT3A, and DNMT3B. A 
fourth enzyme of the same family, previously known as DNMT2, is not a DNA 
methyltransferase as it does not have enzymatic activity87. DNMT3A and 
DNMT3B are “de novo” methyltransferases and can methylate unmethylated 
cytosines. These enzymes are mainly expressed in early embryonic development 
and set up the pattern of methylation88. DNMT1 is the most abundant DNA 
methyltransferase in mammalian cells, and considered to be the key 
maintenance methyltransferase in mammals89. This maintenance 
methyltransferase adds methylation to DNA when one strand is already 
methylated. DNMT1 works throughout the life of the organism to maintain the 
methylation pattern that had been established by the de novo methyltransferases.  
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1.5.4 DNMT1 in mitochondria 
Recently, Shock et al90 reported the presence of 5-hydroxymethylcytosine 
(5hmC), as well as revealing a 5’ flanking genomic DNA sequence upstream of 
the published transcription start sites91 for both human and mouse DNMT1 which 
was in-frame with the highly conserved amino acid sequence of DNMT1. This 
upstream sequence includes two additional in-frame codons for methionine 
(ATG), each in a moderate context for ribosome binding. Overexpression of this 
1st-to-3rd ATG sequence (both mouse and human sequence) in NIH/3T3 cells 
resulted in mitochondrial localisation of this leader peptide, however the study did 
not attempt to overexpress the full length DNMT1 cDNA with the 1st-to-3rd ATG 
sequence90. Furthermore, following a tandem affinity purification (TAP) 
experiment and isolation of mitochondrial fraction, they performed qPCR with 
mtDNA specific primers and showed that DNMT1 can bind mtDNA and change 
the transcription of mitochondrial-encoded proteins such as ND1 (NADH 
dehydrogenase subunit 1) and ND6 (NADH dehydrogenase subunit 6)90. Finally, 
this study confirmed the absence of other DNMTs, such as DNMT3A or DNMT3B, 
in the mitochondrial environment. 
 
1.5.5 Mitochondrial epigenetics and cardiovascular diseases 
From an era of identifying genetic markers to predicting risk of an individual for 
cardiac disease, genomic research has been heading toward understanding the 
pathophysiology of cardiovascular diseases (CVDs). CVDs are influenced by 
several genetic and environmental factors92, and contribution by epigenetic 
mechanisms is known to be involved in the pathogenesis of several CVDs, 




Several studies have shown that mtDNA is susceptible to 5mC and 5hmC 
modification51,90,98-101, and since unmethylated mtDNA is partially responsible for 
triggering a TLR9-mediated inflammatogenic response, control over its 
methylation appears to be a potential therapeutic target for heart failure. The 
mitochondrial genome has already been used in studies of molecular evolution 
and, based on mtDNA mutations, as a biomarker101,102. Additionally, regulation of 
mitochondrial epigenetics (mitoepigenetics) has shown to have applications in 
diagnostics, and could also contribute to therapeutics as a predictor of response 
to therapy103. 
In conclusion, it is becoming apparent that research in the field of mitochondrial 
epigenetics has the tools to improve our understanding of the role of epigenetics 
in the complex mechanisms of regulation of inflammation and cardiovascular 
diseases, and it is expected that mitoepigenetics will provide a new conceptual 
vantage point to view mitochondria not only as an integral part of cell biology, but 





1.6 Research hypothesis and aims 
The hypothesis of this study is that DNMT1 might affect mtDNA methylation 
patterns, thus affecting stimulation of TLR9 by mtDNA containing unmethylated 
CpG motifs and production of proinflammatory cytokines. Therefore, the aim of 
this study is to elucidate the role of a DNA methyltransferase, DNMT1, at a 
mitochondrial level. To achieve this aim, my objectives were to: 
 
1. Obtain DNMT1 overexpression plasmids with different features. 
2. Confirm DNMT1 ability to localise at a mitochondrial level. 
3. Investigate the methylation status of mtDNA following DNMT1 
overexpression. 
4. Develop and refine new tools for DNMT1 overexpression 









2.1 Cell culturing 
2.1.1 HEK293A cells 
Human embryonic kidney cells (HEK293A, Invitrogen Life Technologies®) were 
cultured in 75 cm2 “T75” flasks (Thermo Fisher Scientific®, 178905) with 
Dulbecco’s modified eagle medium (DMEM, Sigma-Aldrich® D6546) containing 
10% foetal bovine serum (FBS, Gibco®, 10270-106) and 1% L-Glutamine-
Penicillin-Streptomycin solution (PSG, Sigma-Aldrich®, G1146). Cells were 
incubated at 37oC with 5% CO2 and passaged at approximately 80% confluency. 
To passage cells, media was aspirated off the flask, and 5 ml phosphate buffered 
saline (PBS, Sigma-Aldrich®, D8537) was used to rinse the cells. 5 ml 0.5 M 
Ethylenediaminetetraacetic acid (EDTA) was added to the cells, which were then 
incubated for 5 minutes at 37oC. Then, 5 ml culture medium were added and the 
suspended cell solution was collected in a 15 ml Falcon™ conical centrifuge tube 
(Fisher Scientific®, 339650) and centrifuged at 100 g for 5 minutes. The 
supernatant was discarded and the pellet of cells was resuspended in 10 ml of 
pre-warmed culture medium. Finally, 2 ml of cell mixture was diluted with 8 ml of 
culture medium and seeded into a new T75 flask. 
 
2.1.2 H9C2 cells 
Rattus norvegicus cardiomyoblasts (H9C2, ATCC® CRL-1446™) were cultured 
in 75 cm2 “T75” flasks with DMEM containing 10% FBS and 1% PSG. Cells were 
incubated at 37oC with 5% CO2 and passaged at approximately 80% confluency. 
To passage cells, media was aspirated off the flask and 5 ml PBS was used to 
rinse the cells. 1ml Trypsin-EDTA solution (Sigma-Aldrich®, T4049) was diluted 
in 4 ml PBS and added to the cells, which were then incubated for 5 minutes at 
37oC. Then, 5 ml culture medium were added and the suspended cell solution 
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was collected in a 15 ml Falcon™ conical centrifuge tube and centrifuged at 100 
g for 5 minutes. The supernatant was discarded and the pellet of cells was 
resuspended in 10 ml of pre-warmed culture medium. Finally, 2 ml of cell mixture 
was diluted with 8 ml of culture medium and seeded into a new T75 flask. 
 
2.1.3 MCE cells 
Mouse cardiac endothelial cells (MCEC, CEDARLANE®, CLU510) were cultured 
in 175 cm2 “T175” flasks (Thermo Fisher Scientific®, 178883) with DMEM 
containing 5% FBS, 1% 200mM L-Glutamine solution (Sigma-Aldrich®, G7513) 
and 1% 1M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 
Gibco®, 15630080). Cells were incubated at 37oC with 5% CO2 and passaged at 
approximately 80% confluency. To passage cells, media was aspirated off the 
flask and 10 ml PBS was used to rinse the cells. 2ml Trypsin-EDTA solution were 
diluted in 8 ml PBS and added to the cells, which were then incubated for 5 
minutes at 37oC. Then, 10 ml culture medium were added and the suspended 
cell solution was collected in a 50 ml Falcon™ conical centrifuge tube (Fisher 
Scientific®, 339650) and centrifuged at 100 g for 5 minutes. The supernatant was 
discarded and the pellet of cells was resuspended in 10 ml of pre-warmed culture 
medium. Finally, 2 ml of cell mixture was diluted with 18 ml of culture medium 




2.2 Molecular cloning and subcloning principles and 
methods 
Molecular cloning is an umbrella term that is defined as a set of experimental 
methods of molecular biology that are used to assemble recombinant DNA 
molecules and to direct their replication within host organisms (i.e. bacteria). 
Subcloning is a technique used to move a particular DNA sequence from a parent 
vector to a destination vector. Restriction enzymes are used to excise the gene 
of interest (the insert) from the parent. The insert is then purified in order to isolate 
it from other DNA molecules. The same restriction enzymes can also be used to 
digest (cut) the destination. The idea behind using the same restriction enzymes 
is to create complementary sticky ends, which will facilitate ligation later on. 
Below follows the list of the cloning techniques that have been used to obtain the 
plasmid vectors:  
 
 Bacterial transformation 
 Mini and maxi preparations 
 Enzyme digestion 
 DNA gel electrophoresis 
 DNA gel extraction 
 DNA ligation 
 DNA sequencing 
 
2.2.1 Bacterial transformation 
Bacterial transformation was performed using MAX Efficiency® DH5α™ 
competent cells (Thermo Fisher Scientific®, 18258012) in order to amplify the 
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constructs at the end of each cloning step. Briefly, DH5α™ cells were thawed on 
ice for 2 minutes, then 1-2 μl of sample (corresponding to 50-500 ng of construct) 
was added to the cells, and the mixture was incubated on ice for another 10-30 
minutes. After this, in order to allow the construct to enter the bacterial 
membrane, heat shock at 42ºC was applied for 45 second. Then the cells were 
put on ice for another 3 minutes, resuspended in 1 ml S.O.C. Medium (Thermo 
Fisher Scientific®, 15544034) and incubated at 37ºC for 1 hour. Finally, the cells 
were spinned at 8000 rpm for 3 minutes, 900 μl of supernatant was discarded 
and the pellet was resuspended in the remaining 100 μl, plated onto LB agarose 
plates with antibiotic selection (depending on the construct) and incubated 
overnight at 37ºC. 
The antibiotic allows for positive selection of colonies formed from single cells 
carrying the construct of interest which is expressing the antibiotic resistance 
gene and therefore allows the cells to survive. The next day, colonies were 
harvested with a toothpick and incubated in 2 ml LB medium (with antibiotic 
selection) overnight at 37ºC. LB agarose plate and LB medium composition are 
shown (Table 2.1 and Table 2.2). 
 
Table 2.1: LB plates reagents. All reagents were added in a 500 ml heat-resistant 
glass bottle and autoclaved. Then, after cooling down, antibiotic was added and 
the mixture was poured into sterile petri-dish and stored at 4ºC. 
LB Plates Amount 
LB Broth powder (Sigma Aldrich®, L3522) 12.5 g 
Bacto Agar (BD®, 214010) 7.5 g 




Table 2.2: LB Broth reagents. All reagents were added in a 500 ml heat-resistant 
bottle and autoclaved. Then, after cooling down, the bottle was stored at 4ºC. 
For better antibiotic preservation, 50 ml working stocks were created. 
LB liquid Amount 
LB Broth powder (Sigma Aldrich®, L3522) 12.5 g 
dH2O 500 ml 
 
2.2.2 Mini preparations (Miniprep) 
The plasmids were extracted from the cells using QIAprep® Spin Miniprep Kit 
(Qiagen®, 27106). A benchtop centrifuge (Eppendorf®, 5415R) was used for all 
the centrifuging steps. 
For each colony, 1 ml of the LB medium containing DH5α™ cells was collected 
in a 1.5 ml Eppendorf tube and centrifuged at 8000 rpm for 3 minutes. 
Supernatant was discarded. The pellet was resuspended in 250 μl Buffer P1 with 
RNase A (100 μg/ml) and lysed with 250 μl Buffer P2. Then, to release the 
plasmid DNA, 350 μl of precipitation Buffer N3 were added to the samples and 
centrifugation at 13,000 rpm for 10 minutes was performed. Supernatant 
containing the plasmid DNA was applied to a QIAprep 2.0 spin column by 
pipetting and centrifuged at 13,000 rpm for 1 minute in order to bind it to the 
column. The column was then washed with 750 μl Buffer PE and centrifuged 
twice at 13,000 rpm for 1 minute to remove the residua wash buffer. Finally, 30 
μl of dH2O were applied onto the column and the DNA was eluted and collected 
in a clean 1.5 microcentrifuge tube through incubation at room temperature for 5 
minutes and centrifugation at 13,000 rpm for 1 minute. The DNA concentration of 
the sample was measured through a NanoDrop 2000 UV-Vis Spectrophotometer 




2.2.3 Enzyme digestion 
Every subcloning step was performed by digesting the sequence of interest with 
the following conditions: 
 
 Up to 1/10 ratio of digestion enzymes in 20 μl final volume 
 200-500 μg of DNA 
 2 μl of digestion buffer (New England Biolabs) 
 1.5 hrs incubation at 37ºC 
 
2.2.4 DNA gel electrophoresis 
Following DNA digestion, DNA gel electrophoresis was performed running the 
samples at 120V for 30 minutes with Tris/borate/EDTA (TBE) buffer (Table 2.3) 
in 1% agarose gel using PowerPac™ Basic Power Supply (Bio-Rad™, 1645050). 
 
Table 2.3: 10X TBE buffer solution reagents. 
TBE buffer solution reagents Amount 
Trizma base 108 g 
Boric acid 55 g 
0.5M EDTA 40 ml 
dH2O 960 ml 
 
2.2.5 DNA gel extraction 
DNA was extracted from the gel using a QIAquick™ gel extraction kit (Qiagen®, 
28704). Relevant DNA bands were visualized under UV light, cut from the gel 
and weighed. Then, 3 volumes of Buffer QG were added and the mixture was 
incubated at 50ºC for 10 minutes. Following incubation, 1 volume of isopropanol 
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was added to the sample, and the mixture was applied to a QIAquick spin column 
and centrifuged at 13,000 rpm for 1 minute, capturing the DNA fragments on the 
column. The column was then washed with 750 μl Buffer PE and centrifuged 
twice at 13,000 rpm for 1 minute. Finally, the DNA was eluted from the column 
by adding 30 μl water and centrifuging at 13,000 rpm for 1 minute. The DNA 
sample was then stored at -20ºC, or used for ligation. 
 
2.2.6 DNA ligation 
DNA ligation steps were performed using a T4 DNA ligase kit (Takara®, 2011) 
(Table 2.4). After mixing all reagents together, standard ligation was achieved 
through overnight incubation at 16ºC. The final DNA sample was then used for 
the next cloning step, starting from DH5α transformation once again. Sequencing 
steps have been performed by Source BioScience Labs (Cambridge). 
 
Table 2.4: Reaction mixture for DNA ligation. 
Reagent Amount 
T4 DNA ligase 4 μl 
DNA insert 3 μl 
DNA plasmid 1 μl 
 
2.2.7 Maxi preparations (Maxiprep) 
After obtaining the final constructs, they were amplified through maxi 
preparations (maxiprep) in order to obtain enough DNA amounts for 
overexpression experiments. Maxiprep was performed according to QIAGEN 
Plasmid Maxi Kit protocol (QIAGEN®, 12165), using a Sorvall® Legend RT large 
bench centrifuge (Sorval®, 75004373) and a high-speed Sorvall® RC-6 Plus 
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centrifuge (Sorvall®, 46910) with a Sorvall® SA-600 rotor (Sorvall®, SO-SA600). 
The high-speed centrifuge step was performed at 16500g by using Nalgene™ 
Oak Ridge High-Speed PPCO centrifuge tubes with sealing cap (Thermo Fisher 
Scientific®, 3139-0050). 
 
2.2.8 Cloning vector: pBluescript II KS(+) features 
All the subcloning steps have been performed using a pBluescript II KS (+) 
(Figure 2.1), which is a cloning vector that was designed to simplify commonly 
used cloning and sequencing procedures (determining expression and 
developing genomic libraries are some applications for which it can be used). 
It contains a multiple cloning site sequence (MCS) with 18 unique restriction 
enzyme recognition sites and an antibiotic (ampicillin) resistance sequence for 
selection. Since this vector does not have a mammalian origin of replication, it 
cannot be used as an expression vector in mammalian cells. 
 
Figure 2.1: pBluescript II KS(+) features. The vector contains a gene for ampicillin 




2.2.9 Expression vector: pCMV-SPORT6 features 
The backbone vector that was used for expressing the different DNMT1 isoforms 
in mammalian cells is pCMV-SPORT6 (Figure 2.2). This vector can be directly 
used for expression of genes under the control of CMV promoter in mammalian 
cells, and it’s a gateway-adapted mammalian expression vector. In pCMV-
SPORT6, the expression of the insert is driven by the CMV promoter. In the 
sequence there is also a MCS with 16 unique restriction enzyme recognition sites 
and an antibiotic (ampicillin) resistance gene for screening. 
 
Figure 2.2: pCMV-SPORT6 features. The vector contains a gene for ampicillin 
resistance and a MCS, as well as M13 and T7 sites for sequencing. Furthermore, 




2.2.10 Original Nuclear DNMT1 vector features  
An expression vector containing the mouse sequence for nuclear Dnmt1 was 
received from Japan, courtesy of Prof. Tajima (University of Osaka). The plasmid 
vector carries a CAG promoter, which is a strong synthetic promoter frequently 
used to drive high levels of gene expression in mammalian expression vectors, 
and the full length mouse nuclear DNMT1 cDNA sequence (which also carries a 
predicted internal nuclear localisation signal, NLS) with Myc-tag and a NLS at 5’ 
region. The mouse nuclear cDNA DNMT1 sequence contains EcoRI sites at both 
5’ and 3’ ends (Figure 2.3) which have been modified by introducing two single 
nucleotide mutations in the internal EcoRI digestion sites (Figure 2.4), but the 
amino acid sequence was not changed from these mutations.  
 
Figure 2.3: Restriction enzyme map from Mus musculus (mouse) DNMT1 original 
cDNA sequence. EcoRI mutations were performed at 150 bp and 4152 bp. 5' and 
3' fragments are highlighted (red and green) and separated by an XhoI site, which 




Figure 2.4: Overview of Prof. Tajima's cloning strategy. The vector contains a 
gene for ampicillin resistance and a MCS, as well as the mouse DNMT1 
sequence. Furthermore, a CMV enhancer and CAG promoter for mammalian 
overexpression are also present. 
 
2.3 Plasmid DNA transfection 
2.3.1 Calcium phosphate protocol 
Cells were seeded on 15 cm2 Cellstar® tissue culture dishes (VWR®, 82050-598) 
and transfected at about 60-70% confluence. Two dishes were used for each 
transfection condition. The reagents used for the 2xBBS solution for calcium 




Table 2.5: 2xBBS Solution reagents. 
2X BBS Solution reagents  
NaCl (Sigma-Aldrich®, S7653) 1.6 g 
Na2HPO4 (Sigma-Aldrich®, S7907) 0.021 g 
BES (Sigma-Aldrich®, B4554) 1.1 g 
dH2O To 100 mL 
 
Briefly, 32 μg of DNA was resuspended in a tube containing 248 μl of 2M Calcium 
chloride (CaCl2) solution (Sigma-Aldrich®, 449709) and 1.72 ml of dH2O. Then, 
the solution was resuspended dropwise in 2 ml of 2x BBS solution and incubated 
at room temperature for 15 minutes. Following incubation, the final solution was 
poured dropwise onto the 15 cm2 tissue culture dishes (2 ml per dish), then the 
dishes were incubated at 37ºC, 5% CO2 for 48 hours prior to subcellular 
fractioning, with a change of culture medium 18 hours after transfection. 
 
2.3.2 FuGene HD® protocol 
For immunocytochemistry purposes, HEK293A cells were seeded in 12 well 
Corning® Costar® cell culture plates (Sigma Aldrich®, CLS3513). A collagen 
coated cover slip was added to the wells, then 20,000 cells/well were seeded in 
1 ml DMEM 10% FBS, 1% PSG per well, and incubated overnight at 37ºC with 
5% CO2. Subsequently, cells were transfected with 1 μg of DNA for each well by 
adding 50 μg of transfection complex (8.8 μg DNA in 414 μl dH2O and 26 μl 




2.4 Immunocytochemistry and imaging 
2.4.1 Staining, fixation and antibody incubation 
Following transfection, the medium was removed from the wells, and each well 
was incubated for 15 minutes at 37ºC with 500 μl of culture medium with 250 nM 
MitoTracker® Red CMXRos staining solution (Thermo Fisher Scientific®, 
M7512). Staining solution was then removed and cells were fixed with a 4% 
paraformaldehyde PBS solution and incubated for 15 minutes at 37ºC. PBS 
solution was then removed and cells were washed three times with a PBS-G 
solution (PBS with 100mM Glycine). After removing PBS-G solution, cells were 
incubated for 15 minutes at room temperature with 300 μl per well of 0.2% Triton-
X PBS solution. 
Prior to antibody incubation, cells were incubated with 500 μl per well of 2% 
Bovine Serum Albumin (BSA, Sigma-Aldrich®, A7906) PBS blocking solution for 
1 hour at room temperature. After removing the blocking solution, cells were 
incubated overnight at 4ºC with an HA-tag antibody (Cell Signalling Technology®, 
C29F4 Rabbit mAb #3724) diluted 1:1000 in a 2% BSA PBS solution. 
Subsequently, cells were washed three times with 1 ml per well of PBS solution 
with MgCa and incubated in the dark with 100 μl of a 1:1000 Alexa Fluor® 488 
Goat Anti-Rabbit IgG secondary antibody PBS solution with 0.1% BSA for 1 hour 
at room temperature. Finally, wells were washed with 1 ml PBS, and cover slips 
were removed for mounting. 
 
2.4.2 Mounting and cell imaging 
Cover slips were labelled and mounted with VECTASHIELD® Mounting Medium 
with DAPI (Vector Laboratories, H1200), and cell imaging was performed using 
Eclipse Ti-E Inverted microscope (Nikon®) with CSU-X1 Spinning Disk Confocal 
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and Andor Ixon3 EM-CCD camera. Following confocal microscopy experiments, 
mounted slides were stored at 4ºC with light shielding. 
 
2.5 Subcellular fractioning 
The protocol for subcellular fractioning was taken from Wieckowski et al (Nature 
Protocols, 2009) and modified as explained below. 
 
2.5.1 Buffers 
After obtaining primary (Table 2.6) and fractioning buffers (Table 2.7), they were 
stored at 4 ºC. Fractioning buffers were used within 1 month to avoid degradation 
of mannitol and sucrose. 
 
Table 2.6: Primary buffers for cell fractioning. 
Buffer Reagents 
0.5 M Hepes 5.96 g HEPES 
40 ml dH2O 
1M Tris 6.07 g Trizma base 
30 ml dH2O 
0.1M EGTA 3.8 g EGTA 
70 ml dH2O 
 
Table 2.7: Fractioning buffers for cell fractioning. 
Buffer Reagents 
IB-1 50 ml IB-2 buffer 
20 ul 0.1 M EGTA 
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IB-2 4.1 g mannitol 
2.6 g sucrose 
3 ml 1M Tris 
80 ml dH2O 
MRB 2.28 g mannitol 
500 ml 0.5M HEPES 
40 mL dH2O 
STM 4.28 g sucrose 
2.5 ml 1M Tris-HCl 
125 μl 2M MgCl2 
47.5 ml dH2O 
NET 2 ml 0.5M HEPES 
37.5 μl 2M MgCl2 
25 ml 1M NaCl 
20 μl 0.5M EDTA 
10 ml 100% glycerol 
5 ml 10% Triton-X 
8 ml dH2O 
 
2.5.2 Measurement of pH 
Buffers IB-1, IB-2 and MRB were equilibrated to pH 7.4 using a BASIC pH Meter 
(Denver Instrument). 
 
2.5.3 Initial fractioning protocol 
After removing the culture medium from the tissue culture dishes, the cells were 
washed in ice-cold PBS (10 ml for each 15 cm2 tissue culture dish). PBS was 
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then aspirated and cells were scraped and collected in a 50 ml falcon tube with 
10 ml ice-cold PBS. Subsequently, samples were centrifuged for 5 minutes at 
600g (4ºC), PBS was withdrawn from the falcon tubes, and cell pellets underwent 
another cycle of resuspension and centrifuging. Finally, PBS was withdrawn from 
the falcon tubes and the cell pellets were resuspended in 400 μl IB-1 buffer, and 
homogenized with a Teflon-glass homogenizer-potter system undergoing 10x 2 
seconds-long stroke/pause cycles at 1000 rpm. 
Homogenized cells were moved into a new 1.5 ml Eppendorf tube (tube #1), 
where 10 up-and-down pipetting cycles with a 1 ml tip were performed. After that, 
samples were centrifuged for 3 minutes at 500g (4ºC), and supernatant was 
moved to a fresh 1.5 ml Eppendorf tube (tube #2). Pellet from tube #1 was 
resuspended in 350 μl IB-1 buffer with 20 up-and-down pipetting cycles using a 
1 ml tip, and centrifuged for 3 minutes at 500g (4ºC). Supernatant was added to 
tube #2. Again, remaining pellet from tube #1 was resuspended in 300 μl IB-1 
buffer with 20 up-and-down pipetting cycles using a 1 ml tip, and centrifuged for 
3 minutes at 500g (4ºC). Supernatant was added to tube #2. Then, final pellet 
from tube #1 was used to isolate nuclear fraction. 
 
2.5.4 Mitochondrial fractioning 
Tube #2 was centrifuged for 5 minutes at 600g (4ºC) and supernatant was moved 
to a fresh 1.5 ml Eppendorf tube (tube #3). Tube #3 was then centrifuged for 10 
minutes at 7000g (4ºC), supernatant was discarded and the remaining pellet was 
resuspended in 500 μl IB-2 buffer and centrifuged for 10 minutes at 7000g (4ºC). 
Supernatant was discarded once more, and the remaining pellet containing the 
purified mitochondrial fraction was resuspended in 50 μl MRB buffer and moved 
to a fresh 1.5 ml Eppendorf tube.  
71 
 
2.5.5 Nuclear Fractioning 
Pellet from tube #1 was resuspended in 500 μl STM buffer with protease inhibitors 
(PI) (Sigma-Aldrich®, P8340) and centrifuged for 15 minutes at 800g (4ºC). The 
supernatant was discarded, and the remaining pellet was resuspended in 300 μl 
STM buffer with PI, vortexed for 15 seconds, and centrifuged 15 minutes at 500g 
(4ºC). Again, supernatant was discarded and pellet was resuspended in 300 μl 
STM buffer with PI, vortexed for 15 seconds, and centrifuged for 15 minutes at 
1000g (4ºC). Supernatant was discarded once more, and pellet was resuspended 
in 200 μl NET buffer with PI, vortexed for 15 seconds, and let rest on ice for 30 
minutes. After that, solution was sonicated for 15 seconds and centrifuged for 30 
minutes at 9000g (4ºC). Finally, the supernatant containing the nuclear fraction 
was moved to a new 1.5 ml Eppendorf tube. 
 
2.6 Protein extraction from whole cell lysates 
Cells were cultured in 6 well Corning® Costar® cell culture plates (Sigma-Aldrich, 
CLS3516). Lysis buffer containing a protease inhibitor (PI) cocktail was prepared 
(Table 2.8). Culture medium was aspirated and the wells were washed with 1 ml 
ice-cold PBS each. Cells were then scraped, collected in a fresh 1.5 ml Eppendorf 
tube and centrifuged at 13000 rpm and 4ºC for 5 minutes. Supernatant was 
discarded, and the pellet was resuspended in 50 μl cold lysis buffer. Samples 
were sonicated for 10 seconds using a SFX 150 Branson Sonifier® (Emerson®) 
and centrifuged at 13000 rpm and 4ºC for 5 minutes. Then, the supernatant 
containing the protein fraction was moved to a new 1.5 ml Eppendorf tube and 





Table 2.8: Lysis buffer reagents. 
Reagent Final concentration 
Tris-HCl (pH7.4) 50 mM 
NaCl 150 mM 
EDTA 1 mM 
EGTA 1 mM 
Na Orthovanadate 2.5 mM 
Na Pyrophosphate 2.5 mM 
Na β-glycerophosphate 1 mM 
TritonX-100 1% 
PMSF 1 mM 
Protease Inhibitors 1:1000 
 
2.7 Protein quantification 
Protein quantification was performed using a Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific®, 23225). Briefly, 10 μl of each protein sample were 
diluted 5 fold in lysis buffer with protease inhibitors (PI). Then, 20 μl of 1:5 
samples were incubated with 160 Pierce™ Reagent A/Reagent B working 
solution at 37ºC for 30 minutes, using a 96 well Corning® Costar® cell culture 
plate (Sigma-Aldrich®, CLS3595). BCA standards were used for comparison. 
Then, the 562 nm absorbance was measured using an Infinite® 200 PRO 
absorbance reader (Tecan Life Sciences), and the samples’ values were then 
interpolated with the standard values in order to determine the protein 




2.8 Western blotting 
2.8.1 Sample preparation and SDS-PAGE 
After measuring the protein concentration, 20-30 μg of protein sample was mixed 
with 5x sample buffer (Table 2.9) with 5% 2-mercaptoethanol (2-ME, Sigma-
Aldrich®, M3148). Samples were either heated to 95ºC for 5 minutes, then loaded 
onto 7.5% and 10% Sodium dodecyl sulphate (SDS) gels (Table 2.10) with SDS-
PAGE buffer (Table 2.9) and Precision Plus Protein Dual Xtra Standards (Bio-
Rad®, 161-0377) and Sodium dodecyl sulphate-Polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed for 80 minutes at 120 V.  
 
Table 2.9: List of solutions used for sample preparation and Western blotting. 
Buffer Reagents 
Sample buffer (5X) 10 ml 0.1% bromophenol blue 
5 ml 1M sodium phosphate (pH 7.0) 
50 ml glycerol 
2 g SDS powder 
dH2O to 100 ml 
SDS-PAGE buffer 3 g Tris 
14.5 g glycine 
1 g SDS powder 
dH2O to 1 l 
Transfer buffer 2.9 g Tris 
14.5 g glycine 
200 ml methanol 
dH2O to 1 l 
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TBS 2.42 g Tris 
8 g NaCl 
HCl to pH 7.4 
dH2O to 1 l 
TBS-T TBS with 0.1% Tween20 
 
Table 2.10: List of gels for Western blotting 
Gel type Reagent 
7.5% SDS-Page 1.5 ml 30% acrylamide 
1.5 ml 1.5 M Tris HCl (pH 8.8) 
30 μl 20% SDS 
45 μl 10% ammonium persulfate 
15 μl TEMED 
dH2O to 6 ml 
10% SDS-Page 2 ml 30% acrylamide 
1.5 ml 1.5 M Tris HCl (pH 8.8) 
30 μl 20% SDS 
45 μl 10% ammonium persulfate 
15 μl TEMED 
dH2O to 6 ml 
Stacking gel 0.9 ml 30% acrylamide 
1.5 ml 0.5 M Tris HCl (pH 6.8) 
30 μl 20% SDS 
45 μl 10% ammonium persulfate 
20 μl TEMED 
dH2O to 6 ml 
75 
 
2.8.2 Wet transfer and densitometric analysis 
Proteins were transferred from SDS-PAGE onto nitrocellulose membrane 
(Thermo Fisher Scientific®, 15269794) at 0.2 A for 2 hours with transfer buffer 
(Table 2.9). After transfer, the membrane was rinsed twice with TBS (Table 2.9) 
and blocked for 1 hour at room temperature using Odyssey® blocking buffer (LI-
COR Biosciences®, 927-40000). After blocking, membranes were incubated 
overnight at 4ºC with the primary antibody diluted in the blocking reagent. Next 
day, the membranes were washed as described earlier, followed by secondary 
antibody incubation at room temperature for 1 hour. Membranes were washed as 
before and developed using the Odyssey Clx imager (LI-COR Biosciences®). 
Image Studio Lite software version 5.2 (LI-COR Biosciences®) was used to 
analyse images and perform densitometric analysis. Primary and secondary 
antibodies used for Western blotting are listed (Table 2.11). 
 







Rabbit anti-mouse/human DNMT1 1:1000 CST, 5032 
Rabbit anti-mouse/human DNMT3A 1:1000 CST, 2160 
Rabbit anti-HA tag 1:1000 CST, 3724 
Mouse anti-mouse/human αtubulin 1:5000 CST, 3873 
Mouse anti-human lamin A/C 4C11 1:2000 CST, 4777 
Rabbit anti-mouse/human VDAC 1:1000 CST, 4661 
Goat anti-rabbit IRDye 800CW 1:15000 Li-Cor, 925-32211 




Miniprep samples were resuspended in UltraPure™ DNase/RNase-free distilled 
water (Thermo Fisher Scientific®, 10977-35) in a final concentration of 100 ng/µl, 
then labelled and shipped to a Source BioScience facility where Sanger 
sequencing was performed overnight. Sequencing data was received through 
email, and analysed using BioEdit Sequence Alignment Editor Software. 
 
2.10 Software for plasmid design 
All figures of plasmid have been created using SnapGene® software (from GSL 
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3.1.1 DNA (cytosine-5)-methyltransferase 1 (DNMT1) overview and 
methylation features 
The DNA of vertebrates contains tissue-specific patterns of methylated cytosine 
residues, which are transmitted though the activity of DNA (cytosine-5)-
Methyltransferase 1 (DNMT1) on hemimethylated DNA104. DNMT1 is the most 
abundant DNA methyltransferase in mammalian cells, and considered to be the 
key maintenance methyltransferase in mammals89. Maintenance 
methyltransferases add methylation to DNA when one strand is already 
methylated, and work throughout the life of the organism to maintain the 
methylation pattern that had been established by the de novo methyltransferases  
(DNMT3A and DNMT3B)88. The crystal structures of both mouse and human 
DNMT1 protein have been solved. These two proteins share 85% sequence 
identity and similar structure, which suggest a common mechanism of action105. 
Mouse DNMT1 is a 1620 residue multimodular protein composed of a replication 
foci-targeting domain (RFD), a DNA-binding CXXC domain, a pair of bromo-
adjacent homology (BAH1 and BAH2) domains, and a C-terminal catalytic 
domain with methyltransferase activity that also contains a Target recognition 
domain (TRD) 105 (Figure 3.1 and Figure 3.2). 
The first 1,100 amino acids constitute the regulatory domain of the enzyme, and 
the remaining residues constitute the catalytic domain. Both domains are 
required for the catalytic function of DNMT1. All sequence specific contacts with 
DNA are made via the CXXC domain (residues 650-699), which targets both the 
major and minor groove of the DNA over a CpG-containing 4-bp footprint. A loop 
segment (Arg684 -Ser685 -Lys686 -Gln687) from the CXXC domain penetrates 
into the major groove and forms base-specific and phosphodiester intermolecular 
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interactions. Lys686 and Gln687 contact the guanine bases in the CpG 
dinucleotide, whereas Ser685 Lys686 interact with the cytosine bases. However, 
these are not the only interactions made with the DNA, as the CXXC domain also 
contains recognition sites of salt bridges from arginines to the phosphodiester 
backbone of the DNA. The CXXC domain shares similarities with CXXC domains 
of histone methyltransferases106,107, and although it has been reported to 
specifically bind unmethylated CpG dinucleotides 107-109, it has been shown that 
the DNA is anchored by the CXXC domain in a position that is distant from the 
active site of DNMT1. This is the result of an auto inhibitory CXXC-BAH1 linker. 
Unmethylated DNA is excluded from the active site of mDNMT1 by the binding of 
the CXXC domain, whereas the presence of the acidic auto inhibitory CXXC-
BAH1 linker positioned directly between the DNA and the active site prevents 
entrance of DNA into the catalytic pocket; furthermore, the BAH2-TRD loop 
anchors the TRD in a retracted position and prevents it from binding in the DNA 
major groove. The CXXC domain also aids in the control of not interacting with 
methylated CpG sites by steric hindrance. If a methyl group were present on the 
CpG dinucleotide, it would unfavourably interact with Arg684 -Ser685 -Lys686 
residues due to steric interference with nearby peptide atoms. The BAH1 and 
BAH2 domains of mDNMT1 are connected by an α-helix (BAH linker) and are 
arranged in a dumbbell configuration, both physically associated with the 
methyltransferase domain. 
The methyltransferase domain of mouse DMNT1 is the main catalytic domain of 
the protein and folds into two subdomains, the TRD, and the catalytic core, which 
are separated by a large cleft in the protein, which is occupied by the DNA.  
Maintenance methylation is tightly coupled to DNA replication110, and 
unmethylated CpG sites are protected from de novo methylation through binding 
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by the CXXC domain as CpG dinucleotides emerge from the replication complex, 
thus increasing the efficiency of maintenance methylation through inhibition of de 
novo methylation. 
 
Figure 3.1: Structural overview of mDNMT1. The CXXC, BAH1, BAH2, and 
methyltransferase domain are coloured in red, light purple, orange and light blue, 
respectively. Adapted from Structure of DNMT1-DNA complex reveals a role for 
autoinhibition in maintenance DNA methylation, Song J et al, Science, 2011105. 
 
 
Figure 3.2: Ribbon representation of mouse DNMT1- S-adenosyl homocysteine 
(AdoHcy) complex in two orthogonal views. DNA and zinc ions are coloured in 
light brown and dark purple, respectively; CXXC-BAH1 linker in dark blue, BAH1-
BAH2 linker in silver, (GK)n-containing BAH2-methyltransferase linker in black, 
and bound AdoHcy as in space-filling representation. Figure taken from Structure 
of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA 




3.1.2 Protein transport mechanism in mitochondria 
Mitochondria have a retained complete genetic system in the matrix, however 
only ~1% of mitochondrial proteome is encoded by the mitochondrial genome 
and synthesized in the matrix111. Mitochondrion-encoded proteins form a few 
subunits of the respiratory chain complexes and are typically inserted into the 
inner membrane by an export and assembly machinery, called the oxidase 
assembly (OXA) machinery. The remaining 99% of the more than 1000 proteins 
constituting the mitochondrial proteome is encoded by nuclear genes, and 
includes genes that were transferred from the endosymbiont to the nucleus as 
well as genes for new mitochondrial proteins that arose during eukaryotic 
evolution; nucleus-encoded mitochondrial proteins are synthesized as precursors 
proteins on cytosolic ribosomes and imported into the organelle112. These 
proteins possess targeting signals that are recognized by receptors on the 
mitochondrial surface and direct the precursors to their functional destination in 
the mitochondrial sub compartment. Two main groups of targeting signals can be 
distinguished38,112,113: the first group is the amino-terminal extensions of 
precursors which represent the classical mitochondrion-targeting signals114-116, 
whilst other precursor proteins are not synthesized with cleavable extensions but 
contain internal targeting signals which remain part of the protein even after 
mitochondrial localisation.  
Precursor proteins are translated in the cytosol and are imported in mitochondria 
through 5 protein import pathways (Figure 3.3), with the translocase of the outer 
membrane (TOM) complex functioning as the main mitochondrial entry gate for 
both cleavable preproteins and most non-cleavable precursors, except for outer-
membrane proteins with α-helical transmembrane segments which are imported 
through the mitochondrial import (MIM) complex117. The classic import pathway 
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is termed “the presequence pathway”, in which the preproteins are imported by 
the TOM and translocase of the inner membrane (TIM23) complexes118,119. Then, 
the presequence translocase-associated motor (PAM) drives protein 
translocation into the matrix120 where the mitochondrial processing peptidase 
(MPP) cleaves off the presequences121. 
The four other protein import pathways are only used for precursor proteins wi th 
internal targeting signals. Depending on the nature of the internal targeting signal, 
the proteins can be internalised by carrier translocase of the inner membrane 
(TIM22)122, inserted into the outer membrane by the sorting and assembly 
machinery (SAM) proteins123 (for β-barrel proteins), or imported via the 
mitochondrial import and assembly (MIA) machinery of the intermembrane 





Figure 3.3: Overview of the five major protein import pathways of mitochondria. 
The presequence pathway starts with the recognition of the presequence protein 
by the TOM. Following internalisation in the IMS, the protein gets translocated to 
the matrix after interaction with the TIM23 complex. Once inside the matrix, the 
presequence is cleaved from the protein by the MPP. Abbreviations: TOM, 
translocase of the outer membrane; TIM23, translocase of the inner membrane; 
MPP, mitochondrial processing peptidase. Figure taken from Mitochondrial 




The aims of this chapter were to examine whether the full length DNMT1 cDNA 
containing 1st-to-3rd ATG sequence can localise at a mitochondrial level. To 
investigate this hypothesis, several plasmid constructs (including a construct 
carrying a DNMT1 cDNA with a mutated consensus sequence for nuclear 





3.3.1 Materials for pCMV-SPORT6-nuclear DNMT1 construct 
To generate the expression vector of nuclear DNMT1 cDNA under the control of 
CMV promoter, the DNMT1 cDNA was digested from the pCAG-NLS-myc-
DNMT1 vector and further modified in order to obtain a pCMV-SPORT6 vector 
carrying the nuclear DNMT1 sequence with an HA-tag at 5’ region. 
 
3.3.1.1 Primer sets for de novo PCR synthesis of HA-tag 
A de novo PCR synthesis of the KpnI-SalI 5’ region was performed, including the 
synthesis of an HA tag. The primers used for De novo PCR are shown (Table 
3.1). 
 
Table 3.1: PCR primers for de novo PCR of KpnI to SalI sequence with HA-tag. 







3.3.1.2 -De novo PCR synthesis conditions for KpnI-SalI DNMT1 fragment 
and cloning strategy 
After obtaining the KpnI-SalI PCR product with HA-tag, it was inserted in an 
empty pBluescript II KS+ vector through KpnI-SalI digestion. Then, its sequence 
was checked. Subsequently, the KpnI-SalI PCR product was inserted in pCMV-
SPORT6, along with SalI-XhoI and XhoI-HindIII fragments of the original DNMT1 
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sequence. Reagents for De novo PCR are listed (Table 3.2) and PCR conditions 
are shown (Figure 3.4). 
 
Table 3.2: PCR reagents for De novo PCR synthesis. 
Reagent Quantity (µl) 
2x Extreme Buffer 12.5 
2 mM dNTPs 5 
dH2O 0.5 
10 µM Forward Primer 0.75 
10 µM Reverse Primer 0.75 
Template (mouse genomic DNA) 10 µg/µl 5 
KOD Xtreme DNA Polymerase 0.5 
 
 
Figure 3.4: De novo PCR synthesis scheme. 
 
3.3.2 Materials for pCMV-SPORT6-whole DNMT1 construct 
First of all, the cDNA of DNMT1 was modified by adding the predicted 
mitochondrial localisation signal (MLS) 1st-to-3rd ATG sequence, coupled with an 
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HA-tag (derived from the Human influenza hemagglutinin surface glycoprotein, 
corresponding to amino acids 98-106), in order to obtain a protein that could 
effectively localise at both mitochondrial and nuclear level. Two different 
strategies in terms of HA-tag positioning were planned. In the first strategy, the 
primers have been designed so that the HA-tag with Kozak sequence would be 
positioned before the 1st ATG, whereas the second strategy had the HA-tag 
positioned right before the 3rd ATG (Figure 3.5). 
 
Figure 3.5: General scheme for final 1st-to-3rd ATG sequences carrying the 
MLS, HA-tag and Kozak sequence. 
 
3.3.2.1 Primer sets for de novo PCR synthesis of MLS 
De novo PCR synthesis was performed in order to obtain these fragments. 




Table 3.3: Primers for 1st-to-3rd ATG sequences with HA-tag. The Kozak 
sequences are underlined, whilst the start codons are highlighted in bold. The 






















3.3.2.2 De novo PCR synthesis conditions for MLS fragments 
The final PCR products from strategy #1 and #2 carrying a KpnI site at 5’ and an 
EcoRI site at 3’ were subcloned in pBluescript II KS+ vector and sequenced to 
check for mutations, respectively. Then, they were inserted into pCMV-SPORT6 
along with the rest of DNMT1 sequence (EcoRI-XhoI 5’ fragment and XhoI-EcoRI 
3’ fragment). Reagents for De novo PCR are listed (Table 3.4), and PCR 




Table 3.4: PCR reagents for De novo PCR synthesis. 
Reagent Quantity (µl) 
2x Extreme Buffer 12.5 
2 mM dNTPs 5 
dH2O 0.5 
10 µM Forward Primer 0.75 
10 µM Reverse Primer 0.75 
Template (mouse genomic DNA) 10 µg/µl 5 
KOD Xtreme DNA Polymerase 0.5 
 
 
Figure 3.6: De novo PCR synthesis scheme. 
 
3.3.2.3 Mitochondrial localisation probability analysis 
After obtaining the 2 different 1st-to-3rd ATG sequences, the chances of 
mitochondrial localisation of the two different DNMT1 cDNAs was calculated 
through Mitoprot II software analysis (http://ihg.gsf.de/ihg/mitoprot.html). 
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3.3.3 Materials for pCMV-SPORT6-mitochondrial DNMT1 construct 
Starting from the pCMV-SPORT6-whole DNMT1 construct, a DNMT1 cDNA was 
modified in order to allow the protein to only localise at a mitochondrial level. To 
achieve this, the NLS was disrupted through mutation. 
 
3.3.3.1 Uniprot analysis 
In order to identify the predicted site for the NLS, mouse DNMT1 protein 
sequence was analysed using Uniprot website (http://www.uniprot.org/uniprot/ ). 
The results were then used to plan which residues to mutate, and PCR primers 
for mutagenesis were designed accordingly. 
 
3.3.3.2 Mutagenesis of NLS 
Mutations of the NLS was performed using Geneart® site-directed mutagenesis 
Kit (Invitrogen Life Technologies®, A13282), and involved the disruption of NLS 
by replacing some Arginine (R) and Lysine (K) residues of the sequence with the 
amino acid Alanine. Arginine and Lysine possess positively charged side chains 
that allow for nuclear translocation, however mutation with Alanine would disrupt 
this mechanism as Alanine has uncharged side chains. Furthermore, Alanine is 
the smallest of the 21 proteinogenic amino acids, so using Alanine ensured that 
the mutation would not disrupt the secondary structure of the protein due to steric 
hindrance. 
Since the kit is only capable of mutating a maximum of 15 nucleotides for each 
reaction, the complete mutagenesis was performed in two steps. The general 
scheme of the mutagenesis procedure (Figure 3.7) and primers’ sequences 
(Table 3.5) are reported. The mutagenesis kit starts with the template DNA 
getting methylated and then amplified with the primers for mutations. Then, it is 
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transformed in a specific strain of DH5α cells that will digest the methylated 
template, thus only incorporating the mutated PCR product. The first step of 
mutation introduced a SacII digestion site to use as mutagenesis control along 
with the sequencing. Following each mutation step, the DNA sample was 
transformed in DH5α cells, extracted through miniprep and checked through both 
DNA gel electrophoresis after enzyme digestion (SacII) and then sequencing for 
the second mutation step. After confirming the sequence following the first 
mutation step, the second step of the mutagenesis was performed. Again, the 
DNA sample has been transformed in DH5α cells, extracted through miniprep 
and checked through sequencing. Finally, the 1.1 kbp mutated fragment was 
inserted into pCMV-SPORT6 carrying the 5’ fragment of nuclear DNMT1. The 
changes in the amino acidic sequence after mutation are also reported (Figure 
3.8). 
 
Table 3.5: PCR primers for mutation reactions. Residues marked in bold 
represent mutation sites that will convert amino acids to Alanine. SacII 
(CCGCGG) and NotI (GCGGCCGC) sites are underlined. 
Primer Sequence 


























Figure 3.7: General workflow of Geneart site-directed mutagenesis kit. Figure 




Figure 3.8: Changes in NLS amino acidic sequence. 
 
3.3.4 Establishment of overexpression systems for the different DNMT1 
isoform 
3.3.4.1 Immunocytochemistry and cell imaging after overexpression 
HEK293A cells were seeded in a 12-well plate with a collagen coated cover slip 
in each well, and transfected with FuGene HD (as described in subchapter 2.3.2). 
Following transfection, immunocytochemistry on HEK293A cells was performed 
(as described in subchapter 2.4). Five different transfection conditions were 
investigated: an empty pCMV-SPORT6 (used as a negative control), and pCMV-
SPORT6-nuclear DNMT1, pCMV-SPORT6-whole DNMT1 (from strategy #1), 
pCMV-SPORT6-whole DNMT1 (from strategy #2), and pCMV-SPORT6-
mitochondrial DNMT1. 
Following fixation and mounting of cover slips, the first session of pictures was 
taken using an Andor Ixon3 EM-CCD camera connected to an Eclipse Ti-E 
Inverted microscope (Nikon®) with CSU-X1 Spinning Disk Confocal. Then, to 
further confirm localisation, another set of experiments was performed using 
another confocal microscope. 
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3.3.4.2 Western blotting after overexpression and cell fractioning 
Following FuGene HD transfection and overexpression of the different DNMT1 
cDNAs, HEK293A cells were harvested and fractioning was performed (as 
described in subchapter 2.5). Four different transfection conditions were 
investigated: empty pCMV-SPORT6 (negative control), pCMV-SPORT6-nuclear 
DNMT1, pCMV-SPORT6-whole DNMT1 (from strategy #2), and pCMV-SPORT6-
mitochondrial DNMT1. 
Western blotting of both whole cell lysates and nuclear and mitochondrial 
fractions was performed. Membranes were probed for DNMT1, HA-tag, αTubulin 
(whole cell housekeeping), Lamin A/C (nuclear housekeeping) and VDAC 
(mitochondrial housekeeping), using rabbit and mouse fluorescent secondary 
antibodies. Specifications of primary and secondary antibodies used are reported 





3.4.1 Confirmation of pCAG-NLS-DNMT1 vector 
To confirm the DNMT1 cDNA sequence in the pCAG-NLS-DNMT1 vector (Figure 
3.9), enzyme digestion by EcoRI and XhoI and DNA gel electrophoresis were 
performed. Initially, the EcoRI and XhoI restriction sites were investigated through 
digestion and DNA gel electrophoresis (Figure 3.10). The expected bands, such 
as 5’ region of DNMT1 cDNA [DNMT1 EcoRI-XhoI (5’)], 3’ region of DNMT1 
cDNA [DNMT1 XhoI-EcoRI (3’)] and pCAG vector region, were observed. The 
DNMT1 EcoRI-XhoI (5’) was inserted in pCMV-SPORT6 (pCMV-SPORT6-
DNMT1 5’) (Figure 3.11). And the sequence, including start codon and 
modification of 5’ internal EcoRI site, was confirmed. 
The DNMT1 XhoI-EcoRI (3’) was also inserted in pBluescript II KS(+) [pBS II 
KS(+)-DNMT1 3’] (Figure 3.12). The sequence, including 3’ internal EcoRI site 
and stop codon, was confirmed. The vectors, pCMV-SPORT6-DNMT1 5’ and 
pBS II KS(+)-DNMT1 3’, were used for obtaining the pCMV-SPORT6 





Figure 3.9: Restriction enzyme map from Mus musculus (mouse) DNMT1 cDNA 
sequence after Tajima’s modifications. The internal EcoRI sites have been 
disrupted while still maintaining the same amino acid sequence. 5' and 3' 
fragments are highlighted (red and green) and separated by an XhoI site, which 
was used for cloning steps. 
 
 
Figure 3.10: DNA gel electrophoresis of a pCAG-NLS-DNMT1 clone digested 
with EcoRI and XhoI. The 5’ and 3’ fragments have been used for the next cloning 













3.4.2 Generation of pCMV-SPORT6-nuclear DNMT1 construct 
To facilitate the following cloning steps, a HindIII site was created at SmaI site of 
3’ MCS in pBS II KS(+)-DNMT1 3’ using HindIII linker (5’-CAAGCTTG-3’) ligation 
(Figure 3.13). To investigate the expression and localization of the 
overexpressed DNMT1, HA tag sequence was inserted at 5’ region of DNMT1 
cDNA. PCR was performed to generate the 5’ region of DNMT1 with an HA tag 
using the primers (shown in Table 3.3), then the PCR product digested by KpnI 
and SalI was inserted in pBluescript II KS(+) and the sequence was confirmed 
(Figure 3.14). 
To generate the nuclear DNMT1 plasmid, the XhoI-HindIII (3’) fragment was 
digested from pBS II KS(+)-DNMT1 3’ (Figure 3.12) and inserted in pCMV-
SPORT6-DNMT1 5’ (Figure 3.11). Then, the KpnI-SalI PCR product was 
extracted from pBS II KS(+) - DNMT1 5' KpnI-SalI (Figure 3.14) and inserted in 
the pCMV-SPORT6-DNMT1 KpnI-HindIII vector digested with KpnI-SalI (Figure 
3.15) and a digestion check after maxiprep was performed (Figure 3.16). Of note, 
the EcoRI site in the MCS next to KpnI was removed through de novo PCR 
synthesis of KpnI-SalI fragment. 
 
 














Figure 3.16: DNA gel electrophoresis of final pCMV-SPORT6-nuclear DNMT1 
maxiprep sample. Several digestion patterns were checked and all proved to be 
consistent with the restriction enzyme map (Figure 3.15). Since the EcoRI site 
next to KpnI site is not present anymore, a single 9.2 kbp band is produced 
through both EcoRI-only and XhoI-only digestion. 
However, 7.6 kbp and 1.6 kbp bands are obtained through EcoRI-XhoI double 




3.4.3 Generation of pCMV-SPORT6-whole DNMT1 construct 
3.4.3.1 pCMV-SPORT6-whole DNMT1 cloning steps 
To add the predicted MLS (coupled with an HA tag) in the 1st-to-3rd ATG 
sequence to the cDNA of DNMT1, two different strategies in terms of HA-tag 
positioning were planned: strategy #1 (HA tag before the 1st-to-3rd ATG 
sequence) and strategy #2 (HA tag after the 1st-to-3rd ATG sequence). The PCR 
products from strategy #1 and #2 (Table 3.3) were digested by KpnI and EcoRI. 
The enzyme-digested fragments were inserted in pBluescript II KS+ vector and 
confirmed by sequencing, respectively (pBSII KS(+)-Strategy #1 and pBSII 
KS(+)-Strategy #2) (Figure 3.17 and Figure 3.18). After confirming the sequence 
of the MLS fragments, both of them were subcloned in pCMV-SPORT6- DNMT1 
5’ using KpnI and EcoRI restriction sites, respectively (pCMV-SPORT6-MLS-5’ 
DNMT1 #1, Figure 3.19) (pCMV-SPORT6-MLS-5’ DNMT1 #2, Figure 3.20). 
The 3’ fragment of DNMT1 was extracted from pBS II KS(+) - DNMT1 3' HindIII 
by XhoI and HindIII and was subcloned in pCMV-SPORT6-MLS-5’DNMT1 #1 or 
pCMV-SPORT6-MLS-5’DNMT1 #2 vector (Figure 3.21 and Figure 3.22). Finally, 
two whole-cell DNMT1 overexpression vectors were obtained, with the only 
difference being in the positioning of the HA-tag (5’ for strategy #1, before 3rd 
ATG for strategy #2). After having obtained the final vectors, they have been 
transformed in DH5α cells and a maxiprep was performed. Several DNA 
digestion reactions were performed to check for the final constructs, referring to 
the internal endonucleases digestion sites of DNMT1 (Figure 3.23). The final 
maxiprep samples have been used for all overexpression experiments in 




Figure 3.17: Insertion of HA tag-1st-to-3rd ATG sequence from strategy #1 in 





Figure 3.18: Insertion of 1st-to-3rd ATG sequence-HA tag from strategy #2 in 





Figure 3.19: Insertion of the Strategy #1 PCR product in pCMV-SPORT6 vector 





Figure 3.20: Insertion of the Strategy #2 PCR product in pCMV-SPORT6 vector 





Figure 3.21: Insertion of DNMT1 3' fragment in the final pCMV-SPORT6-whole 





Figure 3.22: Insertion of DNMT1 3' fragment in the final pCMV-SPORT6-whole 





Figure 3.23: General scheme of DNMT1 digestion sites. Strategy #2 cDNA is 
shown. 
 
Figure 3.24: DNA gel electrophoresis of final pCMV-SPORT6-whole DNMT1 
Maxiprep sample (strategy #1). Several digestion patterns were checked and all 




Figure 3.25: DNA gel electrophoresis of final pCMV-SPORT6-whole DNMT1 
Maxiprep sample (strategy #2). Several digestion patterns were checked and all 




3.4.3.2 Prediction of mitochondrial localisation using mitoprot II software 
Full lenght DNMT1 cDNAs from strategy #1 and #2 were investigated for 
mitochondrial localisation using mitoprot II software. The cleavage site sequence 
of final strategy #1 could not be calculated (Figure 3.26), whereas the cleavage 
site of final strategy #2 could be identified by the software (Figure 3.27), 
predicting mitochondrial localisation of the DNMT1 cDNA with 1st-to-3rd ATG 
sequence -HA tag from strategy #2.. 
 
 
Figure 3.26: Mitochondrial localisation probability for full length DNMT1 
sequence (Strategy #1). 
 
 
Figure 3.27: Mitochondrial localisation probability for full length DNMT1 
sequence (Strategy #2). 
 
3.4.4 Generation of pCMV-SPORT6-mitochondrial DNMT1 construct 
3.4.4.1 Prediction of nuclear localisation signal using Uniprot analysis 
Analysis of DNMT1 sequence through Uniprot (Figure 3.28) predicted the NLS 
site between residues 175-202 of the nuclear sequence. The mutagenesis was 
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performed at the region to obtain the mitochondrion-specific DNMT1 
overexpression vector, and will be described in the following section. 
 
 
Figure 3.28: Uniprot analysis of DNMT1 cDNA sequence. Full sequence analysis 
is available at: http://www.uniprot.org/uniprot/P13864 
 
3.4.4.2 Disruption of NLS and cloning of mtDNMT1 into pCMV-SPORT6 
According to the result in section 3.4.3.2 using Mitoprot II analysis, the 5’ region 
of DNMT1 was digested from pCMV-SPORT6-whole DNMT1 (Strategy #2) by 
EcoRI and SalI and was inserted into pBluescript II KS (+) (pBS II KS(+) – DNMT1 
5’ EcoRI –SalI, Figure 3.29). To disrupt the predicted NLS (as shown in Figure 
3.8), the first step of mutation was performed using mutation step #1 primer set 
(Table 3.5). The clone generated from the first step was named as pBS II (KS+)-
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NLS Mutagenesis #1 (Figure 3.30). Since the SacII site was generated by the 
mutagenesis, DNA gel electrophoresis after EcoRI-SacII digestion was 
performed (Figure 3.31). Then, the second step of mutation was performed using 
mutation step #2 primer set (Table 3.5). After mutagenesis, the sequence of 
whole 5’ region was confirmed (pBS II KS(+)-NLS Mutagenesis #2, Figure 3.32). 
The EcoRI-SalI fragment with mutated NLS was inserted into EcoRI-SalI digested 
pCMV-SPORT6-MLS 5’ DNMT1 #2 containing KpnI-EcoRI fragment (with MLS 
and HA tag) and SalI-XhoI fragment (Figure 3.33). The DNMT1 XhoI-HindIII 3’ 
fragment from pCMV-SPORT6-whole DNMT1 (Strategy #2) (Figure 3.22) was 
inserted in pCMV-SPORT6-DNMT1 5' mutated NLS and finally mitochondrial-
specific DNMT1 overexpression vector (pCMV-SPORT6-mitochondrial DNMT1) 
was obtained (Figure 3.34). Then, several DNA digestion reactions were 
performed from maxiprep sample to confirm the right digestion pattern (Figure 
3.35), referring to the internal digestion sites of DNMT1 (Figure 3.23). 
The mitochondrial-specific DNMT1 cDNA sequence was analysed by Mitoprot II. 
The probability is 0.8674 (Figure 3.36). The maxiprep sample of pCMV-SPORT6-
mitochondrial DNMT1 has been used for all overexpression experiments, as 




Figure 3.29: Subcloning of EcoRI-SalI DNMT1 fragment in pBluescript II KS(+) 
for NLS mutation. 
 
 




Figure 3.31: DNA gel electrophoresis after the first mutagenesis step. The 
mutagenesis was confirmed for all clones through EcoRI-SacII digestion. 
 
 




Figure 3.33: Insertion of 5' fragment with mutated NLS in pCMV-SPORT6. 
 
Figure 3.34: Final pCMV-SPORT6-mitochondrial DNMT1 with mutated NLS. The 




Figure 3.35: DNA gel electrophoresis of final pCMV-SPORT6-mitochondrial 
DNMT1 maxiprep sample. Several digestion patterns were checked and all 
proved to be consistent with the restriction enzyme map (Figure 3.27). Though 
the EcoRI digestion seems to show a single band, the signal actually comes from 
2 separate bands of similar size (4.4 kbp and 4.8 kbp), i.e. the pCMV-SPORT6 
vector and mitochondrial DNMT1 cDNA. This was confirmed through XhoI 
digestion, which shows a single band of about 10 kbp. 
 
 
Figure 3.36: Mitoprot II analysis of full length mtDNMT1 sequence with mutated 
NLS. The probability of mitochondrial localisation is high, and the sequence has 
a clear cleavage site. 
119 
 
3.4.5 Subcellular localisation of DNMT1 isoforms 
The subcellular localisation of DNMT1 isoforms was investigated through both 
confocal microscopy and western blotting. 
 
3.4.5.1 Confocal microscopy of SPORT6-DNMT1 vectors 
For this experiment, all the plasmids generated as described in subchapters 
3.4.2, 3.4.3 and 3.4.4, as well as empty pCMV-SPORT6 (as a negative control), 
were used. For all transfection condition, pictures of each channel (DAPI for 
nuclear staining, HA-tag for overexpressed DNMT1 and Mitotracker Red for 
mitochondrial staining) were taken. After this, a merged image of the 3 channels  
was created. Larger pictures of the slides were also taken. 
 
3.4.5.1.1 Empty pCMV-SPORT6 localisation 
Nuclear and mitochondrial staining were successful. As expected, no signal was 
obtained from the staining of HA-tag antibody (Figure 3.37 and Figure 3.38), 






Figure 3.37: Confocal microscopy after IC of HEK293A cells transfected with 
empty pCMV-SPORT6 (low magnification). Multiple images were taken, then 
stitched together. Cells have been stained for mitochondria (Mitotracker red, top 
left), HA-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom left). Bottom right 





Figure 3.38: Confocal microscopy after IC of HEK293A cells transfected with 
empty pCMV-SPORT6 (high magnification). Cells have been stained for 
mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top right) and 
nuclei (DAPI, bottom left). Bottom right is a merged image of all channels. Scale 




3.4.5.1.2 pCMV-SPORT6-nuclear DNMT1 localisation 
Localisation of DNMT1 protein overexpressed by pCMV-SPORT6-nuclear 
DNMT1 was examined. The protein stained with HA-tag antibody was 
successfully expressed in the nucleus (Figure 3.39 and Figure 3.40). 
 
 
Figure 3.39: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-nuclear DNMT1 (high magnification). Cells have been stained 
for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top right) and 
nuclei (DAPI, bottom left). Bottom right is a merged image of all channels. Scale 




Figure 3.40: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-nuclear DNMT1 (high magnification). Cells have been stained 
for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top right) and 
nuclei (DAPI, bottom left). Bottom right is a merged image of all channels. Scale 




3.4.5.1.3 pCMV-SPORT6-whole DNMT1 localisation 
Localisation of whole DNMT1 proteins overexpressed by pCMV-SPORT6-whole 
DNMT1 (Strategy #1) and pCMV-SPORT6-whole DNMT1 (Strategy #2) was 
examined. As expected from Mitoprot II prediction, the protein expressed by 
pCMV-SPORT6-whole DNMT1 (Strategy #1) could not localise at a mitochondrial 
level, as only nuclear signal coming from the HA-tag antibody was detected. 
Strong cytosolic signal was also observed in some cells (Figure 3.41 and Figure 
3.42). 
According to Uniprot and Mitoprot II predictions, the protein expressed by pCMV-
SPORT6-whole DNMT1 (Strategy #2) was observed in both nuclear and 
mitochondrial regions in HEK293A cells (Figure 3.43 and Figure 3.44). Even 
though the pattern of localisation was not homogeneous (Figure 3.45), all pCMV-
SPORT6-whole DNMT1 (Strategy #2) transfected cells showed a good mixture 
of nuclear and mitochondrial localisation, indicating that the 1st-to-3rd ATG 




Figure 3.41: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-whole DNMT1 (Strategy #1) (low magnification). Multiple 
images were taken, then stitched together. Cells have been stained for 
mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top right) and 
nuclei (DAPI, bottom left). Bottom right is a merged image of all channels. Scale 





Figure 3.42: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-whole DNMT1 (Strategy #1) (high magnification). Cells have 
been stained for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, 
top right) and nuclei (DAPI, bottom left). Bottom right is a merged image of all 





Figure 3.43: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-whole DNMT1 (Strategy #2) (low magnification). Multiple 
images were taken, then stitched together. Cells have been stained for 
mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top right) and 
nuclei (DAPI, bottom left). Bottom right is a merged image of all channels. Scale 





Figure 3.44: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-whole DNMT1 (Strategy #2) (high magnification). Cells have 
been stained for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, 
top right) and nuclei (DAPI, bottom left). Bottom right is a merged image of all 





Figure 3.45: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-whole DNMT1 (Strategy #2) (high magnification). Cells have 
been stained for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, 
top right) and nuclei (DAPI, bottom left). Bottom right is a merged image of all 




3.4.5.1.4 pCMV-SPORT6-mitochondrial DNMT1 localisation 
Localisation of overexpressed mitochondrial DNMT1 with mutated NLS by 
pCMV-SPORT6-mitochondrial DNMT1 was examined. No HA-tag antibody 
signal from nuclei of successfully transfected cells was observed. Furthermore, a 
clear mitochondrial localisation pattern was observed in all successfully 
transfected cells (Figures 3.46, 3.47 and 3.48) indicating that the 1st-to-3rd ATG 
sequence acts as a mitochondrial localisation signal and the predicted nuclear 
localisation signal allows DNMT1 to localise at a nuclear level. 
By disrupting the NLS through mutation it has been possible to obtain a DNMT1 
isoform that may only interact with mitochondrial DNA due to the nature of its 





Figure 3.46: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-mitochondrial DNMT1 (high magnification). Cells have been 
stained for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top 
right) and nuclei (DAPI, bottom left). Bottom right is a merged image of all 





Figure 3.47: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-mitochondrial DNMT1 (high magnification). Cells have been 
stained for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top 
right) and nuclei (DAPI, bottom left). Bottom right is a merged image of all 





Figure 3.48: Confocal microscopy after IC of HEK293A cells transfected with 
pCMV-SPORT6-mitochondrial DNMT1 (high magnification). Cells have been 
stained for mitochondria (Mitotracker red, top left), HA-tag (Alexafluor 488, top 
right) and nuclei (DAPI, bottom left). Bottom right is a merged image of all 




3.4.5.2 Western blotting after fractioning of HEK293A cells 
Several protocols for transfection and fractioning were performed in order to find 
the best conditions. The final protocols are described in subchapters 2.3 and 2.5. 
The samples were incubated with antibodies for DNMT1 and HA-tag, 
respectively. A certain degree of overexpression was observed in all of the 
samples transfected with plasmids containing DNMT1 sequence compared with 
the proteins transfected with empty SPORT6 vector (Figure 3.49). The samples 
incubated with the antibody for DNMT1 show a faint band in the control sample, 
whereas the other samples show very clear bands. The negative control 
transfected with empty pCMV-SPORT6 vector incubated with the HA-tag 
antibody, as expected, did not show any bands, whereas clear bands could be 
seen in nuclear DNMT1, whole DNMT1 and mitochondrial DNMT1 transfected 
samples. 
Then, the Western blotting using the fractionated samples transfected with 
plasmids containing DNMT1 sequence was then performed. The blots showed a 
good degree of separation after fractioning, with clear Lamin A/C bands in the 
nuclear fraction (with no VDAC clear bands detectable) and clear VDAC bands 
in the mitochondrial fraction (with little to no Lamin A/C bands). However, the 
DNMT1 expression in mitochondrial fraction is low, and Lamin A/C signal was 





Figure 3.49: Western blotting of HEK293A cells following DNMT1 
overexpression. Empty pCMV-SPORT6 as a negative control. Membranes were 
probed with both DNMT1 and HA-tag antibodies. αTubulin was used as an 
housekeeping control for protein expression. 
 
 
Figure 3.50: Western blotting of HEK293A cells nuclear and mitochondrial 
fractions following DNMT1 overexpression. Empty pCMV-SPORT6 as a negative 
control. Membranes were probed with both DNMT1 and HA-tag antibodies. 
Lamin A/C was used as an housekeeping control for the nuclear fraction, whereas 
Voltage-dependent anion channel protein (VDAC) was used as an housekeeping 





Starting from a pCAG-NLS-DNMT1 construct obtained from Prof. Tajima (Japan), 
four constructs for the overexpression of DNMT1 were generated. The first 
construct (pCMV-SPORT6-nuclear DNMT1) was generated to serve as an 
overexpression vector for nuclear DNMT1, thereby replacing it. Furthermore, by 
obtaining this vector it has been possible to replace the Myc-tag and EcoRI 
external restriction site with an HA tag and a KpnI external restriction site. 
Additionally, this cloning strategy resulted in excision of the external NLS site, 
allowing me to examine the localization features of DNMT1 cDNA (carrying the  
internal NLS site) under the control of a CMV promoter. 
Immunocytochemistry analysis following overexpression showed a nuclear-only 
localisation, thereby confirming the efficacy of the internal NLS and of the 
plasmid. 
To obtain a plasmid that could overexpress DNMT1 in both mitochondria and 
nuclei, the predicted MLS sequence (that is, the 1st-to-3rd ATG sequence reported 
by Shock L. et al101) was cloned along with an HA-tag, and inserted at 5’ of the 
nuclear DNMT1 cDNA. In this regard, two different strategies were adopted for 
the creation of this construct, leading to the creation of two separate plasmids. 
The pCMV-SPORT6-whole DNMT1 (Strategy#1) and pCMV-SPORT6-whole 
DNMT1 (Strategy #2) construct were created by adding the MLS sequence, and 
only differed in the positioning of the HA-tag. The first construct (pCMV-SPORT6-
whole DNMT1 (Strategy #1)) created would carry the HA tag before the MLS, 
whereas the second construct (pCMV-SPORT6-whole DNMT1 (Strategy #2)) 
would carry it right before the 3rd ATG. These constructs would localise in the 
mitochondrial matrix through the recognition of a cleavage site by the  
presequence translocase complex within the inner membrane111,113. The 
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cleavage site and chances of mitochondrial localisation of the two DNMT1 
sequences were investigated by using Mitoprot II software. No cleavage site 
could be predicted for pCMV-SPORT6-whole DNMT1 (strategy #1) and the 
chances of mitochondrial localisation were very low (~7.6%). Conversely, 
analysis of pCMV-SPORT6-whole DNMT1 (strategy #2) resulted in identification 
of a cleavage site and high chances of mitochondrial localisation (~87%), 
suggesting that whole DNMT1 (strategy #2) can localise to mitochondria. 
To confirm the mitochondrial localisation, immunocytochemistry after single 
overexpression of the two plasmids was performed, and pCMV-SPORT6-whole 
DNMT1 (Strategy #1) plasmid was therefore abandoned. Furthermore, pCMV-
SPORT6-whole DNMT1 (Strategy #2) could successfully overexpress HA-tagged 
DNMT1 in both nuclear and mitochondrial compartments, suggesting that the 1st-
to-3rd ATG region indeed acts as a MLS and that DNMT1 is localised to 
mitochondria via recognition of the MLS and the presequence pattern, and 
confirming the importance of the NLS site for nuclear localisation. Since pCMV-
SPORT6-whole DNMT1 (Strategy #1) was abandoned, the pCMV-SPORT6-
whole DNMT1 (Strategy #2) plasmid will now be referred to as pCMV-SPORT6-
whole DNMT1. 
Finally, a fourth construct was generated by modifying the pCMV-SPORT6-whole 
DNMT1 overexpression vector; a mutation of the predicted NLS in the DNMT1 
cDNA was performed, and the sequence was analysed through Mitoprot II. 
Software analysis showed a similar cleavage site as pCMV-SPORT6-whole 
DNMT1, with similar chances of mitochondrial localisation (~87%). 
Immunocytochemistry results proved this vector to be able to successfully 
localize in the mitochondrial compartment, but not in the nuclear compartment. 
These results further confirm the importance of a conserved NLS sequence for 
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nuclear localisation126. To date, this is the first study to demonstrate the 
functionality of the predicted NLS as the only sequence required for DNMT1 
nuclear localisation, and presents new opportunities for setting up mitochondria -
specific DNMT1 overexpression systems. 
After obtaining these vectors, Western blotting experiments were performed to 
identify the best transfection protocol as well as a mean to refining the cell 
fractioning protocol. Clear DNMT1 and HA-tag bands were found in whole cell 
lysates of transfected samples, and results of the different housekeeping genes 
used (α-tubulin for whole cell lysates, VDAC for mitochondria and Lamin A/C for 
nuclei) showed that the fractioning protocol is suitable for successful isolation of 
the different cell compartments. However, nuclear and mitochondrial transfected 
samples failed to show proper localization of DNMT1 as per the 
immunocytochemistry studies. Moreover, no HA-tag bands were found in pCMV-
SPORT6-whole DNMT1 or pCMV-SPORT6-mitochondrial DNMT1 transfected 
samples. This could be due to some experimental issues with the fractioning 
protocol127, as a certain degree of cross-contamination between the two fractions 
appears to be unavoidable. 
To conclude, these results altogether confirm the importance of a conserved 
nuclear localisation sequence for nuclear localisation and demonstrate the abi lity 
of the 1st-to-3rd ATG sequence to act as an MLS. Both these sequences proved 
to be important to achieve proper DNMT1 localization, thereby confirming the 
results predicted in the papers by Song J. et al105 (for NLS) and Shock et al (for 
MLS)90. In the next chapter, the methylation status of HEK293A mtDNA 
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4.1.1 Methylation of mitochondrial DNA 
The epigenetic regulation of mtDNA has been an infrequently studied topic and 
remained an open question for a long time. Early studies from the 1970s reported 
controversial results, claiming that there was no methylation of mtDNA in either 
mouse or human cells128,129, and finding methylation in mtDNA from beef heart130. 
Studies conducted between the 1980s and the 1990s reported low levels of 
methylation restricted to CpG dinucleotides in mitochondria of both mouse51 and 
human cells131, or even similar levels of CpG suppression to that of nuclear 
DNA52. 
Since then, even though there has been increasing number of reports confirming 
the presence of methylation at mitochondrial level132-134, and mitochondria have 
been shown to contain the machinery required to epigenetically modify 
mtDNA135,136, the presence of methylation in mtDNA has remained 
controversial99,102,137-139. Moreover, mitochondrial DNA has been linked to heart 
failure36 and its epigenetic regulation has been suggested as a next-generation 
biomarker for diseases103,140. 
 
4.1.2 Interaction between DNMT1 and other DNMTs 
It has been reported that the human de novo enzymes hDNMT3A and hDNMT3B 
form complexes with the maintenance enzyme hDNMT1, as interaction sites exist 
in their sequence141 (Figure 4.1). Interaction sites for DNMT3A and DNMT3B are 
localised on the N-terminal of DNMT1 sequence, with the DNMT3B site 
overlapping part of the NLS, and both DNMT3A and DNMT3B possess 
overlapping interaction sites for the other DNMTs. Furthermore, functional 
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cooperation between hDNMT1 and hDNMT3B has been shown in a human 
colorectal carcinoma line142. 
 
Figure 4.1: Summary of the interaction sites of the human DNMTs. Amino acid 
residues for protein-protein interactions are indicated underneath the interacting 
protein’s name (i.e. hDNMT3A 1-148). Figure taken from Co-operation and 
communication between the human maintenance and de novo DNA (cytosine-5) 
methyltransferases, Kim et al, 2002141. 
 
4.1.3 DNMT3A overview and methylation features 
DNMT3A is involved in de novo methylation of cytosine residues, especially for 
de novo methylation of the CpG dinucleotides in the repeated DNA sequences 
which are present in the pericentric satellite regions of chromosomes88,143. Knock-
out of the Dnmt3a gene has been shown to cause embryonic lethality similar to 
the Dnmt1-/- mouse model88. The structure of DNMT3A includes 3 main parts: an 
N-terminal regulatory domain, a C-terminal catalytic domain and a central linker 
region144,145. The DNMT3A sequence does not contain an MLS. 
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4.1.4 Bisulphite sequencing principles 
DNA modification by bisulphite conversion is a well-established protocol that can 
be performed for DNA methylation analysis. The fundamental principle behind 
bisulphite conversion is that sulphite can be reversibly added to cytosine to 
mediate the deamination of cytosine to uracil. The mechanism by which this 
process is driven was discovered many years ago146-148, and since then methods 
based around bisulphite conversion of DNA account for the majority of new data 
on DNA methylation. 
The protocol begins with the nucleophilic addition of bisulphite to the C-6 position 
of cytosine, which allows the rapid deamination of cytosine into 5,6-dihydrouraci l-
6-sulfonate. Subsequent treatment with an alkaline solution swiftly eliminates the 
sulfonate group and regenerates the double bond, yielding uracil. Unmodified 
cytosines (C) are deaminated to uracil (U), and read as thymines (T) when 
sequenced. Cytosines that are methylated are resistant to the bisulphite 





Figure 4.2: Schematic of bisulphite conversion. The bisulphite treatment 
conversion is divided in sulphonation, hydrolic deamination and alkali 
desulphonation. After this, the DNA strands are amplified and sequenced. Figure 






The aims of the studies in this chapter were to measure methylation changes of 
mtDNA sequences following overexpression of DNMT1, to obtain a DNMT3A 
overexpression construct, test the hypothesis that DNMT1 can interact with 
DNMT3A and allow it to localise at a mitochondrial level, and finally to establish 
a double overexpression system for DNMT1 and DNMT3A and investigate 





4.3.1 Measurement of methylation changes of mtDNA 
In order to assess the effects of overexpression of the different DNMT1 isoforms 
on the methylation status of mitochondrial DNA genes, sequencing analysis 
following bisulphite treatment was performed. Depending of the region of interest, 
three different transfection conditions were investigated: empty pCMV-SPORT6, 
pCMV-SPORT6-whole DNMT1 (strategy #2), and pCMV-SPORT6-mitochondrial 
DNMT1. 
 
4.3.1.1 DNA isolation and bisulphite treatment 
4.3.1.1.1 Bisulphite treatment on circular mtDNA 
For each transfection condition, a total of 400,000 HEK293A cells were seeded 
in a 10 cm Corning® tissue-culture treated culture dish (Sigma Aldrich®, 
CLS430167). The next day, transfection with FuGene HD was performed, and 
DNA was isolated 48 hours after transfection using a QIAamp DNA Blood Mini 
Kit (Qiagen®, 51104). Protocol from Appendix J (Protocol for Crude Cell Lysates 
and Other Samples) was used. 
The DNA including circular mtDNA underwent bisulphite conversion using a EZ-
DNA Methylation Gold Kit (Zymo Research®, D5005). The kit guarantees a 
conversion rate of over 99%. Briefly, 400 ng of DNA from each sample was added 
to 130 µl of CT conversion reagent, and the mixtures were then incubated in a 
thermocycler where they underwent a single cycle of 98º C for 10 minutes, 64º C 
for 150 minutes and cooldown to 4º C. Then, the samples were loaded onto a 
Zymo-Spin ™ IC column with 600 µl of M-Binding Buffer, and centrifuged at 
13,000 rpm for 30 seconds. Flow-through was discarded and column were 
washed with 100 µl M-Wash buffer and centrifuged at 13,000 rpm for 30 seconds. 
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200 µl M-Desulphonation buffer was added to the columns, which were then 
incubated at room temperature for 20 minutes. Following incubation, columns 
were centrifuged at 13,000 rpm for 30 seconds. Flow-through was discarded and 
columns were washed with 200 µl M-wash buffer and centrifuged at 13,000 rpm 
for 30 seconds. Finally, columns were placed into a fresh 1.5 ml Eppendorf tube, 
and samples were eluted by applying 10 µl M-Elution buffer directly to the column 
matrix and centrifuging at 13,000 rpm for 30 seconds. A general scheme of 
bisulphite conversion through EZ-DNA Methylation Gold Kit is shown (Figure 
4.3). 
 
4.3.1.1.2 Bisulphite treatment with linearised mtDNA 
Following the first round of results, an additional step was introduced. Following 
DNA isolation after transfection, isolated DNA was quantified through Nanodrop 
analysis, and 2 µg of each sample were digested overnight at 37ºC using 2 µl 
HindIII high concentration restriction enzyme (New England BioLabs®, R0104T). 
This step was introduced in order to digest and linearise mtDNA and allow the 
bisulphite conversion kit to successfully convert mtDNA residues. Digested DNA 
was then extracted through phenol extraction-ethanol precipitation. 
Briefly, samples were resuspended in dH2O (200 µl final volume), then 100 µl of 
phenol and 100 µl of chloroform-isoamyl alcohol (24:1) were added. Samples 
were vortexed for 30 seconds and then centrifuged at 13,000 rpm for 5 minutes. 
The supernatant was then moved to a new 1.5 eppendorf tube, 20 µl of 3M of 
sodium acetate (NaAc) were added and the samples were vortexed. Then, 2.5 
volumes of 100% ethanol solution (EtOH) were added, the samples were 
incubated on ice for 30 minutes and then centrifuged at 13,000 rpm for 5 minutes. 
Supernatant was discarded. Pellets were washed with 1 ml of 70% EtOH solution, 
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centrifuged at 13,000 rpm for 5 minutes twice (surnatant was removed after both 
centrifuge steps). Pellets were then dried up and resuspended in 30 µl dH2O, and 
DNA was quantified using Nanodrop and used for bisulphite treatment. 
 
 
Figure 4.3: Bisulphite treatment workflow. For this project, the EZ DNA 




4.3.1.2 PCR for mtDNA sequences 
Eluted DNA was used as a template for PCR reactions aiming to amplify given 
mtDNA sequences. For this study, COX2 and the first 215 base pairs of the top 
(light) strand of the D-Loop have been chosen as mitochondrial targets for 
investigation. A 10-bp tag (marked in bold) was added to the 5′- ends of the L-
strand primers in order to increase the annealing temperature of the A–T enriched 
primer sequences. Primers’ sequences (Table 4.1) and PCR conditions (Figure 
4.4) are reported. PCR products were run on a 2% agarose gel to confirm the 
size of the amplicons. 
 
Table 4.1: Primer sets for PCR of mitochondrial genes after bisulphite treatment. 
Primer Sequence Company 
COX2 Forward 5'-ATTGGTTATTAATGGTATTGAATTTA-3' IDT 











Figure 4.4: PCR conditions for COX2 and D-Loop primer sequences. 
 
4.3.1.3 TOPO cloning of PCR products 
Following PCR, PCR products were inserted in a TOPO vector using TOPO® TA 
Cloning® Kit for Subcloning (Thermo Fisher Scientific®, 450641). Briefly, 4 µl of 
PCR product were mixed with 1 µl pCR 2.1-TOPO vector (Figure 4.5) and 1 µl 
salt solution (200 mM NaCl; 10 mM MgCl2), and incubated at 23º C for 15 
minutes. Then, the final vector carrying the PCR product was transformed in 
DH5α cells (according to the protocol described in subchapter 3.3.1.1), colonies 
were picked and DNA was isolated through miniprep. Successful insertion of PCR 
products was confirmed by digesting the samples with EcoRI (New England 




Figure 4.5: pCR 2.1-TOPO vector map. The vector contains sequences for 
Ampicillin as well as Kamanycin selection. The PCR product is inserted between 
2 EcoRI restriction sites, and then sequenced using M13 reverse and forward 
primers. Taken from Thermo Fisher Scientific®. 
 
4.3.1.4 Methylation analysis 
Miniprep samples with the insert were then submitted for sequencing, and the 





4.3.2 Methods for pCMV-SPORT6-DNMT3A construct 
To investigate whether DNMT1-DNMT3A interaction would allow DNMT3A to 
localise at a mitochondrial level and methylate mtDNA, a new cloning strategy for 
a mouse DNMT3A overexpression vector for double overexpression studies was 
planned. The pBluescript II KS(+) vector was used as cloning vector for 
subcloning and sequencing steps, whereas the pCMV-SPORT6 vector was used 
as an expression vector. 
The first step involved PCR of the 5’ fragment, sequence digestion by EcoRI-SacI 
and insertion into pBluescript II KS(+) for sequencing analysis, and insertion into 
pCMV-SPORT6. The second step involved PCR of the 3’ fragment, sequence 
digestion by SacI-XhoI and insertion into pBluescript II KS(+) for sequencing 
analysis, and then insertion into pCMV-SPORT6. To facilitate cloning steps, an 
EcoRI site was created in the forward primer for the 5’ fragment, as well as an 
XhoI site in the reverse primer of the 3’ fragment. Moreover, a Myc-tag sequence 
was added to the 5’ forward primer in order to facilitate detection of the protein 
after overexpression (Figure 4.6). 
 
 
Figure 4.6: Final DNMT3A sequence with Myc-tag and EcoRI-XhoI restriction 
sites. 
 
4.3.2.1 Primer sets for de novo PCR synthesis of DNMT3A fragments 
Using C57BL/6 mouse genomic DNA as a template, PCR primers for the 5’ 
fragment and 3’ fragment of mouse DNMT3A synthesis were designed (Table 
4.2). PCR reagents are reported (Table 4.3). 
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Table 4.2: Primer sets for DNMT3A de novo PCR synthesis. The starting codons 







GGACCTGATGCCCTCCAGCGGCCCCGGGGACACCAG - 3' 
DNMT3A 
Reverse #1 
5'- CTCCTTGACCTTAGGTTTCTCTGTTGTGCT -3' 
DNMT3A 
Forward #2 







Table 4.3: Reagents for DNMT3A de novo PCR synthesis. 
Reagent Quantity (µl) 
2x Extreme Buffer 12.5 
2 mM dNTPs 5 
dH2O 0.5 
10 µM Forward Primer 0.75 
10 µM Reverse Primer 0.75 
Template (mouse cDNA) 10 µg/µl 5 
KOD Xtreme DNA Polymerase 0.5 
 
4.3.2.2 De novo PCR synthesis conditions for DNMT3A fragments 
PCR conditions for DNMT3A 5’ fragment (Figure 4.7) and 3’ fragment (Figure 





Figure 4.7: Conditions for de novo PCR synthesis of DNMT3A 5' fragment. 
 
 
Figure 4.8: Conditions for de novo PCR synthesis of DNMT3A 3' fragment. 
 
4.3.3 Establishment of double overexpression in HEK293A cells 
To establish a DNMT1-DNMT3A double overexpression system in HEK293A 
cells for methylation analysis experiments, HEK293A cells were initially 
transfected with pCMV-SPORT6-DNMT3A plasmid alone for 48 hours, using the 
FuGene HD transfection protocol described in subchapter 2.2.2. Following 
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transfection, proteins were harvested and Western blotting for DNMT3A and Myc-
tag was performed, using the protocol described in subchapter 2.7. A samples of 
HEK293A cells transfected with empty pCMV-SPORT6 was used as a negative 
control, and αTubulin was used as housekeeping gene. DNMT3A, Myc-tag and 
αTubulin primary antibodies are listed in Table 2.7 from subchapter 2.7.2. 
After confirming single DNMT3A overexpression with both antibodies, a DNMT1-
DNMT3A double transfection was performed. The usual FuGene HD protocol 
was performed using half of the DNA amount from pCMV-SPORT6-mitochondrial 
DNMT1 vector and half from pCMV-SPORT6-DNMT3A vector. Moreover, 3 other 
transfection conditions were used for this experiment: empty pCMV-SPORT6 as 
negative control, half pCMV-SPORT6-whole DNMT1/half empty pCMV-SPORT6, 
and half pCMV-SPORT6-DNMT3A/half empty pCMV-SPORT6. The vector 
pCMV-SPORT6-whole DNMT1 was chosen over pCMV-SPORT6-mitochondrial 
DNMT1 in order to investigate the interactions of DNMT3A with the full lenght 
DNMT1 sequence. After 48 hours of transfection, proteins were harvested and 
western blotting for DNMT1 and DNMT3A was performed. 
 
4.3.4 HEK293A immunocytochemistry after DNMTs double overexpression 
To verify localisation of overexpressed DNMT3A and whether DNMT1-DNMT3A 
interaction would happen at cytosolic or nuclear level, two separate sets of 
transfection and immunocytochemistry experiments were performed. Cells were 
seeded, transfected, fixed and stained according to the protocol described in 
subchapter 2.2 and 2.3. 
In the first set of experiments, cells were transfected with 4 different conditions: 
empty pCMV-SPORT6, pCMV-SPORT6-mitochondrial DNMT1, pCMV-
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SPORT6-DNMT3A and finally pCMV-SPORT6-mitochondrial DNMT1 and 
pCMV-SPORT6-DNMT3A altogether. 
In the second set of experiments, cells were once again transfected with 4 
different conditions: empty pCMV-SPORT6, pCMV-SPORT6-whole DNMT1, 
pCMV-SPORT6-DNMT3A, and finally pCMV-SPORT6-whole DNMT1 and 
pCMV-SPORT6-DNMT3A altogether. For both sets of experiments, imaging was 
performed using a TCS SP5 confocal microscope (Leica Microsystems®). 
 
4.3.5 Bisulphite treatment and methylation analysis of mtDNA sequences 
after DNMT3A and whole DNMT1-DNMT3A overexpression in 
HEK293A cells 
After establishing DNMT3A and whole DNMT1-DNMT3A overexpression, 
HEK293A cells were harvested and their DNA was isolated according to the 
protocol described in subchapter 4.3.1.1. Then, DNA was digested with HindIII 
restriction enzyme (New England BioLabs®, R0104T) and bisulphite treatment 
was performed according to the protocol described in subchapter 4.3.1.1.1. After 
purifying bisulphite treated-DNA, PCR for mtDNA sequences was performed. For 
this set of experiments, COX2 and D-Loop Light fragment sequences were 





4.4.1 Methylation analysis of mtDNA sequences after overexpression of 
DNMT1 isoforms 
In this section, the results of methylation analysis of mtDNA sequences following 
overexpression of DNMT1 isoforms are reported. The subchapters have been 
divided by gene of interest. 
 
4.4.1.1 COX2 methylation status after mitochondrial DNMT1 
overexpression 
The methylation analysis of COX2 gene was investigated with or without 
linearization of mtDNA. 
 
4.4.1.1.1 Methylation analysis of circular mtDNA (COX2) 
After performing bisulphite conversion of DNA samples from transfected cells 
(empty pCMV-SPORT6 or pCMV-SPORT6-mitochondrial DNMT1), the 
sequence of interest (COX2) was amplified through PCR using bisulphi te-
converted DNA as a template. Several annealing temperatures were tested in 
order to obtain the best PCR conditions. The PCR products were ran on a 2% 
agarose gel (Figure 4.9). 
After confirming the proper size of the PCR products, they were amplified through 
TOPO-cloning and DH5α transformation. The clones obtained were then 
screened for successful insertion through EcoRI digestion and DNA gel 
electrophoresis (Figure 4.10 and Figure 4.11) and clones incorporating the PCR 




At first, the methylation pattern of both the negative control and the pCMV-
SPORT6-mitochondrial DNMT1 transfected sample showed a high percentage 
of methylation of CpG and non-CpG motifs alike (Table 4.4 and Table 4.5). 
However, mitochondrial DNA has long been known to have little to no methylat ion 
at all, at basal conditions. This result prompted the hypothesis that the circular 
nature of mtDNA would shield it from bisulphite treatment. 
 
4.4.1.1.2 Methylation analysis of linearised mtDNA (COX2) 
A new set of experiments was planned. This time, the DNA samples have been 
digested with a high concentration of HindIII restriction enzyme in order to 
linearise the mtDNA prior to bisulphite treatment and PCR. Then, the methylation 
status of samples transfected with pCMV-SPORT6 or pCMV-SPORT6-
mitochondrial DNA was investigated (Table 4.6 and Table 4.7). 
The total percentage of converted C residues in both the pCMV-SPORT6 and the 
pCMV-SPORT6-mitochondrial DNMT1 transfected samples was increased to 
99.7%, compared to the previously obtained 13.27% (for circular pCMV-
SPORT6) and 11.1% (for circular pCMV-SPORT6-mitochondrial DNMT1) values. 
The percentage of both converted CpG and non-CpG motifs was also similar, 
with 99.5% and 99.7% conversion, respectively. 
This result proved that without proper digestion of mtDNA samples, the circular 
form of the DNA can introduce a bias during bisulphite treatment, granting 
reduced efficacy of the treatment and creating artefact results. This result also 
proved that overexpression of mitochondrial DNMT1 does not impact COX2 gene 
epigenetic regulation in HEK293A cells. Following this result, the HindIII digestion 





Figure 4.9: DNA gel electrophoresis of COX2 PCR samples (300 bp) Empty 
pCMV-SPORT6- or pCMV-SPORT6-mitochondrial DNMT1-transfected DNA 
samples were used as template. 
 
Figure 4.10: Representative DNA gel electrophoresis of TOPO-COX2 miniprep 




Figure 4.11: Representative DNA gel electrophoresis of TOPO-COX2 miniprep 
samples from pCMV-SPORT6-mitochondrial DNMT1 transfected DNA. 
 
Table 4.4: Methylation status analysis of COX2 sequences from pCMV-SPORT6 





Table 4.5: Methylation status analysis of COX2 sequences from pCMV-SPORT6-
mitochondrial DNMT1 transfected samples. N = 12. 
 
 
Table 4.6: Methylation status analysis of COX2 sequences from pCMV-SPORT6 
transfected samples (linearised). Samples were linearised with HindIII digestion 





Table 4.7: Methylation status analysis of COX2 sequences from pCMV-SPORT6-
mitochondrial DNMT1 transfected samples (linearised). Samples were linearised 
with HindIII digestion prior to bisulphite treatment. N = 12. 
 
 
4.4.1.2 D-Loop sequence fragment methylation status after mitochondrial 
DNMT1 overexpression 
The D-Loop represents the regulatory region of mtDNA, where all mRNAs 
originate, so this would represent a good candidate for epigenetic regulation at 
mitochondrial level. Investigation of part of the D-Loop sequence (residues 1-181) 
was performed through bisulphite sequencing and sequencing analysis. After 
optimising the PCR conditions in order to amplify the right sequence (Figure 
4.12), the methylation status of mtDNA samples originated from cells transfected 
with either pCMV-SPORT6 (negative control) (Figure 4.13 and Table 4.8) or 
pCMV-SPORT6-mitochondrial DNMT1 (Figure 4.14 and Table 4.9) was 
investigated. 
No methylation was found in the CpG motifs of pCMV-SPORT6 transfected 
samples, with a conversion rate of 100%, and a 99.3% conversion rate was 
obtained for non-CpG motifs. Similar conversion rates were also obtained for 
pCMV-SPORT6-mitochondrial DNMT1 transfected samples, with 100% 
conversion rate for CpG motifs and 98.9% conversion rate for non-CpG motifs. 
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This result indicated that there is no methylation in residues 1-181 of the D-Loop 
during basal conditions, and that mitochondrial DNMT1 overexpression has no 
impact of the epigenetic regulation of this area of mtDNA in HEK293A cells. The 
result also prompted discussion in regards of DNMT3 isoforms, which do not have 
a mitochondrial localisation signal in their sequence but possess De novo 
methylation features. 
Since DNMT1 sequence contains DNMT3A and DNMT3B interaction sites, the 
possibility of DNMT1 acting as a chaperone for DNMT3A mitochondrial 
localisation will be investigated. 
 
Figure 4.12: DNA gel electrophoresis of D-Loop fragment PCR samples. Empty 
pCMV-SPORT6- of pCMV-SPORT6-mitochondrial DNMT1-transfected DNA 




Figure 4.13: Representative DNA gel electrophoresis of TOPO-D-Loop (1-181) 
miniprep samples (pCMV-SPORT6-transfected DNA). 
 
 
Figure 4.14: Representative DNA gel electrophoresis of TOPO-D-Loop (1-181) 




Table 4.8: Methylation status analysis of D-Loop (1-181) sequences from pCMV-
SPORT6 transfected samples (linearised). Samples were linearised with HindIII 
digestion prior to bisulphite treatment. N = 12. 
 
Table 4.9: Methylation status analysis of D-Loop (1-181) sequences from pCMV-
SPORT6-mitochondrial DNMT1 transfected samples (linearised). Samples were 
linearised with HindIII digestion prior to bisulphite treatment. N = 12. 
 
 
4.4.2 Generation of DNMT3A overexpression vector 
Following PCR using primers for DNMT3A (Table 4.2), the PCR products were 
extracted (Figure 4.15) and digested with EcoRI and SacI in the case of 5’ 
fragment, or SacI and XhoI in the case of 3’ fragment. The two PCR products 
were then inserted in pBluescript II KS(+) in two separate reactions for 
sequencing purposes (Figure 4.16 and Figure 4.17). Transformation of DH5α 
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cells and miniprep were performed and clones with successful insertion were 
sequenced. Miniprep clones were digested with the relative enzymes, and clones 
showing successful insertion were sequenced. 
After choosing one clone with the right sequence for each fragment, pCMV-
SPORT6 vector was digested with EcoRI and XhoI, and a double ligation with the 
5’ and 3’ DNMT3A fragments was performed. This ligation was performed using 
the same fragment ratio for both fragments (vector : fragment = 1 : 3). A map of 
the final construct is shown (Figure 4.18). 
Following ligation, the mixture was transformed in DH5α cells, miniprep was 
performed and the samples were checked through both endonuclease digestion 
(EcoRI-XhoI, EcoRI-SacI, SacI-XhoI) and sequencing. A clone with the right 
sequence was chosen, and DH5α transformation and maxiprep were performed. 
Finally, the maxiprep sample was sequenced and checked through 
endonuclease digestion (EcoRI-XhoI, EcoRI-SacI, SacI-XhoI, KpnI) once more 
(Figure 4.19). After confirming the right fragment length for all digestion patterns 





Figure 4.15: DNA gel electrophoresis of DNMT3A 5' and 3' PCR products. 
 









Figure 4.18: Insertion of DNMT3A 5' and 3' fragments in the final pCMV-SPORT6 




Figure 4.19: DNA gel electrophoresis of DNMT3A maxiprep sample. 
 
4.4.3 Establishment of DNMT1-DNMT3A double overexpression in 
HEK293A cells 
The overexpression and localisation of DNMT3A in the presence or absence of 
DNMT1 was investigated through both Western blotting and 
immunocytochemistry. 
 
4.4.3.1 Western blotting after DNMT1-DNMT3A double overexpression 
The Western blotting results of DNMT1-DNMT3A overexpression in HEK293A 
cells (using whole cell lysates) are shown (Figure 4.20). To compare the 
expression, transfection with empty pCMV-SPORT6, pCMV-SPORT6-mtDNMT1 
and pCMV-SPORT6-DNMT3A was also performed. 
Clear DNMT1 and HA-tag bands were found in both single and double 
transfection (HA-tag bands are highlighted with red arrows). Moreover, a very 
strong signal was obtained through DNMT3A and Myc-tag probing of single 
170 
 
DNMT3A and mtDNMT1-DNMT3A transfected samples. This experiment 
successfully confirmed double overexpression of mtDNMT1 and DNMT3A. 
 
Figure 4.20: Western blotting after overexpression of mitochondrial DNMT1, 
DNMT3A, and both. αTubulin was used as housekeeping gene. 
 
4.4.3.2 Immunocytochemistry DNMT1-DNMT3A localisation studies 
To investigate whether co-overexpression of DNMT1 and DNMT3A could affect 
DNMT3A localisation, immunocytochemistry was performed. The localisation 
features of whole DNMT1 and mitochondrial DNMT1 were tested, then a 
combination of whole DNMT1-DNMT3A and mitochondrial DNMT1-DNMT3A 
were investigated. Empty pCMV-SPORT6 analysis was also performed (Figure 
4.21 and Figure 4.22). No signal from HA-tag staining was obtained. 
Staining after overexpression of single whole DNMT1 (Figure 4.23 and Figure 
4.24) or mitochondrial DNMT1 (Figure 4.25 and Figure 4.26) confirmed the 
results obtained in chapter 3: whole DNMT1 was able to localise at both nuclear 




After confirming this result, the localisation of both whole DNMT1 and DNMT3A 
after whole DNMT1-DNMT3A overexpression was investigated through HA-tag 
(for DNMT1) (Figure 4.27 and Figure 4.28) or Myc-tag staining (for DNMT3A) 
(Figure 4.29 and Figure 4.30). Whole DNMT1 showed a whole-cell localisation 
as predicted, while DNMT3A showed a clear nuclear and cytosolic localisation. 
No evident signs of mitochondrial localisation of DNMT3A could be observed 
except for 2 cells (Figure 4.30) where the signal from the Myc-tag secondary 
antibody was very strong. This could be due to photo bleaching or signal from the 
ATP synthase (red) channel leaking into the Myc-tag (green) channel. However, 
since this would correlate well with the idea that DNMT3A interaction site within 
DNMT1 sequence would be critical for DNMT3A localisation at a mitochondrial 
level. Therefore, this combination of overexpression on the methylation status of 
mtDNA will be investigated through bisulphite sequencing, and will be discussed 
in the next subchapter. 
Localisation of mitochondrial DNMT1 after double overexpression was 
investigated through HA-tag (Figure 4.31 and Figure 4.32) and was confirmed 
to happen only at a mitochondrial level, as previously confirmed. DNMT3A 
localisation features were also investigated through Myc-tag staining (Figure 
4.33 and Figure 4.34). No evident signs of DNMT3A mitochondrial localisation 
could be detected, while strong nuclear overexpression was observed in all of the 
successfully transfected cells. Altogether, these results show that DNMT3A 





Figure 4.21: Immunocytochemistry of HEK293A cells transfected with empty 
pCMV-SPORT6. Cells have been stained for mitochondria (ATP synthase, top 
left), HA-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom left). Bottom right 





Figure 4.22: Immunocytochemistry of HEK293A cells transfected with empty 
pCMV-SPORT6 (big picture of 9 images). Cells have been stained for 
mitochondria (ATP synthase, top left), HA-tag (Alexafluor 488, top right) and 
nuclei (DAPI, bottom left). Bottom right is a merged image of all channels. Scale 





Figure 4.23: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-whole DNMT1. Cells have been stained for mitochondria (ATP 
synthase, top left), HA-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom 





Figure 4.24: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-whole DNMT1 (big picture of 9 images). Cells have been stained for 
mitochondria (ATP synthase, top left), HA-tag (Alexafluor 488, top right) and 
nuclei (DAPI, bottom left). Bottom right is a merged image of all channels. Scale 





Figure 4.25: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-mitochondrial DNMT1. Cells have been stained for mitochondria (ATP 
synthase, top left), HA-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom 





Figure 4.26: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-mitochondrial DNMT1 (big picture of 9 images). Cells have been 
stained for mitochondria (ATP synthase, top left), HA-tag (Alexafluor 488, top 
right) and nuclei (DAPI, bottom left). Bottom right is a merged image of all 





Figure 4.27: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-whole DNMT1 and pCMV-SPORT6-DNMT3A (DNMT1 staining). Cells 
have been stained for mitochondria (ATP synthase, top left), HA-tag (Alexafluor 
488, top right) and nuclei (DAPI, bottom left). Bottom right is a merged image of 





Figure 4.28: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-whole DNMT1 and pCMV-SPORT6-DNMT3A (big picture of 9 images) 
(DNMT1 staining). Cells have been stained for mitochondria (ATP synthase, top 
left), HA-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom left). Bottom right 





Figure 4.29: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-whole DNMT1 and pCMV-SPORT6-DNMT3A (DNMT3A staining). 
Cells have been stained for mitochondria (ATP synthase, top left), Myc-tag 
(Alexafluor 488, top right) and nuclei (DAPI, bottom left). Bottom right is a merged 





Figure 4.30: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-whole DNMT1 and pCMV-SPORT6-DNMT3A (big picture of 9 images) 
(DNMT3A staining). Cells have been stained for mitochondria (ATP synthase, top 
left), Myc-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom left). Bottom 





Figure 4.31: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-mitochondrial DNMT1 and pCMV-SPORT6-DNMT3A (DNMT1 
staining). Cells have been stained for mitochondria (ATP synthase, top left), HA-
tag (Alexafluor 488, top right) and nuclei (DAPI, bottom left). Bottom right is a 





Figure 4.32: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-mitochondrial DNMT1 and pCMV-SPORT6-DNMT3A (big picture of 9 
images) (DNMT1 staining). Cells have been stained for mitochondria (ATP 
synthase, top left), HA-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom 





Figure 4.33: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-mitochondrial DNMT1 and pCMV-SPORT6-DNMT3A (DNMT3A 
staining). Cells have been stained for mitochondria (ATP synthase, top left), Myc-
tag (Alexafluor 488, top right) and nuclei (DAPI, bottom left). Bottom right is a 





Figure 4.34: Immunocytochemistry of HEK293A cells transfected with pCMV-
SPORT6-mitochondrial DNMT1 and pCMV-SPORT6-DNMT3A (big picture of 9 
images) (DNMT3A staining). Cells have been stained for mitochondria (ATP 
synthase, top left), Myc-tag (Alexafluor 488, top right) and nuclei (DAPI, bottom 




4.4.4 Methylation analysis of mtDNA sequences after DNMT3A 
overexpression and mitochondrial DNMT1-DNMT3A double 
overexpression 
In this section, the results of methylation analysis of mtDNA sequences following 
overexpression of DNMT3A and/or mitochondrial DNMT1 and DNMT3A double 
overexpression are reported. The subchapters have been divided by gene of 
interest. 
 
4.4.4.1 COX2 methylation status after mitochondrial DNMT1 and DNMT3A 
overexpression 
The methylation status of COX2 was investigated after pCMV-SPORT6-DNMT3A 
or pCMV-SPORT6-mitochondrial DNMT1 and pCMV-SPORT6-DNMT3A 
overexpression. First, the PCR conditions for COX2 amplification were checked, 
using DNA isolated from cells transfected with either conditions (Figure 4.35). 
After successful subcloning of the ~215 bp PCR products in the TOPO-vector 
(Figure 4.36 and Figure 4.37), the sequencing was performed. The sequencing 
data was then analysed for bisulphite conversion (Table 4.10 and Table 4.11). 
Similar results were obtained in both pCMV-SPORT6-DNMT3A and pCMV-
SPORT6-mitochondrial DNMT1/pCMV-SPORT6-DNMT3A transfected clones, 
with a conversion rate of CpG motifs of 99.5% for both conditions, and a 
conversion rate of non-CpG motifs of 99.9% and 99.8%, respectively. These 
results indicate that DNMT3A does not play a role in COX2 epigenetic regulation 





Figure 4.35: DNA gel electrophoresis of COX2 PCR samples using pCMV-
SPORT6-DNMT3A, or pCMV-SPORT6-mitochondrial DNMT1 and pCMV-
SPORT6-DNMT3A transfected DNA samples as template. 
 
Figure 4.36: Representative DNA gel electrophoresis of TOPO-COX2 miniprep 





Figure 4.37: Representative DNA gel electrophoresis of TOPO-COX2 miniprep 
samples from pCMV-SPORT6-mitochondrial DNMT1 and pCMV-SPORT6-
DNMT3A transfected DNA. 
 
Table 4.10: Methylation status analysis of COX2 sequences from pCMV-





Table 4.11: Methylation status analysis of COX2 sequences from pCMV-
SPORT6-mitochondrial DNMT1 and pCMV-SPORT6-DNMT3A transfected 
samples. N = 12. 
 
 
4.4.4.2 D-Loop sequence fragment methylation status after mitochondrial 
DNMT1 and DNMT3A overexpression 
Finally, the methylation status of D-Loop (fragment 1-181) was investigated after 
pCMV-SPORT6-DNMT3A or pCMV-SPORT6-mitochondrial DNMT1 and pCMV-
SPORT6-DNMT3A overexpression. The PCR conditions for D-Loop (fragment 1-
181) amplification were checked, using DNA isolated from cells transfected with 
either conditions (Figure 4.38). The expected band was obtained (~215 bp), 
along with another unexpected band of about 180 bp length, even after using 
stringent PCR conditions. The PCR products were then amplified through TOPO-
cloning and DH5α transformation. The clones obtained were then screened for 
successful insertion through EcoRI digestion and DNA gel electrophoresis 
(Figure 4.39 and Figure 4.40) and clones incorporating the PCR product as well 
as the unexpected PCR band were sequenced. The sequencing data was then 
analysed for bisulphite conversion (Table 4.12 and Table 4.13). 
In the samples obtained from pCMV-SPORT6-DNMT3A transfected cells, only 3 
clones containing the correct sequence could be found, even after increasing 
PCR stringency and repeating the whole protocol. After analysis, all these 
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samples showed a 100% conversion rate of C residues at both CpG and non-
CpG motifs. 
Additionally, 3 samples containing the unexpected PCR product were 
sequenced, to check the nature of this insert. The sequencing data showed a 
sequence that did not have any similarity with the D-Loop fragment sequence. 
Furthermore, since this DNA was treated with bisulphite sequencing, it was not 
possible to investigate the nature of this sequence further as all the C residues 
were converted to U (which is read as a T during sequencing). 
None of the clones obtained from samples transfected with pCMV-SPORT6-
mitochondrial DNMT1 and pCMV-SPORT6-DNMT3A contained the expected D-
Loop fragment sequence. However, 3 clones were investigated. The same 
unexpected sequence was identified. 
At this point, it was concluded that DNMT3A could not modify the methylation 
status of this D-Loop fragment in HEK293A cells. However, as this DNA 
methyltransferase has De novo methylation features, it is possible that its 
overexpression might have caused changes in the epigenetic regulation of 





Figure 4.38: DNA gel electrophoresis of D-Loop fragment PCR samples using 
pCMV-SPORT6-DNMT3A, or pCMV-SPORT6-mitochondrial DNMT1 and pCMV-
SPORT6-DNMT3A transfected DNA samples as template. 
 
Figure 4.39: Representative DNA gel electrophoresis of TOPO-D-Loop (1-181) 
miniprep samples originated from pCMV-SPORT6-DNMT3A transfected DNA. 
The clones containing the expected PCR product are highlighted in red. 
 
Figure 4.40: Representative DNA gel electrophoresis of TOPO-D-Loop (1-181) 
miniprep samples originated from pCMV-SPORT6-mitochondrial DNMT1 and 
pCMV-SPORT6-DNMT3A transfected DNA. 
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Table 4.12: Methylation status analysis of D-Loop (1-181) sequences from 
pCMV-SPORT6-DNMT3A transfected samples (linearised). Samples were 
linearised with HindIII digestion prior to bisulphite treatment. N = 3.
 
Table 4.13: Methylation status analysis of D-Loop (1-181) sequences from 
pCMV-SPORT6-DNMT3A and pCMV-SPORT6-mitochondrial DNMT1 
transfected samples (linearised). Samples were linearised with HindIII digestion 






In this chapter, methylation analysis of mtDNA following overexpression of 
DNMTs, generation of a DNMT3A plasmid and localisation studies following  
overexpression were performed. The protocols performed in this chapter showed 
some limitations in regards to the output and quality of the data obtained. First of 
all, the bisulphite sequencing method proved to be very time consuming, and had 
to be adapted to dealing with mitochondrial DNA in order to yield consistent data. 
However, some interesting data was obtained. 
That is, through comparison of bisulphite sequencing from non-linearized and 
linearized DNA samples, it has emerged that linearization of mtDNA by restriction 
enzymes is required in order to avoid protection from bisulphite treatment and 
reduced conversion rate. By not performing digestion of DNA before bisulphite 
treatment, a severe bias is introduced in the protocol. Therefore, digestion of the 
mtDNA samples had to be performed prior to bisulphite sequencing in order to 
avoid false positives, as mtDNA circular form seemed to be able to protect it from 
bisulphite treatment, as shown after the first round of sequencing experiments 
and analysis. This feature of mtDNA has never been investigated in any of the 
papers where high percentages of mtDNA methylation were shown51,52,130-133. 
To further support this claim, a recent paper150 by Liu B. et al (published after this 
study was conducted) demonstrated that the linear mtDNA has significantly 
higher conversion efficiency compared with circular mtDNA, and that the average 
methylation levels of 9 different mtDNA regions (including D-Loop) was less than 
2% after linearization. 
We can therefore rule that the papers claiming high percentages of mtDNA 
methylation after bisulphite treatment and sequencing were biased, and that the 
digestion step is crucial for proper mtDNA methylation analysis. However, the 
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bisulphite sequencing protocol, whilst being able to yield single base resolution 
for successful sequencing and methylation analysis, cannot discriminate between 
5mC and 5hmC, and would not be suitable to understand the actual methylation 
status of mtDNA if changes in the conversion rate of C residues would have been 
found. 
Another problem was posed by using HEK293A cells. Whilst representing a good 
candidate for setting up an easy, consistent and reliable overexpression system, 
these cells do not possess cardiac features nor represent a cardiac-specific cell 
line. Also, as shown by the immunocytochemistry data, the low transfection 
efficiency might hinder DNA methylation features of DNMT1 isoforms and 
DNMT3A. Analysis of COX2 or D-Loop sequences following pCMV-SPORT6-
whole DNMT1 or pCMV-SPORT6-mitochondrial DNMT1 overexpression did not 
show any increase in the methylation of CpG motifs of these sequences, with 
almost 100% bisulphite conversion rate for all investigated clones. Overall, the 
results suggest that DNMT1 isoforms can’t affect the methylation status of the 
investigated mtDNA sequences. 
Following these results, major efforts were made to obtain a mouse DNMT3A 
overexpression vector. This vector was obtained using the same initial backbone 
used to obtain other DNMT1 overexpression constructs, i.e. pCMV-SPORT6. 
Furthermore, a Myc-tag was added to the original DNMT3A sequence to be used 
for Western blotting overexpression studies and immunocytochemistry 
localisation studies. Through this vector (pCMV-SPORT6-DNMT3A), I tested the 
hypothesis that whole DNMT1 and mitochondrial DNMT1 isoforms could interact 
with DNMT3A through an interaction site and allow it to localise at a mitochondrial 
level through their MLS. 
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First, a double overexpression system for mitochondrial DNMT1 and DNMT3A 
was set up, as this was the initial condition thought to be able to yield DNMT3A 
localisation within mitochondria141. Western blotting analysis confirmed the 
transfection protocol as strong bands from both mitochondrial DNMT1 and 
DNMT3A were observed. Then, localisation of DNMT3A was analysed through 
immunocytochemistry. No signs of DNMT3A mitochondrial localisation were 
observed in the mitochondrial DNMT1-DNMT3A transfected samples. Some of 
the cells transfected with pCMV-SPORT6-whole DNMT1 and pCMV-SPORT6-
DNMT3A showed DNMT3A signal coming from mitochondria (Figure 4.30). 
However, it is possible that the signal was due to bleaching or bleeding of the red 
channel into the green channel, as no other cell showed DNMT3A mitochondrial 
localisation and the overall signal was very bright. 
After this set of experiments, the methylation status of COX2 mtDNA gene 
following transfection with pCMV-SPORT6-whole DNMT1 and pCMV-SPORT6-
DNMT3A was investigated in HEK293A cells through bisulphite sequencing. No 
changes in the methylation status of COX2 CpG motifs were detected, so the 
hypothesis that whole DNMT1 could affect DNMT3A localisation was abandoned, 
along with the hypothesis that DNMT3A would be able to affect COX2 gene 
methylation status. These results, along with the aforementioned issues, 
compelled me to look for more high-throughput and methylation-specific methods 
for methylation analysis. Furthermore, these results prompted me to investigate 
methylation features of DNMT1 isoforms, especially mitochondrial DNMT1, in a 
cardiac-specific environment, using a stronger and more consistent 
overexpression system as well as a more high-throughput system for detection 
of methylation changes in mtDNA following overexpression. 
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In the final chapter of my thesis I attempted to resolve the aforementioned issues 
through the creation of adenoviral and lentiviral vectors, using a cardiac-specific 





 : DNMT1 interaction studies, 
generation of DNMT1 lentivirus and 





5.1.1 Overexpression tools 
In this chapter, viral overexpression tools for DNMT1 overexpression were 
investigated. Specifically, adenoviral vectors were used to setup a transient 
overexpression system in cell lines other than HEK293 (i.e. MCEC), whereas a 
lentiviral vector for mtDNMT1 was obtained in order to create a MCEC cell line 
with stable mtDNMT1 overexpression. 
 
5.1.1.1 Adenoviral vectors 
The adenovirus is a 80-100 nm, non-enveloped, icosahedral capsid, double-
stranded DNA virus, and it was first isolated from human adenoids in 1953151. 
The adenovirus has over 50 known serotypes152, with the serotypes 2 and 5 being 
the most commonly used as a starting point to generate adenoviral vectors153. 
Vectors based on adenovirus are among the most commonly utilized platforms 
for gene delivery to cells in molecular biology studies and also for gene therapy 
applications, due to its advantageous characteristics such as high cloning 
capacity (up to 8 kb), ability to infect a wide variety of cell types and tissues and 
relative safety due to it remaining episomal in transduced cells. 
The first suggestion that adenoviruses (Ad) could be used as a vector system for 
expression of foreign genes came in the late 1970s154,155 with the identification of 
spontaneous recombinants between Ad and SV40 which expressed T antigen 
fused to and Ad structural protein. However, it was with the creation of cell lines 
that could complement viruses deleted of the essential early region 1 (E1) that 
the modern Ad-based vectors were developed156. This cell line allowed for the 
development of Ad-based vectors that could not replicate in most cell lines or 
tissues, whilst still providing high levels of expression of an exogenous transgene. 
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Nowadays, the vast majority of studies involving Ad vectors use the simple E1-
deleted, first generation Ad vectors. Since E1 is required for virus replication, 
these vectors do not replicate in most cell lines but can be easily propagated in 
the E1 complementing cell lines, such as HEK293A cells156. Furthermore, most 
of the first-generation vectors currently in use are also lacking the early region 3 
(E3), which is not required for virus replication in culture, and it has been shown 




Figure 5.1: Comparison between the wildtype Ad genome (serotype 5) and 
adenovirus-based Ad vectors. The early genes (E1-E4) and the region from which 
the major late transcript is produced are shown (transcripts produced from 
alternative splicing are not shown). In the Ad vectors, the gene of interest is 
usually introduced to replace the E1 region and is placed under control by a 
heterologous promoter (dark arrow above ΔE1). Adapted from Wong C.M. et al, 




5.1.1.2 Lentiviral vectors 
Lentiviral vectors are generated from Lentiviruses, which are members of the viral 
family Retroviridae (retroviruses) and are characterized by their use of viral 
reverse transcriptase (RT) and integrase (IN) for stable insertion of viral genomic 
information into the host genome. Apart from sustained gene delivery through 
stable vector integration into the host genome, lentiviral vectors offer several 
attractive properties as gene-delivery vehicles, including the ability to deliver 
complex genetic elements, replicate in non-dividing cells158, broad tissue tropism, 
no expression of viral proteins after vector transduction, and a relatively easy 
system for vector manipulation and production. Lentiviral vectors have been used 
successfully to transduce various cell types, such as neurons, hepatocytes, 
hematopoietic stem cells, retinal cells, dendritic cells, myocytes and islet cells159-
162. 
The majority of lentiviral vectors are based on HIV-1, which has a single-stranded 
positive-sense RNA genome of approximately 9 kb in length that encodes nine 
viral proteins. The three major structural genes, Gag, Pol and Env, encode viral 
core proteins, a set of enzymes required for viral replication (RT, IN) and the viral 
surface glycoprotein gp160 (which is cleaved into gp120, referred to as the 
surface subunit or SU, and gp41, which is referred to as the transmembrane 
subunit or TM), respectively. Additionally, the viral genome also encodes the 
regulatory proteins Tat and Rev, which activate viral transcription and control the 
splicing and nuclear exports of viral transcripts, respectively. Each virion contains 
Gag, Pol and Env proteins, accessory proteins Vif, Vpr and Nef, and two copies 
of viral genomic RNA. 
After infection, the proviral DNA is integrated into the host genome by viral IN163. 
Although there are safety considerations inherent to developing and using 
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vectors which can integrate into a host genome, and particular consideration must 
be given to the possibility of generating replication-competent lentiviruses (RCL), 
these vectors represent a potent tool for basic and translational research. To 
reduce the likelihood of the production of RCLs in vector preparations, many 
laboratories have developed a number of ‘generations’ of lentiviral vectors to 
reduce this risk. 
The first generation of lentiviral vectors is referred to as those vectors that first 
split the system into three separate plasmids to increase safety, rather than the 
early replication-competent prototypes of HIV vectors. First generation 
replication-deficient recombinant HIV-1 vectors are produced from three separate 
elements: a packaging construct, an Env plasmid encoding a viral glycoprotein 
and a transfer vector genome construct (Figure 5.2)164. The packaging construct 
expresses HIV Gag, Pol and regulatory/accessory proteins from a strong 
mammalian promoter to generate viral particles, the Env plasmid expresses a 
viral glycoprotein (usually Vesicular stomatitis virus protein G, VSV-G) to provide 
the vector particles with a receptor-binding protein, and the transfer vector 
plasmid contains the transgene(s) and all of the essential elements for packaging, 
reverse transcription and integration, but expresses no HIV proteins. To increase 
safety further, second-generation vectors have been developed by removing 
accessory genes in the system (Vif, Vpu, Vpr and Nef), which are important for 
HIV as a pathogen but can be depleted in second-generation lentivectors160 
(Figure 5.2). 
Most currently available lentiviral vectors and packaging constructs, including the 
ones used in this study, are based on the second-generation lentiviral vectors, 
but third-generation, as well as further modifications for improved biosafety (i.e. 
codon optimization for Rev-independent Gag-Pol expression) and vector 
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performance (i.e. packaging elements from different HIVs for altered vector 
tropism) also exist165-167. 
 
 
Figure 5.2: First (A) and second (B) generation of HIV-derived lentivectors.  
The first generation includes all of the viral proteins (except Env) in a packaging 
plasmid. VSV-G is provided by a different plasmid, and the transgene is 
expressed under a strong viral promoter such as CMV. For the second generation 
of vectors, all of the accessory proteins are excluded from the packaging plasmid. 
Figure adapted from Sakuma T. et al, Lentiviral vectors: basic to translational, 




5.1.2 Methylated-DNA immunoprecipitation methylation analysis 
To investigate the methylation status of mtDNA sequences with a high-
throughput approach, a methylated-DNA immunoprecipitation (MeDIP) 
methylation analysis system was established. MeDIP consists in the 
immunoprecipitation of methylated DNA fragments using an antibody to 5-methyl 
cytosine (5-mC)168 (Figure 5.3). The monoclonal antibody against 5-mC allows 
enrichment for methylated DNA independent of DNA sequence169, which can 
then be analysed by a variety of methods: the detection of a gene of interest in 
the methylated DNA fraction can be done by polymerase chain reaction (PCR), 
hybridization to genomic arrays, and even high-throughput sequencing170. Since 
the establishment of MeDIP171, the technique has emerged as one of the most 
widely used methods in the scientific community, and has been used to derive 
methylation maps in different organisms76,172, for epigenetic mapping in cancer168 





Figure 5.3: MeDIP principles. DNA is fragmented by sonication and denatured. 
Methylated DNA is precipitated using an antibody against 5mC. Purified 
methylated DNA (IP) and sonicated control DNA (Input) are then investigated with 
any of the available downstream applications (qPCR, Microarray, NGS). Figure 
adapted from Palmke N. et al, Comprehensive analysis of DNA-methylation in 





The aim of this chapter was to generate adenoviral vectors for nuclear DNMT1 
and mitochondrial DNMT1, establish DNMT1 overexpression through adenoviral 
infection, investigate mtDNA methylation through MeDIP and establish MeDIP in 
London, generate a mtDNMT1 lentivirus and obtain stable mtDNMT1 
overexpression in MCE cells, and identify a potential co-factor for increased DNA 





5.3.1 Generation of Adenoviral vectors for nDNMT1, mtDNMT1 and DNMT3A 
5.3.1.1 Gateway cloning 
To increase efficiency of nuclear DNMT1, mitochondrial DNMT1 and DNMT3A 
overexpression, new adenoviral vectors carrying these sequences were 
generated. For this purpose, the Gateway® technology (Life Technologies®) was 
used starting from the nuclear DNMT1, mitochondrial DNMT1 and DNMT3A 
overexpression vectors (Figures 5.4, 5.5 and 5.6). The Gateway cloning System 
(Invitrogen™) is a molecular biology method that enables to efficiently transfer 
DNA-fragments between plasmids using a proprietary set of recombination 
sequences, the "Gateway att" sites, and two proprietary enzyme mixes, called 
"LR Clonase", and "BP Clonase". Gateway cloning allows transfer of DNA 
fragments between different cloning vectors while maintaining the reading frame. 




















Figure 5.7: Gateway® workflow for creation of adenoviral vectors. The workflow 
is divided in 2 main steps: in the BP clonase step, the sequence of interest is 
inserted in an “entry clone” vector and amplified through miniprep. Then, the entry 
clone plasmid is used in the LR clonase step to obtain the final expression clone. 




5.3.1.2 BP Clonase reaction 
First, insertion of the genes in a donor vector was performed using a BP 
Clonase™ II kit (Thermo Fisher Scientific®, 11789020). Figure 5.8 shows 
pDONR™221 map. Briefly, the vectors were linearized through HpaI digestion 
(New England BioLabs®, R0105S), which is an enzyme that does not cut DNMT1 
or DNMT3A sequences, but has a single restriction site on pCMV-SPORT6.  
About 2 µl of the digested samples were ran on a 1% agarose gel to confirm the 
single cut. Then, the remaining samples were extracted, resuspended in 20 µl TE 
Buffer and quantified at the NanoDrop. The reaction components (Table 5.1) 
were then added to a 1.5 ml microcentrifuge tube at room temperature and mixed. 
2 µl of BP Clonase™ II enzyme mix were added to each sample, then all samples 
were incubated at 25ºC for 1 hour. After this, 1 µl of Proteinase K solution was 
added to terminate the reactions, then the samples were incubated at 37ºC for 
10 minutes. Reaction mixtures were then transformed into DH5α cells with 
Kanamycin selection, colonies were picked and miniprep was performed. 
The pDONR-nuclear DNMT1 and pDONR-mitochondrial DNMT1 clones were 
checked through XhoI-HindIII and KpnI-HindIII double digestions, whereas 
pDONR-DNMT3A clones were checked through SacI-KpnI and EcoRI-XhoI 




Figure 5.8: pDONR™221 map. 
 
Table 5.1: BP Clonase™ II reaction components. 
Reagent Quantity 
attB-PCR product (cut DNMT1/DNMT3A) 1-7 µl (150 ng) 
Donor vector (pDONR) (150 ng/µl) 1 µl 





5.3.1.3 LR Clonase reaction 
LR Clonase™ II kit (Thermo Fisher Scientific®, 11791020) protocol was then 
performed. The reaction components (Table 5.2) were added to a 1.5 ml 
microcentrifuge tube at room temperature and mixed. Two µl of LR Clonase™ II 
enzyme mix were added to each sample, then all samples were incubated at 
25ºC for 1 hour. After this, 1 µl of Proteinase K solution was added to terminate 
the reactions, then the samples were incubated at 37ºC for 10 minutes. Reaction 
mixtures were then transformed into DH5α cells with Ampicillin selection, colonies  
were picked and miniprep was performed. 
pDEST-nuclear DNMT1, pDEST-mitochondrial DNMT1 and pDEST-DNMT3A 
clones digestion pattern was investigated using EcoRI, HindIII, KpnI, SacI and 
XhoI restriction enzymes. Furthermore, in order to better confirm insertion in 
pDEST V5 (Figure 5.9), PCR primers for 5’-end and 3’-end of nuclear DNMT1 
and mitochondrial DNMT1 were designed using Primer3 online tool 
(http://primer3.ut.ee/). The sequence of the primer sets and the reagents used 
(Table 5.3 and 5.4), as well as the PCR conditions (Figure 5.10 and Figure 5.11) 
are reported. 
 
Table 5.2: LR Clonase™ II reaction components. 
Reagent Quantity 
Entry clone (pDONR-DNMT1/pDONR-DNMT3A) 1-7 µl (150 ng) 
Destination vector (pDEST V5) (150 ng/µl) 1 µl 





Figure 5.9: pAd/CMV/V5 DEST vector. 
 
Table 5.3: PCR primers for 5'-end and 3'-end DNMT1 sequences. 
Primer Sequence 
DNMT1 5’ Forward 5'-ATTGGTTATTAATGGTATTGAATTTA-3' 
DNMT1 5’ Reverse 5'-CTCCACAAATTTCAAAACATTAAC-3' 
DNMT1 3’ Forward 5’-AGGAAGAGAGGATTTTAATTTAAATTATT-3’ 





Table 5.4: Reagents for PCR check of DNMT1 5' and 3' regions. 
Reagent Quantity (µl) 
2x Extreme Buffer 12.5 
2 mM dNTPs 5 
10 µM Forward Primer 1 
10 µM Reverse Primer 1 
DNA Template (LR clones) (50 ng) 5 
KOD Xtreme DNA Polymerase 0.5 
 
 





Figure 5.11: PCR conditions for check of DNMT1 3’ sequence in LR clones. 
 
5.3.1.4 Generation of adenoviral particles in HEK293A cells 
After confirming proper insertion, 8 µg of each of the final clones were linearized 
with PacI (New England BioLabs®, R0547S) and transfected in HEK293A cells 
using Lipofectamine™ 3000 (Thermo Fisher Scientific®, L3000008). From this 
step onwards, a Class II Biosafety Cabinet was used for adenovirus manipulation. 
HEK293A cells were seeded to be in a 12-well cell culture plate to reach 80% 
confluence at transfection. The Lipofectamine™, the DNA and the P3000™ 
reagent were diluted in Opti-MEM™ reduced serum medium (Thermo Fisher 
Scientific™, 31985070) according to the protocol and incubated at room 
temperature for 15 minutes, then the DNA-lipid complexes were added to the 
cells which were then incubated for 2 days at 37ºC. After 2 days, the medium was 
replaced to 10% FCS DMDM culturing medium, and medium change for 
performed every 2 days for 2 weeks. 
When signs of cell lysis were detected, adenoviruses were extracted from the 
cells. Medium and cells were collected using a 15 ml falcon tube for each well, 
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and centrifuged at 1200 rpm for 5 minutes. Then, all but 1 ml of medium was 
discarded and the cells were resuspended and underwent 3 freeze-thaw cycles 
(-80ºC for 15 minutes, 37ºC for 5 minutes). The samples from each falcon were 
moved to a 1.5 ml Eppendorf and centrifuged at 2200 rpm for 10 minutes, the 
supernatant containing the first generation of adenoviruses was then aliquoted in 
100 µl aliquots and stored at -80ºC. 
 
5.3.1.5 Purification of adenoviral vectors 
HEK293A cells were seeded in several 15 cm cell culture dishes (2 for each 
adenovirus), and when they reached 80% confluence they were infected with 20 
µl first generation adenovirus for each cell culture dish and incubated at 37ºC for 
2 days. The second generation of adenovirus was extracted from the cells 
following the same protocol as per the first generation, and it was purified using 
an Adeno MINI Purification ViraKit™ (Virapur, 003059). After equilibrating the 
purification filters by adding 400 µl of Loading Buffer A and centrifuging at 2200 
rpm for 5 minutes, the cell lysates were added on the purification filters and 
centrifuged at 2200 rpm for 5 minutes. The filters were then washed twice with 
400 µl of Wash Buffer B and centrifuged at 2200 rpm for 5 minutes at each wash. 
The virus were collected in 1.5 ml Eppendorf tubes by elution in 400 µl Elution 
Buffer C and centrifugation at 2200 rpm for 5 minutes. To optimize storage and 
cryo-protection, 40 µl of glycerol for each tube were added to the final samples 





5.3.1.6 Titration of adenoviral vectors 
To obtain the titer of adenoviral vectors for overexpression and methylation 
analysis studies, Clontech™ Adeno-X™ Rapid Titer Kit (Takara™, 632250) was 
used. HEK293A cells were seeded in a 24-well cell culture plate in a 
concentration of 250,000 per well, immediately infected with 100 µl of 10 -4, 10-5 
and 10-6 serial dilutions of nuclear DNMT1, mitochondrial DNMT1 and DNMT3A 
adenoviral stocks and incubated at 37ºC for 48 hours. Then, the medium was 
aspirated, cells were fixed with 1 ml ice-cold methanol per well and incubated at 
-20ºC for 10 minutes. After fixation, methanol was aspirated and the wells were 
rinsed 3 times with 1 ml PBS (1% BSA). 
Then, after adding 500 µl of Anti-Hexon antibody (1:1000 in PBS with 1% BSA) 
to each well, the plate was incubated 1 hour at 37ºC, washed three times with 1 
ml PBS (1% BSA) and incubated 1 hour at 37ºC once again with secondary Rat 
Anti-Mouse antibody (HRP conjugate). After 1 hour, the secondary antibody was 
aspirated and the wells were washed three times with 1 ml PBS (1% BSA). 
Finally, wells were stained by incubating them with 250 µl 1X DAB working 
solution (10X DAB Substrate 1:10 1x Stable Peroxidase Buffer) at room 
temperature for 10 minutes. Cells with positive hexon protein staining (brown 
cells) were counted under the microscope and the Infectious units (ifu) were 
calculated with the formula: 
 
i.f.u./ml = (10 cells/field)*(313 fields/well) / (0.1 ml)*(10-5/ml) 
 




Figure 5.12: Derivation of Area counted in Fields/well. Taken from Adeno-X™ 
Rapid Titer Kit protocol. 
 
5.3.2 Establishment of DNMT1 overexpression through infection with 
adenoviral vectors 
In order to confirm efficacy of adenoviral vectors, about 300,000 H9C2 cells were 
seeded in each well of a 6-well cell culture plate with 10% FCS DMEM. The next 
day, the medium was replaced with serum-free DMEM and infection with 5 
different conditions was performed: no infection (negative control), infection with 
LacZ adenovirus (negative control), infection with nuclear DNMT1 adenovirus, 
mitochondrial DNMT1 adenovirus and DNMT3A adenovirus. For all adenoviral 
vectors, 2 different amounts of multiplicity of infection (MOI) were calculated using 
the titer values and used for infection (MOI 10 and MOI 100). After 24 hours, the 
medium was replaced with 2 ml serum-free DMEM and the cells were grown for 
an additional 24 hours. Then, proteins were extracted and western blotting was 
performed. Western blotting membranes were probed with DNMT1 and DNMT3A 
primary antibodies, using αTubulin as a housekeeping control. 
 
5.3.3 Cell culturing for mtDNA methylation analysis experiments in 
Goettingen 
The preliminary experiments that led to the first Methylated-DNA 
immunoprecipitation (MeDIP) results were performed at Universitätsmedizin 
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Göttingen (UMG) in Elisabeth Zeisberg’s lab. To investigate the effects of DNMT1 
overexpression on the mtDNA of cardiac-specific cell lines, the MCE (Mouse 
Cardiac Endothelial) cell line was chosen (Cedarlane®, CLU510). These cells 
were cultured in DMEM (Sigma-Aldrich®, D5796) with 5% FCS and 1% 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Thermo Fisher 
Scientific®, 15630080). 
 
5.3.4 MOI calculation for MCEC 
To establish the best MOI to use for MCEC infection, MCEC cells were seeded 
in a Nunc® Lab-Tek® II Chamber Slide™ (Sigma-Aldrich®, C6807) in a 
concentration of 10,000 cells per well. The next day, the medium was replaced 
with serum-free DMEM and cells were infected with an Ad-GFP eGFP adenovirus 
(Vector Biolabs®, #1060) using 3 different MOIs: 5, 10 and 20. Twenty four hours 
after infection, the medium was replaced once again with 5% FCS DMEM, and 
positive cells were counted under a bright field microscope with 4x magnification. 
After comparing the positive cells to the total amount of cells, a percentage of 
infection efficiency for MCEC was calculated. 
 
5.3.5 Design and validation of D-Loop primers for methylation analysis 
To obtain quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
primers that could only amplify for mitochondrial sequences, 2 different online 
tools were used. First of all, the Mus musculus mitochondrion genome (GenBank: 
EF108336.1) was investigated in order to obtain the D-Loop sequence (residues 
15423-16299). These residues were then divided in 100-250 fragments and used 
as an input in Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0/primer3/) to 
obtain primer set candidates. Every primer set candidate was then used as an 
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input for UCSC In-Silico PCR Tool (https://genome.ucsc.edu/cgi-bin/hgPcr) using 
the following settings: 
 
 Genome: Mouse 
 Assembly: Dec2011 (GRCm38/mm10) (it's the latest one so this should be 
correct) 
 Target: UCSC genes 
 
This additional step was performed in order to select primer sets that could only 
amplify mitochondrial sequences and not nuclear insertions of mitochondrial 
origin (NUMTs). After crossing several candidates, 5 primer sets were obtained. 
These primer sets have been designed to cover the majority of the D-Loop 
sequence (92.3%), leaving only 85 out of 877 residues uncovered between 
primer set #3 and #4. Primer sets’ sequences are shown (Table 5.5). 
To validate the affinity of the primers to mouse DNA, PCR and qPCR were 
performed. For PCR, B6 Mouse genomic DNA from 2 different mice (specimen 
#233 and #234) was used as a template. Furthermore, a negative control was 
ran by replacing gDNA with dH2O. After PCR, the samples were ran on a 1% 
agarose gel and their size was compared to the expected band size (Table 5.6). 
The PCR reagents (Table 5.7) as well as the PCR conditions (Figure 5.13) are 
reported. After confirming the size of the bands, primer validation through qPCR 
was performed using a StepOnePlus™ Real-Time PCR System (Thermo Fisher 
Scientific®, 4376598). Serial dilutions of B6 mouse gDNA (specimen #233) were 
used as a template (1:10 initial dilution, then 1:2, 1:4, 1:8, 1:16 and 1:32), then 
the Ct values for each primer set were plotted and R2 value was calculated. 
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Finally, another qPCR was performed where 2 different templates were used, 
MCEC DNA obtained from the nuclear fraction, and MCEC DNA obtained from 
the mitochondrial fraction. This was performed in order to confirm the predictions 
obtained from the UCSC In-silico PCR tool. The qPCR reagents (Table 5.8) as 
well as the qPCR conditions (Figure 5.14 and Figure 5.15) are reported. 
 
Table 5.5: D-Loop PCR primers sequences for qPCR after MeDIP. 
Primer Sequence 
D-Loop #1 Forward 5'-CCACCAGCACCCAAAGCT-3' 
D-Loop #1 Reverse 5'-TGGTGTATGTCAGATAACACAGA-3' 
D-Loop #2 Forward 5’-TCTGTGTTATCTGACATACACCA-3’ 
D-Loop #2 Reverse 5’-GAGAAGAGGGGCATTGGTGG-3’ 
D-Loop #3 Forward 5’-ACTATCCCCTTCCCCATTTG-3 
D-Loop #3 Reverse 5’-TGTTGGTCATGGGCTGATTA-3 
D-Loop #4 Forward 5’-AGTCTAGACGCACCTACGGT-3 
D-Loop #4 Reverse 5’-GCATTAAGAGGAGGGGGTGG-3 
D-Loop #5 Forward 5’-CCCCCTCCTCTTAATGCCAAA-3 





Table 5.6: Expected band sizes for D-Loop primers PCR products. 







Table 5.7: PCR reagents for MeDIP primers check. 
Reagent Quantity (µl) 
Taq DNA Polymerase PCR Buffer 10X 
(Thermo Fisher Scientific®, 18067017) 
2.5 
MgCl2 1M solution 
(Thermo Fisher Scientific®, AM9530G) 
2.5 
dH2O 14.2 
10 µM Forward Primer (#1-#5) 1 
10 µM Reverse Primer (#1-#5) 1 
Template (B6 mouse gDNA) 2 
DMSO (Sigma Aldrich®, D9170) 0.5 
dNTP (100 mM) 
(Thermo Fisher Scientific®, 10297018) 
1 
Taq DNA Polymerase 






Figure 5.13: PCR conditions for D-Loop primers check. Rather than optimising 
melting temperature for each primer set, an additional step of 8 cycles with 
varying annealing temperature (62ºC to 54ºC) was added. 
 
Table 5.8: Reagents for qPCR reaction. Every condition was ran in duplicate. 
Reagent Quantity (µl) 
SYBR® Green PCR Master Mix 
(Thermo Fisher Scientific®, 4309155) 
10 
dH2O 6 
10 µM Forward Primer (#1-#5) 1 
10 µM Reverse Primer (#1-#5) 1 
DNA Template 






Figure 5.14: Conditions for first qPCR using D-Loop primers. In this experiment, 




Figure 5.15: Conditions for second qPCR using D-Loop primers. In this 
experiment, DNA obtained from MCEC nuclear and mitochondrial fractions was 
used as template. 
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5.3.6 Methylated-DNA immunoprecipitation (MeDIP) of MCEC mtDNA after 
infection and fractioning 
After validating the D-Loop qPCR primers, a MeDIP experiment was performed. 
MCEC were seeded on several 15 cm cell-culture dishes (2 for each infection 
condition) in 20 ml 5% FCS-1% HEPES DMEM culture medium. When the cells 
reached 80-90% confluence (18 * 107 cells/dish), infection with the different 
adenovirus (Adeno-eGFP, Adeno-nuclear DNMT1, Adeno-mitochondrial 
DNMT1) was performed. Culture medium was removed and MCEC cells were 
infected with MOI10 adenovirus in serum free DMEM with 1% HEPES. 
The next day, the medium containing adenovirus was removed and fresh DMEM 
with 5% FCS and 1% HEPES was added to the cells. Then, 48 hours after 
infection, the cells were harvested and fractioning was performed. After obtaining 
the mitochondrial fraction, its DNA was harvested using a QIAamp DNA Blood 
Mini Kit (Qiagen®, 51104). 
Protocol from Appendix J (Protocol for Crude Cell Lysates and Other Samples) 
was used. The mtDNA samples were then quantified at the NanoDrop, and 825 
ng of each sample were used for MeDIP-qPCR and mtDNA methylation analysis. 
A Methylamp™ Methylated DNA Capture Kit (Epigentek®, P-1015-48) was used 
for the MeDIP step. 
Briefly, 100 µl of buffer MC1 and 1 µl of anti-5-Methylcytosine (5-mC) antibody (1 
mg/ml) was added to each of the wells (1 for each sample), then the wells were 
covered with parafilm and incubated at room temperature for 60 minutes. During 
incubation, the 5-mC antibody would bind to the bottom of the wells and will be 
able to interact with the DNA samples. While waiting for the incubation to finish, 
the mtDNA samples were processed through sonication. This was performed in 
order to break the DNA into 100-600 bp and allow for successful 
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immunoprecipitation and qPCR steps. This sonication step was performed using 
a 600W Ultrasonic Sonicator (Misonix®, S-4000) connected to a 5.5’’ cup horn 
(QSonica®, 431C2) through a 20 kHz Converter (QSonica®, CL5) (Figure 5.16). 
The samples were initially resuspended in 110 µl buffer MC2. The cup horn was 
filled with water and ice and the samples were positioned in a tube rack 
(QSonica®, 440) and immersed in the cup horn. Then, sonication was performed 
with the following conditions: 
 
 Amplitude: 40 (Represents % of total power) 
 Process time: 10’ 
 Pulse ON: 20’’ 
 Pulse OFF: 20’’ 
 
After sonication, the samples were warmed up to 95ºC for 2 minutes and 
immediately placed on ice until the following step. 
At this point, 10 µl were withdrawn from each sample (eGFP, nuclear DNMT1 
and mitochondrial DNMT1) to a 1.5 ml tube to be used as input (the part of the 
sample that would not receive the MeDIP treatment) and put on ice. After 1 hour, 
the 5-mC antibody solution was removed from the wells which were then washed 
3 times with 150 µl MC1 buffer and 1 time with 150 µl MC3 buffer by pipetting in 
and out. At this point, 100 µl of each the sonicated DNA samples was added to 
each well, and the wells were covered with parafilm and incubated at room 
temperature for 120 minutes at 80 rpm on an orbital shaker. Then, the 
supernatant was removed and the wells were washed 3 times with 150 µl buffer 
MC3. To release the DNA from the DNA-antibody complex, the wells were treated 
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with 1 µl proteinase K in 60 µl buffer MC4, capped and incubated for 1 hour at 
65ºC. 
Afterwards, samples were resuspended in 180 µl 100% ethanol, mixed with 100 
µl buffer MC5, applied to spin columns and centrifuged at 13,000 rpm for 30 
seconds. Flowthrough was discarded, and 2 additional centrifuge steps were 
performed adding 200 µl 90% ethanol per column at each step. Finally, the DNA 
was eluted in 20 µl buffer MC6 through centrifugation at 13,000 rpm for 30 





Figure 5.16: Setup for the S-4000 sonicator. The sonicator's tip (on the left) was 
removed and replaced with a 5'5 cuphorn (on the right) and a 20 kHz converter 




5.3.7 Quantitative Real-time PCR after MeDIP 
To obtain a percentage of changes in global methylation of the different D-Loop 
sequences, the MeDIP mtDNA samples were used as a template and tested with 
the 5 primer sets for D-Loop sequences through quantitative real-time PCR (qRT-
PCR). Samples were mixed with qPCR reagents (Table 5.9) and qPCR was 
performed. To calculate the percentage of global methylation compared to the 
input, the ratio between the cycle threshold (Ct) value of the MeDIP sample and 
the input was calculated as follows: 
 Pull down (MeDIP) Ct value – Input Ct value = ΔCt 
 2–ΔCt = quantity 
This way, it is possible to calculate a percentage of methylated CpG motifs in the 
MeDIP sample compared to the input (which contains both methylated and 
unmethylated CpG residues). Then, a comparison between the negative control 
(eGFP sample) and the treated samples (nuclear DNMT1 and mitochondrial 
DNMT1 overexpression) can be performed by setting the 2–ΔCt value of the eGFP 
sample to 1 and calculating a fold increase. 
 
Table 5.9: Reagents for qPCR reaction. Every sample was ran in triplicates 
(including input samples). 
Reagent Quantity (µl) 
SYBR® Green PCR Master Mix 10 
dH2O 3 
10 µM Forward Primer (#1-#5) 1 
10 µM Reverse Primer (#1-#5) 1 
DNA Template (MeDIP/Input mtDNA) 5 
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5.3.8 Establishment of MeDIP protocol in London 
To establish a reliable MeDIP protocol in London, several conditions were 
optimized. 
 
5.3.8.1 Sonicator specs 
A new 500W Sonicator with a 20 kHz converter (Fisher Scientific®, 12981151) 
and a cup horn (Fisher Scientific®, 15370372) was obtained. Furthermore, to limit 
sonication side effects on hearing, a sound enclosure (Fisher Scientific®, 
15351211) was used. 
 
5.3.8.2 Sonication conditions 
The sonication conditions have been adjusted to reflect changes in the sonicator 
model and power compared to the one used in Goettingen. Therefore, the 
sonication conditions used were the following: 
 
 Amplitude: 48 
 Process time: 10’ 
 Pulse ON: 20’’ 
 Pulse OFF: 20’’ 
 
5.3.8.3 DNA sonication and screening of band size 
To identify whether the sonication conditions would yield DNA fragments between 
150-1000 bp, several DNA samples from different origins were used: 
 B6 Mouse genomic DNA 
 pCMV-SPORT6-nuclear DNMT1 plasmid (10 kbp length) 
 pCMV-SPORT6-mitochondrial DNMT1 plasmid (10 kbp length) 
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 MCEC genomic DNA (GFP infected) 
 MCEC genomic DNA (Adeno-nuclear DNMT1 infected) 
 MCEC genomic DNA (Adeno-mitochondrial DNMT1 infected) 
 
About 800 ng of each of the DNA samples were resuspended in either H2O or 
MC2 Buffer (from Methylamp™ Methylated DNA Capture Kit) to a final volume of 
110 µl. This was done to test whether resuspension in different solution would 
alter the sonication pattern. A 1.5 ml centrifuge tube was used for each condition 
and sample. Then, sonication was performed using the conditions described in 
subchapter 5.3.8.2, and after sonication the samples were loaded onto a 2% 
agarose gel and ran for 40 minutes at 120V. Finally, the smears caused by 
sonication were investigated in order to confirm the protocol. 
 
5.3.8.4 MCEC transfection with adenovirus, fractioning and MeDIP-qPCR 
For MCEC infection, fractioning and MeDIP-qPCR experiments, the usual 
protocols (described in subchapters 5.3.2, 2.4 and 5.3.7, respectively) were 
performed. MCE cells were infected with Adeno-eGFP, Adeno-nuclear DNMT1 
and Adeno-mitochondrial DNMT1 vectors using MOI 10, as previously described. 
 
5.3.9 Generation of mtDNMT1 Lentivirus 
To establish a stable mtDNMT1 overexpression system in MCE cells while 





5.3.9.1 Cloning strategy for pLenti-puro-mtDNMT1 lentiviral vector 
First of all, a pLenti-puro vector (Figure 5.17) was obtained from AddGene® 
(#39481, created by Ie-Ming Shih). The backbone is the same as pLenti4/TO/V5-
DEST™ (Thermo Fisher Scientific®, V49810), however the gateway elements 
between the 2 EcoRV sites are lost and the Zeocin resistance gene is replaced 
with a puromycin resistance gene for selection in mammalian cells. The vector 
was supplied in an agar stab and was transformed in DH5α cells. Then, maxiprep 
was performed and the maxiprep sample was checked through XhoI-KpnI, 
EcoRV (New England BioLabs®, R0195) and BglII (New England BioLabs®, 
R0144) digestion. 
The original pCMV-SPORT6-mtDNMT1 vector was then modified by inserting a 
SpeI linker and an XbaI linker at 5’ and 3’ of mtDNMT1 cDNA, respectively. This 
was performed in 2 separate reactions. First, the pCMV-SPORT6-mtDNMT1 
vector was digested with KpnI enzyme according to the usual protocol with the 
addition of 2 µl 10X Alkaline phosphatase to promote dephosphorylation, ran on 
a 1% agarose gel and extracted from the gel. Then, blunting was performed using 
a DNA blunting Kit (Takara®, 6025). This kit allows the conversion of 3'- and 5'-
protruding ends of DNA fragments to blunt ends. Conversion of the two types of 
protruding ends can be accomplished simultaneously by the 3' → 5' exonuclease 
and 5' → 3' polymerase activities of T4 DNA polymerase (Figure 5.18). The 
resulting blunt-ended DNA can be ligated efficiently into a blunt-ended vector 
using the usual DNA ligation protocol. The kit also allows the conversion of 
protruding ends of vector DNA to blunt ends, and blunt-ended vector is used after 
dephosphorylation. 
So after obtaining the digested vector, the blunting reaction was performed with 
the reagents supplied with the kit (Table 5.10). Briefly, DNA sample was mixed 
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with 10x DNA blunting buffer and water to obtain 10 µl final volume. The mixture 
was incubated at 70ºC for 5 minutes and transferred to a 37ºC incubator 
afterwards. Then, 1 µl of T4 DNA polymerase was added and the mixture was 
incubated at 37ºC for 5-15 minutes, vortexed vigorously to deactivate T4 DNA 
polymerase, then placed on ice to ensure deactivation. The sample was then 
used for overnight ligation with SpeI linker. The ligation mixture was transformed 
in DH5α, miniprep and restriction checks with SpeI (New England BioLabs®, 
R0133), SpeI-HindIII and KpnI-HindIII digestion were performed. One of the 
positive colonies was used for XbaI linker insertion after HindIII digestion, 
following the same blunting protocol. After DH5α transformation, the clones were 
checked through SpeI-HindIII and SpeI-XbaI (New England BioLabs®, R0145) 
digestion and sequencing. 
After obtaining the final construct, mtDNMT1 cDNA was inserted into pLenti-puro 
vector in 2 steps: first the 5’ SpeI-XhoI fragment was inserted into pLenti-puro, 
then the 3’ XhoI-XbaI fragment was inserted into pLenti-puro-SpeI-5’mtDNMT1-
XhoI. For the subcloning steps, amplification through HST08 Stellar™ Competent 





Figure 5.17: pLenti-puro vector map. BglII, EcoRI, KpnI, SpeI, XbaI, XhoI, and 
restriction sites are shown. 
 
 




Table 5.10: Reagents for DNA blunting protocol. 
Reagent Amount 
DNA sample (pCMV-SPORT6-mtDNMT1 KpnI digested) 5-10 pmol  
10x DNA Blunting Buffer (with dNTP) 1 µl 
dH2O To 9 µl 
 
5.3.9.2 Packaging and envelope constructs 
For the production of lentivirus in HEK293T cells (ATCC®, CRL-3216™), a 2nd 
generation lentiviral system was used. This system requires a triple transfection 
of HEK293A cells with 3 separate plasmids: 
 
 Lentiviral transfer plasmid encoding insert of interest (mtDNMT1) 
 Packaging plasmid (expressing GAG, POL, TET and REV packaging 
proteins) 
 Envelope plasmid (expressing Vesicular stomatitis virus G protein, VSV-
G) 
 
PAX2 (AddGene®, # 35002, created by Malin Parmar) (Figure 5.19) and 
pMD2.G (AddGene®, 12259, created by Didier Trono) (Figure 5.20) have been 




Figure 5.19: Pax2 packaging construct map. 
 




5.3.9.3 Transfection of HEK293T cells 
For the production of lentiviral particles, transfection of HEK293T cells using 
polyethylenimine hydrochloride (PEI) (764647, Sigma-Aldrich®) was performed. 
For this purpose, a total of 3 T175 flasks of HEK293T cells were cultured unti l 
70% confluence was reached. The reagents for transfection were mixed in 2 
separate 50 ml falcon tubes with 12 ml Opti-Mem for each tube. In one tube only 
3 µl of 10 mM PEI were added. In the second tube, the following amounts of 
plasmids were added: 
 
 90 µg PAX2 
 120 µg pLenti-puro-mtDNMT1 
 30 µg pMD2.G 
 
After this, the contents of both tubes were mixed together (this will be referred to 
as transfection media) and left for 20 minutes at room temperature. Finally, 8 ml 
of transfection media was added to each of the T175 flasks, and incubated for 4 





5.3.9.4 Harvesting of Lentiviral particles from HEK293T cells 
Following transfection for 48 hours, the supernatant containing the lentiviral 
particles was harvested from the T175 flasks, and was placed into clean falcon 
tubes which were centrifuged at 1200 rpm for 5 minutes. The supernatant was 
filtered with a 50 ml syringe through a 0.45mm filter, then put into a new tube. 
The filtered medium containing the virus particles was split into 6 aliquots of 
11.5ml each, in ultra-clear tubes for ultra-centrifugation. Tubes were placed into 
the ultracentrifuge metal vials (previously cleaned with 70% IMS) and finally into 
the rotor of an Ultracentrifuge with Rotor Log Management Function (Hitachi®, 
CP100NX). Tubes were ultra-centrifuged at 19900rpm for 2h at 4°C The 
supernatant was discarded and viruses in each tube were resuspended in 30 µl 
of DMEM medium, then the tubes were combined together and aliquoted in 
eppendorf tubes (40 µl per aliquot). Finally, aliquots were stored at -80°C. 
For the titration of the lentiviral stock, a Lenti-X™ p24 Rapid Titer Kit (Takara®, 
632200) was used. This kit allows you to quickly determine the titer of any HIV-
1-based lentiviral supernatant using standard ELISA methods. The wells of the 
microtiter plate (12 x 8-well strips) are coated with an anti-HIV-1 p24 capture 
antibody, which quantitatively binds the HIV-1 p24 in the lentiviral samples (p24 
is an abundant HIV-1 virus core/capsid protein). Specifically-bound p24 is 
detected in a typical “sandwich” ELISA format using a biotinylated anti-p24 
secondary antibody, a streptavidin-HRP conjugate, and a colour producing 
substrate (Figure 5.21). Colour intensity is measured spectrophotometrically to 
indicate the level of p24 in the samples, which can then be precisely quantified 
against a p24 standard curve. p24 values can then be correlated to virus titer of 
packaging cell supernatants. 
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To test samples quantitatively, a p24 standard curve (0-200 pg/ml) was prepared. 
In order to produce a 200 pg/ml stock solution, 20 µl of the p24 positive control 
stock solution (10 ng/ml) were diluted into 980 µl of fresh complete tissue culture 
medium (DMEM containing 5% FCS and 1% HEPES) for a 1:50 dilution. Then, a 
series of four additional standard dilutions of 100, 50, 25 and 12.5 pg/ml were 
made, and 500 µl of media were dispensed into each of four labelled tubes. Five 
hundred µl of the 200 pg/ml stock were added to the 100 pg/ml tube and mixed. 
Then, using a fresh tip, 500 µl of this solution were transferred into the 50 pg/ml 
tube and mixed. Similar transfers were performed for the 25 and 12.5 pg/ml tubes.  
After selecting a sufficient number or 8-well strips to accommodate all standards, 
test specimens, controls and complete culture medium blanks (negative control) 
in duplicate, 20 µl of lysis buffer were dispensed into each well. Two hundred µl 
of each standard buffer curve dilution, supernatant samples (1:1000, 1:100,000, 
1:500,000 and 1:1,000,000 dilutions) and culture medium were dispensed into 
duplicate wells, then the plate was incubated at 37ºC for 60 minutes. 
After incubation, the content was aspirated from the wells and the plate was 
washed by filling all wells to the brim with wash buffer, aspirate again, and 
repeating the whole process 5 times. Then the plate was inverted and tapped 
firmly on absorbent paper towels. After washing, 100 µl of Anti-p24 antibody were 
dispensed into each well, then incubation at 37ºC for 60 minutes was performed. 
Wells were washed once again following the same protocol, then 100 µl of 
Streptavidin-HRP conjugate were dispensed into each well, and plate was 
incubated at room temperature for 30 minutes. The plate was washed once again, 
and 100 µl of Substrate Solution (from the kit) were dispensed into each well. 
Incubation with light shielding was performed at room temperature for 30 minutes. 
Finally, the reaction was stopped by adding 100 µl Stop Solution (from the kit) 
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Figure 5.21: General scheme of the Lenti-X p24 Rapid Titer Kit. The presence of 
bound p24 in the wells is detected using a biotinylated secondary anti-p24 
antibody, a streptavidin-horseradish peroxidase conjugate, and a colour-
producing substrate. Quantitation is performed by comparing test samples to a 
p24 standard curve. 
 
5.3.10 Generation of stable mtDNMT1 overexpression MCE cell line 
5.3.10.1 Puromycin kill curve 
Before proceeding with the infection of MCE cells, a puromycin kill curve 
experiment was performed. This was done to ensure that the right concentration 
of puromycin would be used to positively select the cells incorporating mtDNMT1 
cDNA and the puromycin resistance gene. MCE cells were seeded onto a 24-
well plate, and when they reached 80% confluence were treated with different 
puromycin concentrations (Figure 5.22). After 3 days, cell death was investigated 
by using a microscope and the lowest dose for 100% cell death was chosen as 






Figure 5.22: Layout of 24 well plate for puromycin kill curve experiment. Numbers 
within the wells indicate puromycin concentration (µg/ml). 
 
5.3.10.2 Infection of MCE cells 
MCE cells were infected with 2 different concentrations of lentiviral particles, 
MOI5 and MOI10. Cells were seeded in 2 T175 flasks. When cells reached 80% 
confluence, culture medium was replaced with DMEM containing antibiotic for 
selection of positive cells (5% FCS, 1% HEPES, 1.5 µg/ml Puromycin). 
Replacement of medium was performed once every 48 hours, and cells were split 
every time they reached 80% confluence. 
 
5.3.10.3 Assessment of mtDNMT1 overexpression 
To assess mtDNMT1 overexpression, western blotting for DNMT1 was 
performed. Proteins were harvested and western blotting was performed 




5.3.11 DNMT1 interaction studies 
To investigate and identify potential mtDNMT1 interaction targets, a Co-IP 
protocol followed by mass spectrometry was performed using MCE cells and both 
DNMT1 lentivirus. 
 
5.3.11.1 Transfection conditions 
MCE cells were seeded on 15 cm culture dishes (2 dishes for each infection 
condition) with 20 ml DMEM with 5% FCS and 1% HEPES for each dish. When 
the cells reached 80% confluence, medium was replaced with 20 ml serum-free 
DMEM and infection with 3 different adenoviruses was performed: Adeno-eGFP 
(as a negative control), Adeno-nuclear DNMT1 and Adeno-mitochondrial 
DNMT1. 
24 hours after infection, medium was replaced with 20 ml DMEM with 5% FCS 
and 1% HEPES and the cells were incubated for additional 24 hours. Then, the 
cells were harvested for Co-immunoprecipitation. 
 
5.3.11.2 Co-immunoprecipitation (Co-IP) protocol 
In order to compare nuclear DNMT1 and mitochondrial DNMT1 interaction 
targets, Co-immunoprecipitation (Co-IP) for the HA-tag was performed using an 
Immunoprecipitation Kit (Sigma-Aldrich®, 11719386001). Culture medium was 
removed from the dishes and the cells were washed twice with 5 ml ice-cold PBS 
per dish to remove any remaining serum proteins from the culture medium. The 
cells were lysed with 1 ml ice-cold lysis buffer, scraped and collected in a 1.5 ml 
centrifuge tube (1 for each condition). Then, to reduce background caused by 




Cells were incubated with 50 µl of the homogeneous protein G agarose 
suspension at room temperature for 3 hours on a rocking platform to form 
antibody-bead complexes. After this, beads were pelleted through centrifugation 
at 13,000 rpm for 20 minutes at 4ºC, then the supernatants were moved to fresh 
1.5 ml tubes. At this point, 100 µl of supernatant from each sample was taken 
and stored at -80ºC to be submitted for mass spectrometry as an IgG negative 
control. The rest of the samples were incubated with 5 µg of the antibody of 
interest for each sample (GFP or HA-tag) for 1 hour at 4ºC on a rocking platform, 
then 50 µl of protein G suspension was added to the mixture and incubated 
overnight at 4ºC on a rocking platform. 
The following day, the Protein G-antibody-protein complexes were collected by 
centrifugation at 13,000 rpm for 30 seconds, the supernatant was discarded and 
1 ml of lysis buffer (wash buffer #1, Table 5.11) was added in order to resuspend 
the beads, then the samples were incubated for 20 minutes at 4ºC on a rocking 
platform. Complexes were collected through centrifugation at 13,000 rpm for 30 
seconds, then the wash-incubation-centrifuge steps were performed again. The 
same procedure was used for further washing steps using wash buffer #2 (Table 
5.12) and wash buffer #3 (Table 5.13). 
 
Table 5.11: Reagents and final concentration for Lysis buffer/Wash buffer #1. 
The reagents were combined and water to a final volume of 25 ml was added. 
Reagent Final concentration (25 ml) 
5 ml Core buffer (CoIP kit) 50 mM Tris-HCl (pH 7.5) 
3.75 ml NaCl 1M 150 mM NaCl 
2.5 ml Detergent mix (CoIP kit) 1% Nonidet P40 
0.5% sodium deoxycholate 
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1 Complete tablet (CoIP kit) 1 tablet/25 ml 
 
Table 5.12: Reagents and final concentration for Lysis buffer/Wash buffer #2 
(high salt concentration). The reagents were combined and water to a final 
volume of 50 ml was added. 
Reagent Final concentration (50 ml) 
10 ml Core buffer (CoIP kit) 50 mM Tris-HCl (pH 7.5) 
25 ml NaCl 1M 500 mM NaCl 
0.5 ml Detergent mix (CoIP kit) 0.1% Nonidet P40 
0.05% sodium deoxycholate 
 
Table 5.13: Reagents and final concentration for Lysis buffer/Wash buffer #3 (low 
salt concentration). The reagents were combined and water to a final volume of 
25 ml was added. 
Reagent Final concentration (25 ml) 
1 ml Core buffer (CoIP kit) 50 mM Tris-HCl (pH 7.5) 
0.25 ml Detergent mix (CoIP kit) 0.1% Nonidet P40 
0.05% sodium deoxycholate 
 
5.3.11.3 Submission of samples and mass spectrometry analysis 
The Co-IP samples were submitted for mass spectrometry analysis to the 
Bioanalytical Mass Spectrometry facility of the Max Planck Institute for 
Biophysical Chemistry in Goettingen. Samples were ran on an agarose gel, 
stained with Coomassie Brilliant Blue R-250 Dye (ThermoFisher Scientific®) and 
submitted for Mass spectrometry. Following submission, the entire procedure 




5.4.1 Generation of adenoviral vectors for nDNMT1 and mtDNMT1 
5.4.1.1 BP Clonase results 
Clones of pDONR™221-nuclear DNMT1, pDONR™221-mitchondrial DNMT1 
and pDONR™221-DNMT3A were obtained through BP clonase reaction 
(Figures 5.23, 5.24 and 5.25). These clones were then checked through DNA 
gel electrophoresis after enzyme digestion, according to the restriction sites 
included within the sequences (Figures 5.26, 5.27 and 5.28). After confirming the 
successful recombination for all vectors, these were used for LR Clonase 
reaction. 
 
Figure 5.23: pDONR™221-nuclear DNMT1 entry clone after BP reaction. This 




Figure 5.24: pDONR™221-mitochondrial DNMT1 entry clone after BP reaction. 





Figure 5.25: pDONR™221-mitochondrial DNMT1 entry clone after BP reaction. 
This construct was then used for LR reaction. 
 
 
Figure 5.26: DNA gel electrophoresis of empty pDNOR and pDONR-Nuclear 
DNMT1 after BP reaction. After confirming the restriction pattern, the clone was 





Figure 5.27: DNA gel electrophoresis of empty pDNOR and pDONR-
Mitochondrial DNMT1 after BP reaction. After confirming the restriction pattern, 
the clone was used for LR clonease reaction. 
 
Figure 5.28: DNA gel electrophoresis of empty pDNOR and pDONR-DNMT3A 
after BP reaction. After confirming the restriction pattern, the clone was used for 
LR clonease reaction. 
250 
 
5.4.1.2 LR Clonase results 
Clones of pAd/CMV/V5 DEST-Nuclear DNMT1, pAd/CMV/V5 DEST-
Mitochondrial DNMT1 and pAd/CMV/V5 DEST-DNMT3A were obtained through 
LR clonase reaction (Figures 5.29, 5.30 and 5.31). These clones were then 
checked through DNA gel electrophoresis after enzyme digestion, according to 
the restriction sites included within the sequences (Figures 5.32, 5.33 and 5.34). 
This confirmed successful recombination of DNMT3 into pAD/CMV/V5 DEST. 
Since it was not possible to confirm recombination of nuclear DNMT1 and 
mitochondrial DNMT1 through DNA gel electrophoresis due to several restriction 
bands, two PCR for 5’ and 3’ DNMT1 sequences were performed. The PCR 
product were ran on a DNA gel and the expected bands were obtained (Figure 
5.35). After confirming the successful recombination for all vectors, these were 
linearised through PacI digestion and used for HEK293A transfection. 
 




Figure 5.30: pAd/CMV/V5 DEST - Mitochondrial DNMT1 final clone. 
 




Figure 5.32: DNA gel electrophoresis of empty pAd/CMV/V5 DEST and 
pAd/CMV/V5 DEST-Nuclear DNMT1 after LR reaction. Since the restriction 
pattern for pAd/CMV/V5 DEST-Nuclear DNMT1 could not be confirmed properly, 






Figure 5.33: DNA gel electrophoresis of empty pAd/CMV/V5 DEST and 
pAd/CMV/V5 DEST-Mitochondrial DNMT1 after LR reaction. Since the restriction 
pattern for pAd/CMV/V5 DEST-Mitochondrial DNMT1 could not be confirmed 






Figure 5.34: DNA gel electrophoresis of empty pAd/CMV/V5 DEST and 





Figure 5.35: DNA gel electrophoresis after PCR for DNMT1 5’ and 3’ fragments. 
In order to confirm successful LR clonase recombination, pAd/CMV/V5 DEST-
nuclear DNMT1 and pAd/CMV/V5 DEST-mitochondrial DNMT1 clones were 
used as template. 
 
5.4.1.3 Generation and titration of adenoviral particles 
After obtaining adenoviral particles from transfected HEK293A cells, the titer was 
calculated (Table 5.14). From these samples, aliquots were created and stored 
at -80ºC. 
 
Table 5.14: Titer calculation of adenoviral vectors. 
Adenovirus Titer 
Adeno-Nuclear DNMT1 6.322 * 109 ifu/ml 
Adeno-Mitochondrial DNMT1 4.82 * 109 ifu/ml 





5.4.2 Establishment of DNMT1 overexpression through adenoviral vectors 
5.4.2.1 Preliminary overexpression experiments in H9C2 cells 
The overexpression features of the adenoviral vectors were investigated through 
H9C2 cells infection and western blotting (Figure 5.36 and Figure 5.37). No 
infection, as well as infection with Adeno-LacZ vector, were used as a negative 
control. Two different multiplicities of infection (MOI) were investigated. After 
confirming Adeno-Nuclear DNMT1, Adeno-Mitochondrial DNMT1 and Adeno-
DNMT3A overexpression features, these vectors were used for infection of MCE 
cells, a mouse-derived cell line. 
 
Figure 5.36: Western blotting of H9C2 cells samples infected with Adeno-Nuclear 
DNMT1 and Adeno-Mitochondrial DNMT1. No infection, as well as infection with 
Adeno-LacZ, were used as negative control. Two different multiplicities of 
infections were investigated. After infection, clear nuclear and mitochondrial 





Figure 5.37: Western blotting of H9C2 cells samples infected with Adeno-
DNMT3A. Two different multiplicities of infections were investigated. No infection 
was used as negative control. After infection, strong DNMT3A bands could be 
observed in all infected sample, especially in MOI 100 samples. 
 
5.4.2.2 Assessment of MOI for MCE cells 
To assess the best MOI to use for infection of MCE cells, infection of MCEC with 
Adeno-GFP was performed. Then, the cells were observed under a brightfield -
fluorescence microscope (Figure 5.38) and positive cells were counted. After 
obtaining an infection efficiency of over 95%, MOI 10 was selected for infection 





Figure 5.38: Representative images of MCEC cells infected with Adeno-eGFP 
vector (MOI 10). Total number of cells were imaged through brightfield (on the 
left), and successfully infected cells were counted through fluorescence 
microscopy (on the right). 
 
5.4.3 Validation of D-Loop primers for methylation analysis after MeDIP 
After designing the D-Loop primer sets through in silico PCR, these were checked 
through both PCR (using H2O as negative control) (Figure 5.39) and real-time 
qPCR (Figure 5.40) using B6 mouse genomic DNA as a template for both 
experiments. The PCR experiment yielded the expected band size for all primer 
sets, whilst no bands were obtained when replacing B6 mouse gDNA template 
with water. Furthermore, the R2 (coefficient of correlation) value obtained through 
real-time qPCR of all primer sets was above 0.99 for all primer sets investigated, 
allowing to further confirm the efficiency and specificity of all designed primer 
sets. 
Finally, to confirm whether the primers could specifically target mtDNA 
sequences and not NUMTs, a qPCR experiment using both nuclear DNA and 
mtDNA from MCE cells was performed. 
All primer sets proved to be able to amplify mtDNA sequences more selectively 
than NUMTs, as expected from in silico PCR predictions (these primer sets 
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should not amplify for NUMTs) (Figure 5.41). After these validation steps, all 
primers were used for qPCR reactions after MeDIP. 
 
 
Figure 5.39: DNA gel electrophoresis after PCR using D-Loop primers. B6 mouse 
gDNA from 2 specimen was used as a template. Water was used as a negative 
control. 
 
Figure 5.40: Calculation of R2 value (coefficient of correlation) after real-time 





Figure 5.41: Testing the specificity of D-Loop primers using nuclear DNA and 
mtDNA from MCE cells. Values are expressed as mtDNA relative amount 
(mtDNA/gDNA). Unpaired two-tailed t-test statistical analysis was performed. 
Legend: *** = P Value < 0.001, *** = P Value < 0.0001. 
 
5.4.4 MeDIP methylation analysis following nDNMT1 and mtDNMT1 
overexpression in MCEC 
After overexpressing nuclear DNMT1 and mitochondrial DNMT1 in MCEC 
through infection with adenoviral vectors, the methylation of mtDNA was 
investigated through MeDIP-qPCR. Infection with Adeno-eGFP was used as a 
negative control. Mitochondrial fraction was purified from infected cells and 
mtDNA was extracted from it. Then, the mtDNA samples were used as a template 
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for MeDIP, and the final samples were used for real-time qPCR, using the 5 
different D-Loop primer sets. 
The amount of CpG motifs for each PCR product depends on the sequence 
targeted by the primer sets (Figure 5.42), though the system does not allow for 
single base resolution. First, the fold increase of global methylation compared to 
the eGFP was calculated (Figure 5.43). No increase was found in any of the D-
Loop sequences of samples infected with nuclear DNMT1, suggesting it not 
playing a key role in affecting D-Loop methylation levels. Conversely, a 3-to-5 
fold increase in global methylation was found in D-Loop sequences of samples 
infected with mitochondrial DNMT1 compared to eGFP control samples. This 
could mean that mtDNMT1 would not only be able to localise at a mitochondrial 
level, but also affect its DNA methylation patterns. 
Even though the increase in methylation (compared to the input) was higher in 
D-Loop sequences of mtDNMT1-infected samples compared to eGFP- or nuclear 
DNMT1-infected samples, the absolute value was still under 1% (Figure 5.44). 
However, these results looked promising, and further efforts were made in order 
to establish and optimise this protocol in London. 
 
 
Figure 5.42: CpG amounts for D-Loop areas. Primer set #3 amplifies for the 





Figure 5.43: Fold increase methylation (compared to eGFP) of mtDNA D-Loop 
sequences.  eGFP, nuclear DNMT1 or mitochondrial DNMT1 overexpression 
through adenoviral vectors. Values with standard deviation (1 biological replicate, 





Figure 5.44: Increase in methylation (showed as a percentage increase) of 
mtDNA D-Loop sequences. eGFP, nuclear DNMT1 or mitochondrial DNMT1 
overexpression through adenoviral vectors. Values with standard deviation (1 
biological replicate, 3 technical replicates). 
 
5.4.5 Establishment of MeDIP protocol in London 
5.4.5.1 Screening of DNA band sizes after sonication 
As some of the sonicator’s components used in Goettingen could not be obtained 
when setting up the sonication system in London, efforts were required in order 
to optimise the sonication step before MeDIP. The sonication conditions used 
were the same used in Goettingen, and DNA from different sources (B6 mouse 
gDNA, pCMV-SPORT6 nuclear DNMT1, pCMV-SPORT6 mitochondrial DNMT1, 
MCEC gDNA from cells infected with adeno-eGFP, adeno-nuclear DNMT1 and 
adeno-mtDNMT1) was used as a template for sonication. Initially, the DNA 
samples were resuspended in H2O, sonicated, and ran on a 2% DNA gel (Figure 
5.45). Afterwards, the resuspension buffer was changed to MC2 buffer from the 
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MeDIP kit, in order to better mimic the sonication conditions during the actual pre-
MeDIP sonication (Figure 5.46). 
The samples showed a different sonication pattern depending on both their origin 
and the sonication buffer. B6 mouse gDNA, pCMV-SPORT6 Nuclear DNMT1 and 
pCMV-SPORT6 Mitochondrial DNMT1 samples sonicated with water yielded a 
smear comprised between 400 bp and 100 bp, whereas MCEC gDNA samples’ 
smear was evenly distributed between 1500 bp and 200 bp. When H2O was 
replaced with MC2 buffer, the smear of B6 mouse gDNA, pCMV-SPORT6 
Nuclear DNMT1 and pCMV-SPORT6 Mitochondrial DNMT1 samples appeared 
to be mainly localised between 1000 bp and 200 bp. 
Since the two pCMV-SPORT6 vectors possess features that resemble mtDNA 
own features (circular double strand, small size), and the fragments size for these 
samples fell under the optimal range for MeDIP samples, the sonication 
conditions as well as the sonication buffer (MC2) were confirmed and adopted for 
the actual pre-MeDIP sonication step. 
 




Figure 5.46: DNA gel electrophoresis of DNA samples after sonication (MC2 
buffer). 
 
5.4.5.2 D-Loop methylation analysis 
Several attempts were performed in order to replicate the data obtained in 
Goettingen. Each time, the procedure was repeated from the infection step. 
Following infection, mitochondrial fraction was obtained, then mtDNA was 
extracted from the fraction and MeDIP-qPCR was performed. The best attempt 
(Figure 5.47) was then combined with the results obtained in Goettingen (Figure 
5.48). Though statistical analysis was not performed due to sample amount 
(N=2), there seems to be a tendency of increased methylation of primer sets #1 
to #4 sequences after mitochondrial DNMT1 overexpression. However, the 





Figure 5.47: Fold increase methylation (compared to eGFP) of mtDNA D-Loop 
sequences (performed in London). eGFP, nuclear DNMT1 or mitochondrial 
DNMT1 overexpression through adenoviral vectors. Values with standard 





Figure 5.48: Fold increase methylation (compared to eGFP) of mtDNA D-Loop 
sequences (Combined values). eGFP, nuclear DNMT1 or mitochondrial DNMT1 
overexpression through adenoviral vectors. Values with standard deviation, 2 




5.4.6 Generation of mtDNMT1 lentivirus 
5.4.6.1 pLenti-puro-mtDNMT1 cloning results 
To test whether a more stable, consistent and strong overexpression of DNMT1 
isoforms would be required in order to successfully impact mtDNA methylation 
patterns, generation of mtDNMT1 lentivirus for stable mtDNMT1 overexpression 
in MCE cells was performed. 
Digestion of the pLenti maxiprep sample confirmed the restriction pattern (Figure 
5.49). After this, insertion of SpeI and XbaI linkers in the pCMV-SPORT6-
mtDNMT1 vector through blunting and ligation was successfully completed 
(Figure 5.50). The insertion of mtDNMT1 into pLenti was performed in two steps. 
First, the SpeI-XhoI 5’ fragment was digested from pCMV-SPORT6-SpeI-
mtDNMT1-XbaI and inserted into pLenti-puro (Figure 5.51), then the XhoI-XbaI 
3’ fragment was digested from pCMV-SPORT6-SpeI-mtDNMT1-XbaI and 
inserted into pLenti-puro-SpeI-XhoI mtDNMT1 5’ (Figure 5.52). 
Digestion of the final pLenti-puro-mtDNMT1 maxiprep sample allowed to confirm 
proper insertion of mtDNMT1 (Figure 5.53), and the vector was used for HEK293 
transfection. 
 






Figure 5.50: pCMV-SPORT6-SpeI-mtDNMT1-XbaI map. 
 




Figure 5.52: Final map for pLenti-puro-SpeI-mtDNMT1-XbaI plasmid. 
 
Figure 5.53: DNA gel electrophoresis of pLenti-puro-SpeI-mtDNMT1-Xba I 
maxiprep sample. 
 
5.4.6.2 Puromycin concentration 
After 3 days of treatment, the puromycin concentration that yielded 100% cell 
death in non puromycin resistant MCE cells is 1.5 µg/ml. 
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5.4.6.3 Lentivirus titer 
After obtaining Lenti-Mitochondrial DNMT1 (Lenti-mtDNMT1) lentiviral particles 
from transfected HEK293 cells, the titer was calculated (Table 5.15). From this 
samples, aliquots were created and stored at -80ºC. 
 
Table 5.15: Titer calculation of Lenti-Mitochondrial DNMT1 vector. 
Lentivirus Titer 
Lenti-Mitochondrial DNMT1 1.85 * 109 ifu/ml 
 
5.4.7 Establishment of mtDNMT1 stable overexpression in MCE cells 
For establishing stable overexpression of mtDNMT1 in MCE cells, cells were 
seeded in a T75 flask and infected with Lenti-mtDNMT1 with MOI 5. After 2 days 
the cells were cultured with 1.5 µg/ml concentration of puromycin in order to 
select them. Visible cell death was observed after 3 days, and the remaining cells 
were expanded until the T75 flask was confluent. 
The cell line was then expanded, cryotubes were created and stored at -80ºC, 
and DNMT1 expression analysis was performed through western blotting 
analysis (Figure 5.54 and Figure 5.55). The establishment of a stable mtDNMT1 
overexpression in MCE cells could not be confirmed. This could be due to issues 
with packaging during production of lentivirus. 
 
Figure 5.54: Western blotting of MCEC wild type and MCEC Lenti-mtDNMT1 
samples for DNMT1 expression analysis. MCEC Lenti-mtDNMT1 cells have been 




Figure 5.55: Analysis of western blotting signal of MCEC wild type and MCEC 
Lenti-mtDNMT1 samples. DNMT1 signal was normalised on the housekeeping 
(αTubulin), then the DNMT1 signal from MCEC Lenti-mtDNMT1 was normalised 
on the DNMT1 signal from MCEC wild type. Statistical analysis is two-tailed t-
test. 
 
5.4.8 DNMT1 interaction studies 
5.4.8.1 CoIP preliminary gel and Mass Spectrometry data 
Before performing mass spectrometry, the samples obtained through CoIP were 
ran on a preliminary gel (Figure 5.56). A DNMT1 band could not be detected in 
either of the mitochondrial DNMT1-overexpressed CoIP samples (IgG- and HA- 
incubated samples), whereas a clear band could be observed in the nuclear 
DNMT1-overexpressed (HA) sample. Then, mass spectrometry was performed. 
The signal was expressed as a quantitative value, normalised on total spectra 
signals. 
The signal for the mitochondrial DNMT1-overexpressed CoIP samples (IgG and 
HA-IP) was equal to the one obtained from the eGFP-overexpressed CoIP 
273 
 
samples (Table 5.16). That is, the amount of DNMT1 obtained from this samples 
after HA immune precipitation was negligible compared to the negative control. 
Since the point of this study was to investigate the ability of the mitochondrial 
DNMT1 isoform to bind to a potential co-factor required for mtDNA methylation 
(and further perform double overexpression experiments after identifying this co-
factor), it was concluded that this CoIP-MS experiment was unsuccessful. 
There might be different reasons which caused this: first of all, it is possible that 
something went wrong during one of the CoIP steps. It is also possible that, even 
though little to no DNMT1 signal could be observed in the mtDNMT1 (HA) pre-
MS gel, some mtDNMT1 was immunoprecipitated during the CoIP step, but the 
software for MS analysis failed to recognize mtDNMT1 sequence as an actual 
DNMT1 sequence. 
Finally, mtDNMT1 overexpression in MCE cells might require a more stable way 
of overexpression, i.e. developing a MCE-mtDNMT1 stable overexpression cell 
line through lentivirus infection. Given more time, the hypothesis of a mtDNMT1 
co-factor for enhanced mtDNA methylation should be investigated with the 
aforementioned conditions. 
 
Figure 5.56: Pre-Mass spectrometry agarose gel for CoIP samples. 
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Table 5.16: Mass spectrometry results after CoIP. Signal is expressed as a 
quantitative value, normalised on total spectra. Samples mtDNMT1 (IgG) and 






In this chapter, in order to achieve higher DNMT1 overexpression and evaluate 
its effects on mtDNA methylation, adenoviral vectors for nuclear DNMT1, 
mitochondrial DNMT1 and DNMT3A were generated through BP and LR clonase 
reactions. After generating adenoviral particles through HEK293A and performing 
titration, preliminary overexpression experiments were performed on H9C2 cells. 
Indeed, a certain level of overexpression could be found for every adenoviral 
vector, with Adeno-DNMT3A showing a really high degree of overexpression. 
At this point, the adenoviral vectors were shipped to Prof. Zeisberg’s laboratory 
in Goettingen, where the preliminary MeDIP studies were performed. Once there, 
optimization of MOI was performed in a Mouse Cardiac Endothelial (MCE) cell 
line through and Adeno-GFP vector carrying the same backbone of the other 
adenoviral vectors (serotype V); a MOI of 10 resulted in more than 95% infection 
efficiency. 
After this, primers for qPCR of D-Loop sequences after MeDIP were designed 
through in silico PCR online tools. The primers were designed to obtain almost 
100% coverage of the whole D-Loop, but full coverage could not be obtained due 
to designing constraints. The primers were then successfully validated through 
both PCR and qPCR using B6 mice genomic DNA as a template, and their 
specificity to mitochondrial sequences was further confirmed through qPCR using 
both genomic and mitochondrial DNA obtained from MCE cells. All of the D-Loop 
primer sets showed high affinity and specificity for mitochondrial-only sequences, 
confirming the prediction from the in silico PCR software in regards to their 
inability to amplify for NUMTs175,176. 
Then, infection of MCE cells using Adeno-GFP, Adeno-nuclear DNMT1 and 
Adeno-mtDNMT1 was performed, and a first round of MeDIP-qPCR experiments 
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was performed using the D-Loop primer sets and using mtDNA samples obtained 
from infected MCE cells as a template. Overall, the infection with Adeno-
mitochondrial DNMT1 resulted in a 3-to-5 fold increase in CpG methylation 
compared to Adeno-GFP. However, the total % of methylation compared to the 
input samples was still below 1%. 
After performing these experiments, I returned to London where I completed the 
remaining experiments described in this chapter. A sonication system with a new 
model of sonicator was set up, and the sonication step was optimised again using 
DNA samples from several origins (B6 mouse genomic DNA, MCEC genomic 
DNA, pCMV-SPORT6-Nuclear DNMT1, pCMV-SPORT6-Mitochondrial DNMT1). 
After identifying the best sonication conditions, several rounds of MeDIP-qPCR 
were performed, but most failed due to no amplification of the samples after 
qPCR. 
In the successfully completed round of MeDIP-qPCR, some of the primer set 
samples (#1 and #5) failed to show a good amplification pattern, even though 
their affinity to mitochondrial DNA sequences was validated thoroughly. In these 
samples, the Ct value did not allow to calculate a fold-increase in methylation. 
In the Adeno-mitochondrial DNMT1 infected samples, the primer sets #2 and #4 
samples showed a 5-to-15 fold-increase compared to the Adeno-eGFP infected 
samples, whereas primer set #3 did not show any evident fold-increase. In the 
Adeno-nuclear DNMT1 infected sample, the primer set #2 and #4 samples 
showed a 7- and 2-fold increase in CpG methylation compared to the Adeno-
eGFP samples, respectively. 
The results obtained in London were then combined with the results obtained in 
Goettingen, but statistical analysis could not be performed due to restricted 
sample size. In the case of primer sets #1 (for nuclear DNMT1-overexpressed 
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samples) and #5 (for nuclear DNMT1- and mitochondrial DNMT1-overexpressed 
samples), the fold-increase could not be calculated after the experiments 
performed in London due to the absence of signal in the replicates. Overall, the 
establishment of the MeDIP-qPCR protocol proved to be more complicated than 
expected, looking promising but still far from being reliable and replicable. 
It is possible that this method might not be ideal for investigation of mtDNA 
sequences as the absence of CpG islands might pose a problem in the reliability 
and replication of results, as the system might not be sensitive enough to pick up 
changes that fluctuate below 5%. This might be due to the fact that the MeDIP 
method relies on the binding specificity and affinity of the monoclonal anti -5-
methylcytosine antibody, which has better binding efficiency onto high-density of 
nearby methylated CpG sites177. It is also possible that a higher yield of mtDNA 
(1-2 µg or more) might be required before MeDIP can be performed in order to 
avoid loss of amplification and data, however the MeDIP kit is not optimised to 
handle amounts over 1 µg, and this might also pose a problem in terms of 
replicability. 
In the previous chapter, DNA methylation of mtDNA sequences following plasmid 
overexpression of DNMT1 isoforms showed a low ratio compared to the control. 
We wondered whether the reason was the low transfection ratio achieved through 
plasmid transfection, so adenoviral vectors were obtained. However, even though 
the infection efficiency of adenoviral vectors is high, the transient infection and 
overexpression time might still not be enough to exert an effect on the methylation 
status of mtDNA sequences. 
To verify this hypothesis, a lentivirus for mitochondrial DNMT1 stable 
overexpression in MCEC was generated. After many months of cloning, the final 
sequence was obtained and lentiviral particles were generated and titrated. After 
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infecting MCE cells and selecting infected cells through puromycin selection, the 
overexpression of mtDNMT1 was investigated through Western blotting. 
The DNMT1 overexpression was not statistically significant. This might mean 
either that there might have been problems during the packaging of the lentiviral 
particles, as the pLenti-puro-mtDNMT1 sequence is over 10 kbp long178, or that 
the overexpressed isoform is not stable enough. Furthermore, it is possible that 
the level of DNMT1 overexpression achieved with this method is not high enough 
to be detected, or that the overexpressed protein is not stable enough and, as 
the overexpression is not as potent as the one achieved through plasmid or 
adenovirus, it gets degraded before it can be detected. 
Finally, in an attempt to further elucidate mtDNMT1 role in mitochondria, I started 
working on the identification of potential DNMT1 co-factors for mtDNA 
methylation. However, the first CoIP-MS attempt failed to show overexpression 









6.1 General overview of findings 
This study represents one of the first attempts at elucidating the role of mtDNMT1 
on the methylation status of mtDNA. Since it has been reported that mtDNA is 
involved in heart failure through TLR9 stimulation by unmethylated CpG 
motifs34,36,179 and that DNMT1 sequence contains an MLS90 and might be able to 
localise at a mitochondrial level, the purpose of this study was to investigate 
whether it was possible for mtDNMT1 to localise in mitochondria, increase 
mtDNA methylation and limit TLR9 stimulation. 
Overexpression plasmids for DNMT1 isoforms were initially obtained, and 
allowed to confirm the data from the bibliography as well as to shed more light on 
the role of the predicted NLS and MLS to effectively allow for DNMT1 nuclear or 
mitochondrial localisation, respectively. Disruption of NLS resulted in inability of 
DNMT1 to localise at nuclear level, and most importantly, by adding the MLS to 
DNMT1 it has been possible to obtain mitochondrial localisation of this protein. 
These plasmids are not commercially available and represent a starting point to 
obtain gold standard DNMT1 overexpression plasmids to study the role of 
mitochondrial epigenetics in cardiovascular research as well as in other fields134. 
Moreover, these vectors have been used to generate adenoviral and lentiviral 
vectors for mtDNMT1, which are also not commercially available. These vectors 
are also important for the field as they might allow for more efficient and stable 
overexpression of the mtDNMT1 isoform. 
This study also allowed to shed some light in regards to the role of methylation in 
mtDNA. The presence of methylation in mtDNA has always remained 
controversial over the years132,133,138,140, and this study identified some of the 
reasons why this has been the case. As shown in the results chapters, it emerged 
how important it is to use linearized mtDNA for mtDNA methylation analysis, and 
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that the basal level of CpG methylation in mtDNA is below 1%. By not digesting 
the mtDNA prior to bisulphite treatment, the circular form of the DNA can shield 
it from the base conversion operated by bisulphite, thereby increasing the amount 
of falsely non-converted C residues in their sequences. It is therefore critical to 
make sure that mtDNA is fully digested prior to methylation analysis in order to 
maximise the activity of bisulphite treatment. 
Since no comments in regards to the linearization of mtDNA were found in many 
papers claiming high methylation of mtDNA sequences52,132,133,180, it is likely that 
circular mtDNA was used, suggesting that the data shown is an artefact. To 
further support this hypothesis, a comparison between circular and linear mtDNA 
was recently reported150. 
The study has also shown how it is possible to investigate the methylation status 
of mitochondrial sequences through the MeDIP-qPCR protocols. Since it has 
been shown that almost all of the mitochondrial DNA is duplicated into the 
genomic DNA in the form of NUMTs175,176, this study has achieved unbiased 
MeDIP-qPCR methylation analysis by removing 2 of the main issues undermining 
the analysis. 
First, a two-steps fractioning and DNA extraction of the samples to obtain pure 
mtDNA samples, and second, performing MeDIP of mtDNA sequences through 
design of qPCR primers that can specifically target the sequences of interest (i.e. 
D-Loop) without amplifying genomic DNA sequences. The qPCR primers were 
tested and their specificity to mtDNA sequences was confirmed thoroughly. 
Methylation analysis of D-Loop sequences following MeDIP-qPCR experiments 
highlighted a fold-increase in the methylation ratio of immunoprecipitated D-Loop 
sequences compared to the Input, however these results proved difficult to 
replicate and interpret. Since MeDIP is based on the interaction between an 
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antibody and 5mC, and it has been shown that its affinity and specificity increase 
the more CpG residues are present on a given sequence177, it is possible that 
this protocol might not be specific enough to yield true and consistent data. 
Finally, this study took the first steps toward obtaining a cell line with stable 
mtDNMT1 overexpression through lentivirus infection, as well as trying to 
elucidate whether a co-factor is required to obtain mtDNMT1-mtDNA binding and 
increased methylation of mtDNA sequences. Overall, the data obtained suggests 
that the regulation of mitochondrial epigenetics is more complicated than 




6.2 Clinical implications of mtDNA methylation 
In the UK, more than a quarter of deaths (160,000 each year) result from 
cardiovascular diseases (CVD) and an estimated 7 million people suffer from 
CVD (British Heart Foundation statistics, 2016). It is therefore essential to 
understand the mechanisms that underline CVD in order to identify potential 
therapeutic targets. The inflammatory response observed in CVD can propagate 
disease development and ultimately lead to heart failure34. Circulating 
mitochondrial DNA in the form of unmethylated CpG motifs was linked to TLR9 
stimulation and the inflammation process which contributes to heart failure36. 
Although the activity of DNMT1 on mtDNA could not be fully elucidated in this 
study, we can speculate about a protective role during pressure overload and 
mitophagy. Since there have been reports about how DNMT1 can have other 
non-catalytic functions181 and cooperate with DNMT3A in order to achieve de 
novo methylation182, the role of DNMT1 in a mitochondrial environment might be 
to act as a de novo methyltransferase and introduce methyl groups on mtDNA 
CpG residues, resulting in less TLR9 stimulation. By elucidating the role of 
DNMT1 at a mitochondrial level, it would be possible to design drugs that 
increase methylation of mtDNA without impacting the methylation status of gDNA, 
thereby reducing TLR9 stimulation following pressure overload and release of 
inflammatogenic mtDNA unmethylated CpG motifs (Figure 6.1). Therefore, 
targeting mtDNA by modifying its methylation status at certain time points could 




Figure 6.1: Proposed molecular mechanism of action for a methylating agent. 
 
6.3 Study limitations 
In this study, plasmid and adenoviral overexpression systems for several DNMT1 
isoforms were established, and methylation analysis in the form of sequencing 
after bisulphite treatment and MeDIP-qPCR was performed. However, no 
changes in the methylation pattern of mtDNA sequences could be found. The 
reasons for this are many and involve several steps which might need to be 
further refined. 
First, overexpression of mtDNMT1 does not appear to be very strong (especially 
after plasmid transfection where the transfection efficiency is about 20-30%), and 
it is possible that the protein is degraded after overexpression. Moreover, 
transient overexpression of mtDNMT1 might not be enough to elicit changes in 
the methylation pattern of mtDNA, and more stable and persistent 
overexpression might be required instead. Hence, overexpression of mtDNMT1 
through plasmid and adenoviral vectors might have to be abandoned in favour of 
a lentiviral vector system. 
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Second, the systems used in this study for methylation analysis both have their 
limits as they are not high-throughput and require several steps. Bisulphite 
sequencing could not find any methylation after overexpression of nDNMT1, 
mtDNMT1, DNMT3A or mtDNMT1-DNMT3A in the investigated sequences 
(COX2 and part of the D-Loop). The protocol is fully optimized to avoid false 
positives as it includes linearization through HindIII digestion and has single base 
resolution, however it requires design of specific primers, and the ones used 
could not be screened for affinity for NUMTs, as they only amplify converted 
sequences. 
The MeDIP-qPCR protocol was used on mtDNA sequences for the first time, but 
appears to be not fully optimized. The primer sets used have been designed to 
have unique affinity with mtDNA sequences and none with gDNA sequences (i.e. 
NUMTs are not amplified) so there are no false positives, however the results 
obtained were not consistent and replicable. In the future, more concentrated 
samples might be required as the yield for mtDNA is usually quite low even with 
a big starting sample (which requires a high amount of adenovirus, hence 
obtaining a stable overexpression system to eliminate this issue appears to be 
critical). Furthermore, another issue with this system is that it might not be 
sensitive enough to detect changes in single CpG residues, as it was initially 





6.4 Future work 
Another possible limitation of this study is the protective effect that nucleoid 
proteins183-185 within mitochondria might have in regards to epigenetic 
modifications. It is possible that proteins such as TFAM186 (the main component 
of nucleoid structures) might shield mtDNA from being methylated by DNMT1. 
The first step to further elucidate the role of mtDNMT1 at a mitochondrial level 
should be to establish a reliable and stable overexpression system for this 
protein. That is, by obtaining a lentiviral vector that can achieve mtDNMT1 cDNA 
integration within the host genome and reliably overexpress it, it will be possible 
to study the long-term effects of mtDNMT1 overexpression on mtDNA 
methylation. 
Once established stable overexpression, methylation analysis through bisulphite 
sequencing and MeDIP-qPCR should be performed again to test whether the 
limitations of these systems can be overcome. In this regard, performing TFAM 
knock-down before methylation analysis might also allow to test the hypothesis 
of TFAM having a protective role in regards to mtDNA methylation by mtDNMT1.  
Furthermore, investigation of mitochondrial co-factors for mtDNMT1 should be 
performed through Co-IP and mass spectrometry analysis.  
Finally, achieving stable overexpression will allow to study whether mtDNMT1 
can limit TLR9 stimulation following treatment with compounds that mimic 
pressure overload and inhibit oxidative phosphorylation, i.e. Angiotensin II and 




6.4.1 TFAM silencing in MCE cells 
To investigate whether TFAM shielding is the cause of mtDNA protection from 
methylation, a set of TFAM knock-down experiments in MCE cells was performed 
as a preliminary study. MCE cells were seeded in a 6 well plates and immediately 
transfected with 3 different Silencer® Select TFAM siRNAs (ThermoFisher 
Scientific®, 4390771) as well as a Silencer® Select Negative Control No. 1 
scramble siRNA (ThermoFisher Scientific®, 4390843), using Lipofectamine® 
RNAiMAX (ThermoFisher Scientific®, 13778075) as a transfection reagent. 
Briefly, the Lipofectamine® RNAiMAX and the siRNAs were diluted in Opti-
MEM™ reduced serum medium (Thermo Fisher Scientific™, 31985070) 
according to the protocol and incubated at room temperature for 10 minutes, then 
the siRNA-lipid complexes were added to the cells which were then incubated for 
2 days at 37ºC. After 1 day, the medium was replaced to culturing medium, and 
the cells were harvested 48 hours after transfection. 
Proteins were extracted from the pellets and quantified, and Western blotting 
using an Anti-TFAM antibody (Abcam®, ab131607) was performed (Figure 6.2). 
All TFAM siRNAs screened managed to achieve a significant knock-down of 
TFAM (N=3, p < 0.001 or better) (Figure 6.3). 
Therefore, the transfection conditions used in this preliminary study, as well as 
all of the screened TFAM siRNAs represent a good starting point for investigation 
of TFAM protective role in regards to mtDNA methylation by mtDNMT1. Should 
methylation analysis following TFAM knock-down and mtDNMT1 overexpression 
show a significant increase in methylation levels of mtDNA sequences, the 
following steps will involve investigating the expression of mitochondrial proteins, 





Figure 6.2: Western blot of MCEC samples after 48 hours TFAM knock-down. 
 
Figure 6.3: Statistical analysis of TFAM knock-down after 48 hours. T-test 





In conclusion, the work presented in this thesis was an attempt to elucidate the 
role of mtDNMT1 on mtDNA methylation. Herein, several plasmids, adenoviral 
and lentiviral constructs were generated and methylation analysis of mtDNA 
sequences was carried on using both bisulphite sequencing and MeDIP-qPCR 
analysis. I have demonstrated that the 1st-to-3rd ATG DNMT1 sequence can act 
as a mitochondrial localisation signal and that a preserved NLS is indeed required 
for nuclear localisation of this protein. Although many efforts to increase 
methylation of mtDNA sequences were made, it was not possible to observe any 
changes in this regard. 
Moreover, it is still unclear whether the absence of changes in the methylation 
pattern is due to insufficient overexpression, whether a co-factor is necessary or 
whether some of the nucleoid proteins have a protective effect in this regard. It is 
worth mentioning that all the experiments in this study have been performed 
under overexpression conditions rather than through pressure overload and 
inhibition of oxidative phosphorylation conditions via treatment with stimuli (i.e. 
AngII, CCCP) in an attempt to maximize the efficiency of DNMT1 at a 
mitochondrial level. 
Taken together, the results presented in this thesis provide a necessary 
experimental starting point to further clarity to the role of mtDNMT1 at a 
mitochondrial level and its potential role in reducing TLR9 stimulation after 
pressure overload, with the potential to inspire the design of methylating drugs to 
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